Disease on EC 3.4.21.69 - Protein C (activated)
Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Abortion, Habitual
Cross-comparison of the genome sequences from human, chimpanzee, Neanderthal and a Denisovan hominin identifies novel potentially compensated mutations.
Abortion, Habitual
Factor V Leiden and acquired activated protein C resistance among 1000 women with recurrent miscarriage.
Abortion, Habitual
Genetic polymorphisms on the factor V gene in women with recurrent miscarriage and acquired APCR.
Abortion, Habitual
Haemostatic and metabolic abnormalities in women with unexplained recurrent abortion.
Abortion, Habitual
Increased resistance to activated protein C and factor V Leiden in recurrent abortions. Review of other hypercoagulability factors.
Abortion, Habitual
Prevalence of activated protein C resistance among women with recurrent miscarriage.
Abortion, Habitual
Primary recurrent miscarriages: anti-beta2-glycoprotein I IgG antibodies induce an acquired activated protein C resistance that can be detected by the modified activated protein C resistance test.
Abortion, Spontaneous
Are women with polycystic ovary syndrome resistant to activated protein C?
Abortion, Spontaneous
Haemostatic and metabolic abnormalities in women with unexplained recurrent abortion.
Abortion, Spontaneous
Hypercoagulable states in renal transplant candidates: impact of anticoagulation upon incidence of renal allograft thrombosis.
Abortion, Spontaneous
Placental thrombosis and second trimester miscarriage in association with activated protein C resistance.
Abortion, Spontaneous
Second-trimester pregnancy loss is associated with activated C resistance.
Abortion, Spontaneous
The factor V Leiden mutation is not a common cause of recurrent miscarriage.
Abortion, Spontaneous
[Recurrent miscarriage or failed in-vitro fertilization: antibodies against annexin V, cardiolipin, beta-2-glycoprotein-1 and APC-resistance]
Abortion, Spontaneous
[Study on relationship of activated protein C resistance and recurrent spontaneous abortion]
Abruptio Placentae
Activated protein C is effective for disseminated intravascular coagulation associated with placental abruption.
Abruptio Placentae
How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review.
Abruptio Placentae
Resistance to activated protein C and the leiden mutation: high prevalence in patients with abruptio placentae.
Abruptio Placentae
The Normal anticoagulant system and risk of placental abruption: protein C, protein S and resistance to activated protein C.
Abscess
Clinical and laboratory effects of recombinant human activated protein C in the treatment of a patient with sepsis-induced multiple organ failure.
Abscess
[Severe sepsis as a complication of descending necrozing mediastinitis due to a peritonsillar abscess. A case study]
Acquired Immunodeficiency Syndrome
Treatment of severe sepsis secondary to mycobacterium avium-intracellulare with recombinant human activated protein C.
Activated Protein C Resistance
"ProC Global": a functional screening test that predicts recurrent venous thromboembolism.
Activated Protein C Resistance
"Pseudo homozygous" activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds.
Activated Protein C Resistance
A 2-year retrospective analysis of laboratory testing for activated protein C resistance with a factor V-corrected activated partial thromboplastin time-based method.
Activated Protein C Resistance
A 9-year retrospective assessment of laboratory testing for activated protein C resistance: evolution of a novel approach to thrombophilia investigations.
Activated Protein C Resistance
A case control study of deep venous thrombosis in relation to factor V G1691A (Leiden) and A4070G (HR2 Haplotype) polymorphisms.
Activated Protein C Resistance
A case series of 72 neonates with renal vein thrombosis. Data from the 1-800-NO-CLOTS Registry.
Activated Protein C Resistance
A clinical audit of congenital thrombophilia investigation in tertiary practice.
Activated Protein C Resistance
A comparative study of the effect of continuous combined conjugated equine estrogen plus medroxyprogesterone acetate and tibolone on blood coagulability.
Activated Protein C Resistance
A comparison between two activated protein C resistance methods as routine diagnostic tests for factor V Leiden mutation.
Activated Protein C Resistance
A comparison of glass and plastic blood collection tubes for routine and specialized coagulation assays: a comprehensive study.
Activated Protein C Resistance
A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype.
Activated Protein C Resistance
A fast and robust dual-label nonradioactive oligonucleotide ligation assay for detection of factor V Leiden.
Activated Protein C Resistance
A FV multiallelic marker detects genetic components of APC resistance contributing to venous thromboembolism in FV Leiden carriers.
Activated Protein C Resistance
A gene-centric analysis of activated partial thromboplastin time and activated protein C resistance using the HumanCVD focused genotyping array.
Activated Protein C Resistance
A hemi-nested, allele specific, whole blood PCR assay for the detection of the factor V Leiden mutation.
Activated Protein C Resistance
A highly specific functional test for factor V leiden: A modified tissue factor assay for activated protein C resistance.
Activated Protein C Resistance
A modified functional global test to measure protein C, protein S activities and the activated protein C-resistance phenotype.
Activated Protein C Resistance
A multi-laboratory assessment of congenital thrombophilia assays performed on the ACL TOP 50 family for harmonisation of thrombophilia testing in a large laboratory network.
Activated Protein C Resistance
A new dilution for the modified APTT-based assay for activated protein C resistance: improvement of the reliability in patients with a lupus anticoagulant.
Activated Protein C Resistance
A new locus on chromosome 18 that influences normal variation in activated protein C resistance phenotype and factor VIII activity and its relation to thrombosis susceptibility.
Activated Protein C Resistance
A Novel Mutation (G2172-->C) in the Factor V Gene in a Chinese Family with Hereditary Activated Protein C Resistance.
Activated Protein C Resistance
A novel mutation of Arg306 of factor V gene in Hong Kong Chinese.
Activated Protein C Resistance
A possible role for activated protein C resistance in patients with first and second trimester pregnancy failure.
Activated Protein C Resistance
A protein S functional assay yields unsatisfactory results in patients with activated protein C resistance.
Activated Protein C Resistance
A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways.
Activated Protein C Resistance
A role for "acquired" activated protein C resistance in recurrent fetal loss?
Activated Protein C Resistance
A simple procedure that increases the specificity of the activated protein C resistance test in samples containing antiphospholipid antibodies.
Activated Protein C Resistance
Acquired activated protein C resistance and thrombosis in multiple myeloma patients.
Activated Protein C Resistance
Acquired activated protein C resistance associated with anti-protein S antibody as a strong risk factor for DVT in non-SLE patients.
Activated Protein C Resistance
Acquired activated protein C resistance associated with IgG antibodies against beta2-glycoprotein I and prothrombin as a strong risk factor for venous thromboembolism.
Activated Protein C Resistance
Acquired activated protein C resistance caused by lupus anticoagulants.
Activated Protein C Resistance
Acquired activated protein C resistance in myeloma patients with venous thromboembolic events.
Activated Protein C Resistance
Acquired activated protein C resistance in postmenopausal women is dependent on factor VIII:c levels.
Activated Protein C Resistance
Acquired activated protein C resistance in pregnancy is not due to elevated plasma caeruloplasmin levels.
Activated Protein C Resistance
Acquired activated protein C resistance in sarcoma patients.
Activated Protein C Resistance
Acquired activated protein C resistance is associated with IgG antibodies to protein S in patients with systemic lupus erythematosus.
Activated Protein C Resistance
Acquired activated protein C resistance is associated with lupus anticoagulants and thrombotic events in pediatric patients with systemic lupus erythematosus.
Activated Protein C Resistance
Acquired activated protein C resistance is associated with the co-existence of anti-prothrombin antibodies and lupus anticoagulant activity in patients with systemic lupus erythematosus.
Activated Protein C Resistance
Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism.
Activated Protein C Resistance
Acquired activated protein C resistance may be a risk factor for recurrent fetal loss.
Activated Protein C Resistance
Acquired activated protein C resistance, high tissue factor expression, and hyper-homocysteinemia in systemic lupus erythematosus.
Activated Protein C Resistance
Acquired activated protein C resistance, thrombophilia and adverse pregnancy outcomes: a study performed in an irish cohort of pregnant women.
Activated Protein C Resistance
Acquired APC resistance in neurosurgical patients may not be a risk factor for postoperative deep vein thrombosis.
Activated Protein C Resistance
Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism.
Activated Protein C Resistance
Acquired resistance to activated protein C in breast cancer patients.
Activated Protein C Resistance
Activated protein c resistance (APC) and inherited factor V (FV) mis-sense mutation in patients with venous and arterial thrombosis in a haematology clinic.
Activated Protein C Resistance
Activated protein C resistance (APCR) and placental fibrin deposition.
Activated Protein C Resistance
Activated protein C resistance (factor V Leiden) associated with thrombosis in pregnancy.
Activated Protein C Resistance
Activated protein C resistance (FV(Leiden)) and thrombosis: factor V mutations causing hypercoagulable states.
Activated Protein C Resistance
Activated protein C resistance -- in the absence of factor V Leiden -- and pregnancy.
Activated Protein C Resistance
Activated protein C resistance acquired through liver transplantation and associated with recurrent venous thrombosis.
Activated Protein C Resistance
Activated protein C resistance acquired through liver transplantation.
Activated Protein C Resistance
Activated protein C resistance among postmenopausal women using transdermal estrogens: importance of progestogen.
Activated Protein C Resistance
Activated protein C resistance and acute ischaemic stroke: relation to stroke causation and age.
Activated Protein C Resistance
Activated protein C resistance and adverse pregnancy outcome.
Activated Protein C Resistance
Activated protein C resistance and anticardiolipin antibodies in patients with venous leg ulcers.
Activated Protein C Resistance
Activated protein C resistance and anticoagulant proteins in young adults with central retinal vein occlusion.
Activated Protein C Resistance
Activated protein C resistance and antiphospholipid antibodies in recurrent fetal loss: experience of a single referral center in northern iraq.
Activated Protein C Resistance
Activated protein C resistance and deficiencies of antithrombin III, protein C or protein S and the risk of thromboembolic disease in users of oral contraceptives.
Activated Protein C Resistance
Activated protein C resistance and factor V Leiden in Mexico.
Activated Protein C Resistance
Activated protein C resistance and factor V Leiden in patients with hemolysis, elevated liver enzymes, low platelets syndrome.
Activated Protein C Resistance
Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism.
Activated Protein C Resistance
Activated protein C resistance and factor V Leiden mutation are risk factors for cerebral sinus thrombosis.
Activated Protein C Resistance
Activated protein C resistance and factor V Leiden mutation can be associated with first-as well as second-trimester recurrent pregnancy loss.
Activated Protein C Resistance
Activated protein C resistance and factor V Leiden: a review.
Activated Protein C Resistance
Activated protein C resistance and false type 2 protein C deficiency detected after multiple shunt failures in a patient with hydrocephalus.
Activated Protein C Resistance
Activated protein C resistance and graft occlusion after coronary artery bypass surgery.
Activated Protein C Resistance
Activated protein C resistance and inherited thrombosis.
Activated Protein C Resistance
Activated protein C resistance and its correlation with thrombophlebitis in Behçet's disease.
Activated Protein C Resistance
Activated protein C resistance and Japanese NIDDM patients with coronary heart disease.
Activated Protein C Resistance
Activated protein C resistance and low molecular weight lipoprotein (a): dual pathogens for atherothrombosis?
Activated Protein C Resistance
Activated protein C resistance and lupus anticoagulant activity induced by plasma and purified monospecific human IgG anti-beta2-glycoprotein-I antibodies.
Activated Protein C Resistance
Activated protein C resistance and lupus anticoagulant in pregnancy.
Activated Protein C Resistance
Activated protein C resistance and the factor V Leiden mutation in children with thrombosis.
Activated Protein C Resistance
Activated protein C resistance and the FV:R506Q mutation in a random population sample--associations with cardiovascular risk factors and coagulation variables.
Activated Protein C Resistance
Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation.
Activated Protein C Resistance
Activated protein C resistance as a "new" cause of deep venous thrombosis in aviators.
Activated Protein C Resistance
Activated protein C resistance as a basis for venous thrombosis.
Activated Protein C Resistance
Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families.
Activated Protein C Resistance
Activated protein C resistance as measured by residual factor V after Russell's viper venom and activated protein C treatment analyzed as a continuous variable in multiple myeloma and normal controls.
Activated Protein C Resistance
Activated protein C resistance assay as a screening test for thromboembolic disposition.
Activated Protein C Resistance
Activated protein C resistance assay detects thrombotic risk factors other than factor V Leiden.
Activated Protein C Resistance
Activated protein C resistance assay performance: improvement by sample dilution with factor V-deficient plasma.
Activated Protein C Resistance
Activated protein C resistance assay when applied in the general population.
Activated Protein C Resistance
Activated protein C resistance associated with lupus anticoagulants is a high risk in acute mesenteric venous thrombosis.
Activated Protein C Resistance
Activated protein C resistance associated with maternal floor infarction treated with low-molecular-weight heparin.
Activated Protein C Resistance
Activated protein C resistance can be associated with recurrent fetal loss.
Activated Protein C Resistance
Activated protein C resistance caused by a common factor V mutation has a single origin.
Activated Protein C Resistance
Activated protein C resistance caused by Arg506Gln mutation in factor Va.
Activated Protein C Resistance
Activated protein C resistance caused by factor V Arg 506-->Gln mutation has no role in thrombotic manifestations of Behçet's disease.
Activated Protein C Resistance
Activated protein C resistance caused by factor V gene mutation: common coagulation defect in chronic venous leg ulcers?
Activated Protein C Resistance
Activated protein C resistance determined with a thrombin generation-based test is associated with thrombotic events in patients with lupus anticoagulants.
Activated Protein C Resistance
Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women.
Activated Protein C Resistance
Activated Protein C Resistance Does Not Increase Risk for Recurrent Stroke or Death in Stroke Patients.
Activated Protein C Resistance
Activated protein C resistance due to a common factor V gene mutation is a major risk factor for venous thrombosis.
Activated Protein C Resistance
Activated protein C resistance due to a factor V mutation associated with familial ischemic stroke.
Activated Protein C Resistance
Activated protein C resistance due to factor V Leiden, elevated coagulation factor VIII and postoperative deep vein thrombosis in late breast reconstruction with a free TRAM flap: a report of two cases.
Activated Protein C Resistance
Activated protein C resistance during in vitro fertilization treatment.
Activated Protein C Resistance
Activated protein C resistance in a neonate with venous thrombosis.
Activated Protein C Resistance
Activated protein C resistance in anterior ischaemic optic neuropathy.
Activated Protein C Resistance
Activated protein C resistance in antiphospholipid thrombosis syndrome.
Activated Protein C Resistance
Activated protein C resistance in cases of cerebral infarction.
Activated Protein C Resistance
Activated protein C resistance in central retinal vein occlusion.
Activated Protein C Resistance
Activated protein C resistance in cord blood from healthy and complicated newborns.
Activated Protein C Resistance
Activated protein C resistance in homozygous sickle cell disease.
Activated Protein C Resistance
Activated protein C resistance in ischemic stroke not due to factor V arginine506-->glutamine mutation.
Activated Protein C Resistance
Activated protein C resistance in normal and pre-eclamptic pregnancies.
Activated Protein C Resistance
Activated protein C resistance in normal pregnancy.
Activated Protein C Resistance
Activated protein C resistance in patients following venous thromboembolism receiving rivaroxaban versus vitamin K antagonists: assessment using Russell viper venom time-based assay.
Activated Protein C Resistance
Activated protein C resistance in patients with anti-beta 2 glycoprotein I antibodies.
Activated Protein C Resistance
Activated protein C resistance in patients with arterial ischemic stroke.
Activated Protein C Resistance
Activated protein C resistance in patients with central retinal vein occlusion.
Activated Protein C Resistance
Activated protein C resistance in patients with peripheral vascular disease.
Activated Protein C Resistance
Activated protein C resistance in pediatric inflammatory bowel disease.
Activated Protein C Resistance
Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications.
Activated Protein C Resistance
Activated protein C resistance in the Japanese population due to homozygosity for the factor V R2 haplotype.
Activated Protein C Resistance
Activated protein C resistance in Turkish women with severe preeclampsia.
Activated Protein C Resistance
Activated protein C resistance in young adults with central retinal vein occlusion.
Activated Protein C Resistance
Activated protein C resistance in young African American patients with ischemic stroke.
Activated Protein C Resistance
Activated protein C resistance is a risk factor for central retinal vein occlusion.
Activated Protein C Resistance
Activated protein C resistance is uncommon in sudden death due to pulmonary embolism.
Activated Protein C Resistance
Activated protein C resistance phenotype and genotype in patients with primary antiphospholipid syndrome.
Activated Protein C Resistance
Activated protein C resistance phenotype in patients with antiphospholipid antibodies.
Activated Protein C Resistance
Activated protein C resistance shows an association with pregnancy-induced hypertension.
Activated Protein C Resistance
Activated protein C resistance test using factor VIII-deficient plasma: a new approach to the venous thrombotic risk?
Activated Protein C Resistance
Activated protein C resistance, factor V Leiden and assessment of thrombotic risk.
Activated Protein C Resistance
Activated protein C resistance, factor V Leiden and peripheral vascular disease.
Activated Protein C Resistance
Activated protein C resistance, factor V Leiden, and central retinal vein occlusion in young adults.
Activated Protein C Resistance
Activated protein C resistance, factor V Leiden, and retinal vessel occlusion.
Activated Protein C Resistance
Activated protein C resistance, the factor V Leiden mutation, and a laboratory testing algorithm.
Activated Protein C Resistance
Activated protein C resistance, thrombophilia, and inflammatory bowel disease.
Activated Protein C Resistance
Activated protein C resistance--a major risk factor for thrombosis.
Activated Protein C Resistance
Activated protein C resistance: a comparison between two clotting assays and their relationship to the presence of the factor V Leiden mutation.
Activated Protein C Resistance
Activated protein C resistance: a study among 60 thromboembolic patients in the Singapore population.
Activated Protein C Resistance
Activated protein C resistance: automated detection of the factor V Leiden mutation by mismatch hybridization.
Activated Protein C Resistance
Activated protein C resistance: effect of platelet activation, platelet-derived microparticles, and atherogenic lipoproteins.
Activated Protein C Resistance
Activated protein C resistance: from phenotype to genotype and clinical practice.
Activated Protein C Resistance
Activated protein C resistance: molecular mechanisms based on studies using purified Gln506-factor V.
Activated Protein C Resistance
Activated protein C resistance: prevalence and implications in peripheral vascular disease.
Activated Protein C Resistance
Activated protein C resistance: the commonest hereditary hypercoagulation disorder.
Activated Protein C Resistance
Activated protein C resistance: the influence of ABO-blood group, gender and age.
Activated Protein C Resistance
Activated protein C resistance: the most common risk factor for venous thromboembolism.
Activated Protein C Resistance
Activated protein C resistance: What have we learned now that the dust has settled?
Activated Protein C Resistance
Activated Protein C-Resistance Determination and Vascular Access Thrombosis in Populations with High Prevalence of Factor V Leiden.
Activated Protein C Resistance
Acute Budd-Chiari syndrome with fulminant hepatic failure in a pregnant woman with factor V Leiden mutation.
Activated Protein C Resistance
Acute peripheral vertigo: involvement of the hemostatic system.
Activated Protein C Resistance
Acute proptosis in relation to activated protein C resistance: a case report.
Activated Protein C Resistance
Adult transient lupus anticoagulant patients maintain an acquired activated protein C resistance profile.
Activated Protein C Resistance
Allograft loss in renal transplant recipients with Fabry's disease and activated protein C resistance.
Activated Protein C Resistance
An antifibrinolytic effect associated with an anti-factor V antibody in a patient with severe thrombophilia.
Activated Protein C Resistance
An assessment of the comparative utility of functional and molecular level analyses in the investigation of patients with thrombophilia.
Activated Protein C Resistance
An improved algorithm for activated protein C resistance and factor v leiden screening.
Activated Protein C Resistance
An open-label, comparative study of the effects of a dose-reduced oral contraceptive containing 0.02 mg ethinylestradiol/2 mg chlormadinone acetate on hemostatic parameters and lipid and carbohydrate metabolism variables.
Activated Protein C Resistance
Antenatal screening for factor V Leiden mutation: a critical appraisal.
Activated Protein C Resistance
Anterior ischemic optic neuropathy and activated protein C resistance. A case report and review of the literature.
Activated Protein C Resistance
Anti-Domain I ?2-Glycoprotein I Antibodies and Activated Protein C Resistance Predict Thrombosis in Antiphospholipid Syndrome: TAC(I)T Study.
Activated Protein C Resistance
Anti-protein C antibodies are associated with resistance to endogenous protein C activation and a severe thrombotic phenotype in antiphospholipid syndrome.
Activated Protein C Resistance
Anticoagulation with recombinant hirudin following bone marrow transplantation in a patient with activated protein C resistance and heparin-induced antibodies showing cross-reactivity to the heparinoid danaparoid.
Activated Protein C Resistance
Antiphopholipid antibodies and functional activated protein C resistance in patients with breast cancer during anthracycline-based chemotherapy administered through an intravenous port-catheter device.
Activated Protein C Resistance
Antiphospholipid antibodies and thrombosis: association with acquired activated protein C resistance in venous thrombosis and with hyperhomocysteinemia in arterial thrombosis.
Activated Protein C Resistance
Antiphospholipid antibodies predict imminent vascular events independently from other risk factors in a prospective cohort.
Activated Protein C Resistance
APC resistance and third-generation oral contraceptives: Acquired resistance to activated protein C, oral contraceptives and the risk of thromboembolic disease.
Activated Protein C Resistance
APC resistance in childhood thromboembolism: diagnosis and clinical aspects.
Activated Protein C Resistance
APCR, factor V gene known and novel SNPs and adverse pregnancy outcomes in an Irish cohort of pregnant women.
Activated Protein C Resistance
Apixaban Does Not Interfere With Protein S or Activated Protein C Resistance (Factor V Leiden) Testing Using aPTT-Based Methods.
Activated Protein C Resistance
Applying risk assessment models in orthopaedic surgery: effective risk stratification.
Activated Protein C Resistance
Assessment of acquired activated protein C resistance with the FibWave and comparison with the ETP-based APC resistance.
Activated Protein C Resistance
Assessment of activated protein C resistance using a new and rapid venom-based test: STA Staclot APC-R.
Activated Protein C Resistance
Association between in vitro fertilization outcomes and inherited thrombophilias: a meta-analysis.
Activated Protein C Resistance
Association between increased tumor necrosis factor alpha levels and acquired activated protein C resistance in patients with metastatic colorectal cancer.
Activated Protein C Resistance
Association between prothrombin gene polymorphisms and hereditary thrombophilia in Xinjiang Kazakhs population.
Activated Protein C Resistance
Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestogens.
Activated Protein C Resistance
Association of increased C-Reactive Protein and hypocomplementemia with risk factors for thrombosis in women who have susceptibility for poor gestational outcome; importance of preconceptional counseling.
Activated Protein C Resistance
Association of periprocedural neurological deficit in carotid stenting with increased anticardiolipin antibodies.
Activated Protein C Resistance
Association of primary antiphospholipid syndrome with inherited activated protein C resistance.
Activated Protein C Resistance
Association of resistance to activated protein with the presence of Leiden and Cambridge Factor V mutations in Mexican patients with primary thrombophilia.
Activated Protein C Resistance
Association of the R485K polymorphism of the factor V gene with poor response to activated protein C and increased risk of coronary artery disease in the Chinese population.
Activated Protein C Resistance
Atherogenic, hemostatic, and other potential risk markers in subjects with previous isolated myocardial infarction compared with long-standing uncomplicated stable angina.
Activated Protein C Resistance
Basic parameters of thrombophilia in ocular Behçet disease with posterior segment involvement.
Activated Protein C Resistance
Basilar artery thrombosis in a child heterozygous for factor V Leiden mutation.
Activated Protein C Resistance
Beneficial effect of metformin on pregnancy outcome in women with polycystic ovary syndrome is not associated with major changes in C-reactive protein levels or indices of coagulation.
Activated Protein C Resistance
Benzylthiouracil-induced ANCA-associated Vasculitis: A Case Report and Literature Review.
Activated Protein C Resistance
Biological coagulation findings in third-generation oral contraceptives.
Activated Protein C Resistance
Blood viscosity, coagulation, and activated protein C resistance in central retinal vein occlusion: a population controlled study.
Activated Protein C Resistance
Broadsheet number 53: Activated protein C resistance: diagnosis and clinical management.
Activated Protein C Resistance
Budd-Chiari syndrome in the course of Behcet's disease: clinical and laboratory analysis of four cases.
Activated Protein C Resistance
C-reactive protein and markers for thrombophilia in patients with chronic plaque psoriasis.
Activated Protein C Resistance
Calibrated automated thrombin generation in frozen-thawed platelet-rich plasma to detect hypercoagulability.
Activated Protein C Resistance
Careful selection of sample dilution and factor-V-deficient plasma makes the modified activated protein C resistance test highly specific for the factor V Leiden mutation.
Activated Protein C Resistance
Case Study of Pediatric Cerebral Sinus Venous Thrombosis Center of a Low Middle-Income Country.
Activated Protein C Resistance
Causal relationship of susceptibility genes to ischemic stroke: comparison to ischemic heart disease and biochemical determinants.
Activated Protein C Resistance
Central retinal artery occlusion in a patient homozygous for factor V Leiden.
Activated Protein C Resistance
Central retinal vein thrombosis associated with resistance to activated protein C.
Activated Protein C Resistance
Cerebral sinus thrombosis in a young adult with activated protein C resistance and homosysteinaemia.
Activated Protein C Resistance
Cerebral venous sinus thrombosis as presenting feature of ulcerative colitis.
Activated Protein C Resistance
Cerebral venous thrombosis and activated protein C resistance.
Activated Protein C Resistance
Cerebral venous thrombosis. Role of activated protein C resistance and factor V gene mutation.
Activated Protein C Resistance
Cerebrovascular disease risk factors: neuroradiologic findings in patients with activated protein C resistance.
Activated Protein C Resistance
Chagasic cardiomyopathy is independently associated with ischemic stroke in Chagas disease.
Activated Protein C Resistance
Changes in activated protein C resistance during normal pregnancy.
Activated Protein C Resistance
Changes in coagulation and fibrinolysis of post-SARS osteonecrosis in a Chinese population.
Activated Protein C Resistance
Clinical and ethnic characteristics of stroke in an Israeli population: a study in a community hospital population.
Activated Protein C Resistance
Clinical evaluation of a new functional test for detection of activated protein C resistance (Pefakit APC-R Factor V Leiden) at two centers in Europe and the USA.
Activated Protein C Resistance
Clinical outcomes and a high prevalence of abnormalities on comprehensive arterial and venous thrombophilia screening in TIA or ischaemic stroke patients with a patent foramen ovale, an inter-atrial septal aneurysm or both.
Activated Protein C Resistance
Clinical significance of acquired activated protein C resistance in patients with systemic lupus erythematosus.
Activated Protein C Resistance
Clinical significance of activated protein C resistance as a potential marker for hypercoagulable state.
Activated Protein C Resistance
Clinically symptomatic central venous catheter-related deep venous thrombosis in newborns.
Activated Protein C Resistance
Coagulation abnormalities in adults with cryptogenic stroke and patent foramen ovale.
Activated Protein C Resistance
Coagulation Factor Levels and Underlying Thrombin Generation Patterns in Adult Extracorporeal Membrane Oxygenation Patients.
Activated Protein C Resistance
Coagulation factor V and thrombophilia: background and mechanisms.
Activated Protein C Resistance
Coagulation factor V G allele and HR2 haplotype: factor V activity, activated protein C resistance and risk of venous thrombosis.
Activated Protein C Resistance
Coagulation factor V gene 1691G>A polymorphism as an indicator for risk and prognosis of lower extremity deep venous thrombosis in Chinese Han population.
Activated Protein C Resistance
Coagulation factor V gene mutation associated with activated protein C resistance leading to recurrent thrombosis, leg ulcers, and lymphedema: successful treatment with intermittent compression.
Activated Protein C Resistance
Coagulation factor V Leiden mutation was detected in the patients with activated protein C resistance in Thailand.
Activated Protein C Resistance
Coagulation inhibitors and activated protein C resistance in recurrent pregnancy losses in Indian women.
Activated Protein C Resistance
Coagulation management of a patient with factor V Leiden mutation, lupus anticoagulant, and activated protein C resistance: a case report.
Activated Protein C Resistance
Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis.
Activated Protein C Resistance
Coagulopathy parameters in patients with Crimean-Congo hemorrhagic fever and its relation with mortality.
Activated Protein C Resistance
Coexistence of factor V G1691A and factor II G20210A gene mutations in a thrombotic family is associated with recurrence and early onset of venous thrombosis.
Activated Protein C Resistance
Coexistence of factor V Leiden and primary antiphospholipid syndrome: a patient with recurrent myocardial infarctions and thrombocytopenia.
Activated Protein C Resistance
Coexistence of preeclampsia and inherited thrombophilia in Turkish pregnant women.
Activated Protein C Resistance
Combination of activated protein C resistance and antibodies to phospholipids in the development of thrombosis.
Activated Protein C Resistance
Combined and sequential use of activated protein C resistance and molecular genetic test for the diagnosis of factor V Leiden: a new laboratory approach.
Activated Protein C Resistance
Combined heterozygous plasminogen deficiency and factor V Leiden defect in the same kindred.
Activated Protein C Resistance
Comparative analysis of "APTT vs RVVT" based activated protein C resistance assay in the diagnosis of Factor V Leiden mutation.
Activated Protein C Resistance
Comparative effects of a contraceptive vaginal ring delivering a nonandrogenic progestin and continuous ethinyl estradiol and a combined oral contraceptive containing levonorgestrel on hemostasis variables.
Activated Protein C Resistance
Comparative study of response to treatment with supraphysiologic doses of B-vitamins in hyperhomocysteinemic hemodialysis patients.
Activated Protein C Resistance
Comparison of a transdermal contraceptive patch vs. oral contraceptives on hemostasis variables.
Activated Protein C Resistance
Comparison of Phenotypic Activated Protein C Resistance Testing With a Genetic Assay for Factor V Leiden.
Activated Protein C Resistance
Comparison of the effects of two low fat diets with different alpha-linolenic:linoleic acid ratios on coagulation and fibrinolysis.
Activated Protein C Resistance
Comparison of three activated protein C resistance tests in the risk assessment of venous thrombosis in non-carriers of the factor V Leiden mutation.
Activated Protein C Resistance
Comprehensive review of the impact of direct oral anticoagulants on thrombophilia diagnostic tests: Practical recommendations for the laboratory.
Activated Protein C Resistance
Congenital thrombophilia associated to obstetric complications.
Activated Protein C Resistance
Contribution of the cystathionine beta-synthase gene (844ins68) polymorphism to the risk of early-onset venous and arterial occlusive disease and of fasting hyperhomocysteinemia.
Activated Protein C Resistance
Correlation between the functional assay for activated protein C resistance and factor V Leiden in the neonate.
Activated Protein C Resistance
Cross-comparison of the genome sequences from human, chimpanzee, Neanderthal and a Denisovan hominin identifies novel potentially compensated mutations.
Activated Protein C Resistance
Cutaneous necrosis in pregnancy secondary to activated protein C resistance in hereditary angioedema.
Activated Protein C Resistance
Cutaneous necrosis revealing the coexistence of an antiphospholipid syndrome with acquired protein S deficiency, factor V Leiden and hyperhomocysteinemia.
Activated Protein C Resistance
Deep venous thrombosis in a preterm newborn of a mother with activated protein C resistance.
Activated Protein C Resistance
Deficiencies of proteins C, S and antithrombin and activated protein C resistance--their involvement in the occurrence of Arterial thromboses.
Activated Protein C Resistance
Detection of a common mutation in factor V gene responsible for resistance to activate protein C causing predisposition to thrombosis.
Activated Protein C Resistance
Detection of factor V Leiden in Thai patients with venous thrombosis.
Activated Protein C Resistance
Detection of the factor VLeiden mutation. Development of a testing algorithm combining a coagulation assay and molecular diagnosis.
Activated Protein C Resistance
Determinants and associations of homocysteine and prothrombotic risk factors in Kuwaiti patients with cerebrovascular accident.
Activated Protein C Resistance
Determinants of acquired activated protein C resistance and D-dimer in breast cancer.
Activated Protein C Resistance
Determination of activated protein C resistance in anticoagulated and lupus positive patients.
Activated Protein C Resistance
Determination of Factor V Leiden Mutation and R2 Polymorphism in Cis Position.
Activated Protein C Resistance
Development and application of an automated chromogenic thrombin generation assay that is sensitive to defects in the protein C pathway.
Activated Protein C Resistance
Diagnosis and clinical characteristics of inherited activated protein C resistance.
Activated Protein C Resistance
Diagnosis of activated protein C resistance (factor V Leiden)
Activated Protein C Resistance
Diagnosis of activated protein C resistance in retinal vein occlusion.
Activated Protein C Resistance
Diagnosis strategies in activated protein C resistance: is genotyping still necessary?
Activated Protein C Resistance
Diagnostic issues in thrombophilia: a laboratory scientist's view.
Activated Protein C Resistance
Diagnostic Testing Approaches for Activated Protein C Resistance and Factor V Leiden: A Comparison of Institutional and National Provider Practices.
Activated Protein C Resistance
Diagnostic testing for coagulopathies in patients with ischemic stroke.
Activated Protein C Resistance
Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families.
Activated Protein C Resistance
Discordance Between Functional Screening and Genetic Confirmatory Diagnostic Tests: A Retrospective Analysis of Activated Protein C Resistance and Factor 5 Leiden Testing Over a 5-Year Period.
Activated Protein C Resistance
Discrimination between normal wildtype and carriers of coagulation factor V Leiden mutation by the activated protein C resistance test in the presence of factor V deficient plasma.
Activated Protein C Resistance
Do placental lesions reflect thrombophilia state in women with adverse pregnancy outcome?
Activated Protein C Resistance
DOAC-Remove abolishes the effect of direct oral anticoagulants on activated protein C resistance testing in real-life venous thromboembolism patients.
Activated Protein C Resistance
Does activated protein C resistance increase the risk of systematic embolism in non rheumatic atrial fibrillation?
Activated Protein C Resistance
Doppler velocimetry and thrombophilic screening at middle trimester of gestation: preliminary data.
Activated Protein C Resistance
Double heterozygosity for Factor V Leiden and Factor V Cambridge mutations associated with low levels of activated protein C resistance in a Spanish thrombophilic family.
Activated Protein C Resistance
Double inherited thrombophilias and adverse pregnancy outcomes: fashion or science?
Activated Protein C Resistance
Dural puncture and activated protein C resistance: risk factors for cerebral venous sinus thrombosis.
Activated Protein C Resistance
Dural sinus thrombosis associated with activated protein C resistance: MR imaging findings and proband identification.
Activated Protein C Resistance
Early cerebral sinovenous thrombosis in a child with acute lymphoblastic leukemia carrying the prothrombin G20210A variant: a case report and review of the literature.
Activated Protein C Resistance
Edoxaban improves atrial fibrillation and thromboembolism through regulation of the Wnt-?-induced PI3K/ATK-activated protein C system.
Activated Protein C Resistance
Effect of dabigatran on a prothrombinase-based assay for detecting activated protein C resistance: an ex vivo and in vitro study in normal subjects and factor V Leiden carriers.
Activated Protein C Resistance
Effect of Freezing Plasma at -20°C for 2 Weeks on Prothrombin Time, Activated Partial Thromboplastin Time, Dilute Russell Viper Venom Time, Activated Protein C Resistance, and d-Dimer Levels.
Activated Protein C Resistance
Effect of gender-affirming hormone use on coagulation profiles in transmen and transwomen.
Activated Protein C Resistance
Effect of platelet phospholipid exposure on activated protein C resistance: implications for thrombophilia screening.
Activated Protein C Resistance
Effect of raloxifene on activated protein C (APC) resistance in postmenopausal women and on APC resistance and homocysteine levels in elderly men: two randomized placebo-controlled studies.
Activated Protein C Resistance
Effect of thrombophylaxis on uterine and fetal circulation in pregnant women with a history of pregnancy complications.
Activated Protein C Resistance
Effect of urinary versus recombinant follicle-stimulating hormone on platelet function and other hemostatic variables in controlled ovarian hyperstimulation.
Activated Protein C Resistance
Effects of (pre-)analytical variables on activated protein C resistance determined via a thrombin generation-based assay.
Activated Protein C Resistance
Effects of anticoagulation protein defect in maternal plasma on spontaneous abortion.
Activated Protein C Resistance
Effects of hormone replacement on hemostasis in spontaneous menopause.
Activated Protein C Resistance
Effects of oral contraceptives on hemostasis and thrombosis.
Activated Protein C Resistance
Effects of Oritavancin on Coagulation Tests in the Clinical Laboratory.
Activated Protein C Resistance
Effects of switching from oral to transdermal or transvaginal contraception on markers of thrombosis.
Activated Protein C Resistance
Effects of the oral, direct factor Xa inhibitor edoxaban on routine coagulation assays, lupus anticoagulant and anti-Xa assays.
Activated Protein C Resistance
Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays.
Activated Protein C Resistance
Effects of vaginally administered high estradiol doses on hormonal pharmacokinetics and hemostasis in postmenopausal women.
Activated Protein C Resistance
Effects on hemostasis after two-year use of low dose combined oral contraceptives with gestodene or levonorgestrel.
Activated Protein C Resistance
Elevated prothrombin and activated protein C resistance in patients with thoracic aortic atheroma.
Activated Protein C Resistance
Emerging risk factors for stroke: Patent foramen ovale, proximal aortic atherosclerosis, antiphospholipid antibodies, and activated protein C resistance.
Activated Protein C Resistance
Emerging technologies and quality assurance in hemostasis: a review of findings from the Royal College of Pathologists of Australasia Quality Assurance Program.
Activated Protein C Resistance
Endogenous or exogenous coagulation factor level and the response to activated protein C.
Activated Protein C Resistance
Endogenous thrombin potential for predicting risk of venous thromboembolism in carriers of factor V Leiden.
Activated Protein C Resistance
Enhanced coagulation activation in preeclampsia: the role of APC resistance, microparticles and other plasma constituents.
Activated Protein C Resistance
Epidemiology of activated protein C resistance and factor v leiden mutation in the mediterranean region.
Activated Protein C Resistance
Epidemiology, risk and prognostic factors in mesenteric venous thrombosis.
Activated Protein C Resistance
Estimates of Within-Subject Biological Variation of Protein C, Antithrombin, Protein S Free, Protein S Activity, and Activated Protein C Resistance in Pregnant Women.
Activated Protein C Resistance
Estimating the cost of redundancy in molecular diagnostics: the case of activated protein C resistance and factor V Leiden.
Activated Protein C Resistance
Estrogens, lipoproteins, and cardiovascular risk factors: an update following the randomized placebo-controlled trials of hormone-replacement therapy.
Activated Protein C Resistance
Ethnic differences in markers of thrombophilia: implications for the investigation of ischemic stroke in multiethnic populations: the South London Ethnicity and Stroke Study.
Activated Protein C Resistance
Etiology and portal vein thrombosis in Budd-Chiari syndrome.
Activated Protein C Resistance
Evaluation of a global screening assay for the investigation of the protein C anticoagulant pathway.
Activated Protein C Resistance
Evaluation of a new chronometric assay for factor V Leiden-dependent APC resistance.
Activated Protein C Resistance
Evaluation of a tissue factor dependent factor V assay to detect factor V Leiden: demonstration of high sensitivity and specificity for a generally applicable assay for activated protein C resistance.
Activated Protein C Resistance
Evaluation of activated protein C resistance in stored plasma.
Activated Protein C Resistance
Evaluation of natural coagulation inhibitor levels in various hypertensive states of pregnancy.
Activated Protein C Resistance
Evaluation of plasma activity level of anticoagulant proteins in patients with acute lymphoblastic leukemia in Shafa hospital Ahwaz 2010.
Activated Protein C Resistance
Evaluation of risk factors for thrombophilia in patients with cerebral venous thrombosis.
Activated Protein C Resistance
Evaluation of smoking as a risk factor for activated protein C resistance during pregnancy.
Activated Protein C Resistance
Evaluation of the roles of the Leiden V mutation and ACE I/D polymorphism in subtypes of ischaemic stroke.
Activated Protein C Resistance
Evidence against heterozygous coagulation factor V 1691 G-->A mutation with resistance to activated protein C being a risk factor for coronary artery disease and myocardial infarction.
Activated Protein C Resistance
Evolving methods for single nucleotide polymorphism detection: Factor V Leiden mutation detection.
Activated Protein C Resistance
Exercise-induced activation of coagulation in subjects with activated protein C resistance.
Activated Protein C Resistance
Exogenous hormones, the risk of venous thromboembolism, and activated protein C resistance.
Activated Protein C Resistance
Extensive venous and arterial thrombosis associated with an inhibitor to activated protein C.
Activated Protein C Resistance
External quality assessment and the laboratory diagnosis of thrombophilia.
Activated Protein C Resistance
Factor V (His 1299 Arg) in young Turkish patients with cerebral infarct.
Activated Protein C Resistance
Factor V A4070G (His1299Arg) mutation in Turkish pediatric patients with thrombosis.
Activated Protein C Resistance
Factor V Arg306 --> Gly mutation is not associated with activated protein C resistance and is rare in Taiwanese Chinese.
Activated Protein C Resistance
Factor V Cambridge mutation and activated protein C resistance assays.
Activated Protein C Resistance
Factor V Cambridge: a new mutation (Arg306-->Thr) associated with resistance to activated protein C.
Activated Protein C Resistance
Factor V gene (1691A and 4070G) and prothrombin gene 20210A mutations in patients with Behçet's disease.
Activated Protein C Resistance
Factor V gene mutation is a risk factor for cerebral venous thrombosis.
Activated Protein C Resistance
Factor V I359T: a novel mutation associated with thrombosis and resistance to activated protein C.
Activated Protein C Resistance
Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency.
Activated Protein C Resistance
Factor V Leiden and acquired activated protein C resistance among 1000 women with recurrent miscarriage.
Activated Protein C Resistance
Factor V Leiden and post thromboembolic pulmonary hypertension.
Activated Protein C Resistance
Factor V Leiden in absence of activated protein C resistance after orthotopic liver transplantation in a patient without thrombosis but with familial thrombophilia.
Activated Protein C Resistance
Factor V Leiden in Greek thrombophilic patients: relationship with activated protein C resistance test and levels of thrombin-antithrombin complex and prothrombin fragment 1 + 2.
Activated Protein C Resistance
Factor V Leiden is associated with repeated and recurrent unexplained fetal losses.
Activated Protein C Resistance
Factor V Leiden mutation in a case with ischemic stroke: which relationship? A case report.
Activated Protein C Resistance
Factor V Leiden mutation is not increased in patients with inflammatory bowel disease.
Activated Protein C Resistance
Factor V Leiden mutation: an unrecognized cause of hemiplegic cerebral palsy, neonatal stroke, and placental thrombosis.
Activated Protein C Resistance
Factor V Leiden prevalence in venous thromboembolism patients.
Activated Protein C Resistance
Factor V Leiden, activated protein C resistance, and retinal vein occlusion.
Activated Protein C Resistance
Factor V Leiden: is it the chief contributor to activated protein C resistance in Asian-Indian patients with deep vein thrombosis?
Activated Protein C Resistance
Factor V mutations in Iranian patients with activated protein C resistance and venous thrombosis.
Activated Protein C Resistance
Factor V variants, activated protein C resistance and venous thromboembolism.
Activated Protein C Resistance
Factor V1691 G-A, prothrombin 20210 G-A, and methylenetetrahydrofolate reductase 677 C-T variants in Turkish children with cerebral infarct.
Activated Protein C Resistance
Factor XII deficiency is strongly associated with primary recurrent abortions.
Activated Protein C Resistance
False positive activated protein C resistance test due to anti-phospholipid antibodies is corrected by platelet extract.
Activated Protein C Resistance
Familial antithrombin III deficiency in a Malay patient with massive thrombosis.
Activated Protein C Resistance
Familial coagulation-inhibiting and fibrinolytic protein deficiencies in juvenile transient ischaemic attacks.
Activated Protein C Resistance
Familial coexistence of primary antiphospholipid syndrome and factor VLeiden.
Activated Protein C Resistance
Familial thrombophilia and activated protein C resistance: thrombotic risk in pregnancy?
Activated Protein C Resistance
Fatal pulmonary artery thrombosis in a patient with Behçet's disease, activated protein C resistance and hyperhomocystinemia.
Activated Protein C Resistance
Fetal stroke and congenital parvovirus B19 infection complicated by activated protein C resistance.
Activated Protein C Resistance
First-trimester repeated abortion is not associated with activated protein C resistance.
Activated Protein C Resistance
Flow cytometric analysis of autonomous growth of erythroid precursors in liquid culture detects occult polycythemia vera in the Budd-Chiari syndrome.
Activated Protein C Resistance
Functional activated protein C resistance assays: correlation with factor V DNA analysis is better with RVVT-than APTT-based assays.
Activated Protein C Resistance
Functional diagnosis of activated protein C resistance in patients with antiphospholipid antibodies.
Activated Protein C Resistance
Further evidence that activated protein C resistance affects protein C coagulant activity assays.
Activated Protein C Resistance
Further evidence that activated protein C resistance can be misdiagnosed as inherited functional protein S deficiency.
Activated Protein C Resistance
Genetic abnormalities of the protein C system: shared risk factors in young adults with migraine with aura and with ischemic stroke?
Activated Protein C Resistance
Genetic analysis of factor V Leiden in a family with history of thrombosis and venous leg ulcers.
Activated Protein C Resistance
Genetic determinants of hemostasis phenotypes in Spanish families.
Activated Protein C Resistance
Genetic polymorphisms on the factor V gene in women with recurrent miscarriage and acquired APCR.
Activated Protein C Resistance
Haemostatic and metabolic abnormalities in women with unexplained recurrent abortion.
Activated Protein C Resistance
Haemostatic changes and acquired activated protein C resistance in normal pregnancy.
Activated Protein C Resistance
Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17?-estradiol, compared with those of levonorgestrel/ethinyl estradiol. A double-blind, randomised study.
Activated Protein C Resistance
Hemiretinal Artery Occlusion in an 11-Year-Old Child with Dextrocardia.
Activated Protein C Resistance
Hemostatic alterations in patients with acute, unilateral vestibular paresis.
Activated Protein C Resistance
Heparin induced thrombocytopenia in a patient with factor V Leiden following cardiac surgery.
Activated Protein C Resistance
Heparin-induced thrombocytopenia and fatal thrombosis in a patient with activated protein C resistance.
Activated Protein C Resistance
Herbal Fufang Xian Ling Gu Bao prevents corticosteroid-induced osteonecrosis of the femoral head-A first multicentre, randomised, double-blind, placebo-controlled clinical trial.
Activated Protein C Resistance
Hereditary angioedema associated with heterozygous factor V Leiden mutation in a patient with Purpura fulminans.
Activated Protein C Resistance
Heterogeneity of activated protein C resistance phenotype in subjects with compound heterozygosity for HR2 haplotype and FV Leiden mutation (R506Q) in factor V gene.
Activated Protein C Resistance
High coagulation factor VIII and von Willebrand factor in patients with lymphoma and leukemia.
Activated Protein C Resistance
High prevalence of a mutation in the factor V gene within the U.K. population: relationship to activated protein C resistance and familial thrombosis.
Activated Protein C Resistance
High prevalence of activated protein C resistance and factor V Leiden mutation in an Arab population and patients with venous thrombosis in Kuwait.
Activated Protein C Resistance
High prevalence of activated protein C resistance due to factor V leiden mutation in cases of intrauterine fetal death.
Activated Protein C Resistance
High prevalence of activated protein C resistance in patients with systemic sclerosis.
Activated Protein C Resistance
High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia.
Activated Protein C Resistance
High prevalence of prothrombotic abnormalities in multifocal osteonecrosis: description of a series and review of the literature.
Activated Protein C Resistance
High prevalence of thrombophilia among young patients with myocardial infarction and few conventional risk factors.
Activated Protein C Resistance
Homocysteine levels, haemostatic risk factors and patency rates after endovascular treatment of the above-knee femoro-popliteal artery.
Activated Protein C Resistance
Homocysteine levels, haemostatic risk factors and patency rates after endovascular treatment of the common iliac arteries.
Activated Protein C Resistance
Homocysteine levels, haemostatic risk factors and restenosis after carotid thrombendarterectomy.
Activated Protein C Resistance
Homozygosity for factor V Leiden leads to enhanced thrombosis and atherosclerosis in mice.
Activated Protein C Resistance
Homozygosity for the HR2 Haplotype: Is It a Risk Factor for Thrombosis?
Activated Protein C Resistance
Homozygous patients with APC resistance may remain paucisymptomatic or asymptomatic during oral contraception.
Activated Protein C Resistance
Hormone replacement therapy: prothrombotic vs. protective effects.
Activated Protein C Resistance
How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review.
Activated Protein C Resistance
Hypercoagulability Evaluation in Antiphospholipid Syndrome without Anticoagulation Treatment with Thrombin Generation Assay: A Preliminary Study.
Activated Protein C Resistance
Hypercoagulability test strategies in the protein C and protein S pathway.
Activated Protein C Resistance
Hypercoagulability: interaction between inflammation and coagulation in familial Mediterranean fever.
Activated Protein C Resistance
Hypercoagulable state and methylenetetrahydrofolate reductase (MTHFR) C677T mutation in patients with beta-thalassemia major in Kuwait.
Activated Protein C Resistance
Hypercoagulable state in patients with advanced gastrointestinal cancer: evidence for an acquired resistance to activated protein C.
Activated Protein C Resistance
Hypercoagulable states in patients with hepatocellular carcinoma.
Activated Protein C Resistance
Hypercoagulable states in renal transplant candidates: impact of anticoagulation upon incidence of renal allograft thrombosis.
Activated Protein C Resistance
Hyperhomocyst(e)inemia and a common methylenetetrahydrofolate reductase mutation (Ala223Val MTHFR) in patients with inherited thrombophilic coagulation defects.
Activated Protein C Resistance
Hyperhomocysteinaemia and activated protein C resistance in Behçet's disease.
Activated Protein C Resistance
Hyperhomocysteinaemia and protein S deficiency in complicated pregnancies.
Activated Protein C Resistance
Hyperhomocysteinemia and hypercoagulable state in carotid plaque evolution. Novel risk factors or coincidental risk predictors?
Activated Protein C Resistance
Hyperhomocysteinemia and other thrombotic risk factors in women with placental vasculopathy.
Activated Protein C Resistance
Identification and functional characterization of a novel F5 mutation (Ala512Val, FVB onn ) associated with activated protein C resistance.
Activated Protein C Resistance
Idiopathic intracranial hypertension and anticardiolipin antibodies.
Activated Protein C Resistance
Impact of activated protein C resistance on general vascular surgical patients.
Activated Protein C Resistance
Implementation of a cost-effective unlabeled probe high-resolution melt assay for genotyping of factor v leiden.
Activated Protein C Resistance
Importance of levonorgestrel dose in oral contraceptives for effects on coagulation.
Activated Protein C Resistance
Improved distinction of factor V wild-type and factor V Leiden using a novel prothrombin-based activated protein C resistance assay.
Activated Protein C Resistance
Incidence and clinical manifestations of activated protein C resistance and factor V Leiden in young patients with venous thromboembolic disease in Spain.
Activated Protein C Resistance
Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy.
Activated Protein C Resistance
Incidence of activated protein C resistance caused by the ARG 506 GLN mutation in factor V in 113 unrelated symptomatic protein C-deficient patients. The French Network on the behalf of INSERM.
Activated Protein C Resistance
Incidence of deep venous thrombosis in patients undergoing obesity surgery.
Activated Protein C Resistance
Incidence of thrombophilia and venous thrombosis in transsexuals under cross-sex hormone therapy.
Activated Protein C Resistance
Incidental discovery of a dural arteriovenous fistula in a patient with activated protein C resistance.
Activated Protein C Resistance
Increased acquired activated protein C resistance in unselected patients with hematological malignancies.
Activated Protein C Resistance
Increased incidence of venous thrombosis in patients with shortened activated partial thromboplastin times and low ratios for activated protein C resistance.
Activated Protein C Resistance
Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism.
Activated Protein C Resistance
Increased resistance to activated protein C and factor V Leiden in recurrent abortions. Review of other hypercoagulability factors.
Activated Protein C Resistance
Increased Thrombophilic Tendency in Pediatric Cystic Fibrosis Patients.
Activated Protein C Resistance
Influence of inherited and acquired thrombophilic defects on the clinical manifestations of mixed cryoglobulinaemia.
Activated Protein C Resistance
Influence of plasma platelets on activated protein C resistance assay.
Activated Protein C Resistance
Influence of storage conditions on activated protein C resistance assay.
Activated Protein C Resistance
Inherited activated protein C resistance in a patient with familial primary antiphospholipid syndrome.
Activated Protein C Resistance
Inherited and acquired thrombophilia: pregnancy outcome and treatment.
Activated Protein C Resistance
Inherited prothrombotic states and ischaemic stroke in childhood.
Activated Protein C Resistance
Inherited thrombophilia in unprovoked venous thromboembolism: Is non 'O' blood group an additional culprit in Indian patients?
Activated Protein C Resistance
Inherited thrombophilia is associated with deep vein thrombosis in a Colombian population.
Activated Protein C Resistance
Insight into the hypercoagulable state of high-risk thrombotic APS patients: Contribution of a?2GPI and aPS/PT antibodies.
Activated Protein C Resistance
Instrument effect on the activated protein C resistance plasma assay performed by a commercial kit.
Activated Protein C Resistance
Intercellular adhesion molecule-1 (ICAM-1) expression is upregulated by thrombin in human monocytes and THP-1 cells in vitro and in pregnant subjects in vivo.
Activated Protein C Resistance
Internal jugular vein thrombosis in patients with ovarian hyperstimulation syndrome.
Activated Protein C Resistance
Intracardiac thrombus causing systemic embolism in a child with idiopathic ventricular tachycardia and heterozygous activated protein C resistance.
Activated Protein C Resistance
Intraindividual consistency of the activated protein C resistance phenotype.
Activated Protein C Resistance
Investigation of inherited thrombophilias in patients with pulmonary embolism.
Activated Protein C Resistance
Iron-deficiency anaemia in childhood: a risk factor for severe venous thrombosis?
Activated Protein C Resistance
Is acquired activated protein C resistance a cardiovascular risk?
Activated Protein C Resistance
Is activated protein C resistance following orthotopic liver transplantation a risk factor for venous thrombosis?
Activated Protein C Resistance
Is elevated level of soluble endothelial protein C receptor a new risk factor for retinal vein occlusion?
Activated Protein C Resistance
Is lipoprotein(a) regulating prostaglandin I2-synthesis stimulating plasma factor?
Activated Protein C Resistance
Ischemic colitis and acquired resistance to activated protein C in a woman using oral contraceptives.
Activated Protein C Resistance
Ischemic colitis revisited: a prospective study identifying hypercoagulability as a risk factor.
Activated Protein C Resistance
Ischemic stroke associated with activated protein C resistance and aortic valvular papillary fibroelastoma.
Activated Protein C Resistance
Ischemic stroke in young patients with activated protein C resistance. A report of three cases belonging to three different kindreds.
Activated Protein C Resistance
Isolated cortical vein thrombosis and activated protein C resistance.
Activated Protein C Resistance
Isolation and characterization of an antifactor V antibody causing activated protein C resistance from a patient with severe thrombotic manifestations.
Activated Protein C Resistance
Issues concerning the laboratory investigation of inherited thrombophilia.
Activated Protein C Resistance
Juvenile temporal arteritis and activated protein C resistance.
Activated Protein C Resistance
Laboratory assessment of Activated Protein C Resistance/Factor V-Leiden and performance characteristics of a new quantitative assay.
Activated Protein C Resistance
Laboratory evaluation of hypercoagulable states in patients with central retinal vein occlusion who are less than 56 years of age.
Activated Protein C Resistance
LABORATORY EVALUATION OF HYPERCOAGULABLE STATES IN PATIENTS WITH CENTRAL RETINAL VEIN OCCLUSION WHO ARE LESS THAN 56 YEARS OF AGE.
Activated Protein C Resistance
Laboratory investigation of thrombophilia: the good, the bad, and the ugly.
Activated Protein C Resistance
Laboratory screening of thrombophilia. Evaluation of the diagnostic efficacy of a global test to detect congenital deficiencies of the protein C anticoagulant pathway.
Activated Protein C Resistance
Laboratory Testing for Activated Protein C Resistance (APCR).
Activated Protein C Resistance
Laboratory testing for activated protein C resistance: rivaroxaban induced interference and a comparative evaluation of andexanet alfa and DOAC Stop to neutralise interference.
Activated Protein C Resistance
Lack of activated protein C resistance in healthy Hong Kong Chinese blood donors--correlation with absence of Arg506-Gln mutation of factor V gene.
Activated Protein C Resistance
Lack of association between inherited thrombophilic risk factors and idiopathic sudden sensorineural hearing loss in Italian patients.
Activated Protein C Resistance
Lack of Association between Recurrent Pregnancy Loss and Inherited Thrombophilia in a Group of Colombian Patients.
Activated Protein C Resistance
Lack of rivaroxaban influence on a prothrombinase-based assay for the detection of activated C protein resistance: an Italian ex vivo and in vitro study in normal subjects and factor V Leiden carriers.
Activated Protein C Resistance
Learning from peer assessment: the role of the external quality assurance multilaboratory thrombophilia test process.
Activated Protein C Resistance
Left ventricular intracardiac thrombus in a patient with Behçet disease successfully treated with immunosuppressive agents without anticoagulation: a case report and review of the literature.
Activated Protein C Resistance
Lemierre syndrome variant: Staphylococcus aureus associated with thrombosis of both the right internal jugular vein and the splenic vein after the exploration of a river cave.
Activated Protein C Resistance
Life threatening pulmonary embolus in a factor V Leiden carrier on oral contraceptives: a case report.
Activated Protein C Resistance
Livedoid vasculopathy in a patient with factor V mutation (Leiden).
Activated Protein C Resistance
Liver transplant acquired activated protein C resistance presenting with deep vein thrombosis 4 years after transplant.
Activated Protein C Resistance
Liver transplantation for acute Budd-Chiari syndrome in identical twin sisters with Factor V leiden mutation.
Activated Protein C Resistance
Longitudinal evaluation of activated protein C resistance among normal pregnancies of Hispanic women.
Activated Protein C Resistance
Low birthweight in relation to placental abruption and maternal thrombophilia status.
Activated Protein C Resistance
Low prevalence of activated protein C resistance and coagulation factor V Arg506 to Gln mutation among Japanese patients with various forms of thrombosis, and normal individuals.
Activated Protein C Resistance
Low prevalence of activated protein C resistance and coagulation factor V Arg506 to Gln mutation among Korean patients with deep vein thrombosis.
Activated Protein C Resistance
Low prevalence of factor V:Q506 in 41 patients with isolated pulmonary embolism.
Activated Protein C Resistance
Low-Molecular-Weight Heparin Added to Aspirin in the Prevention of Recurrent Early-Onset Preeclampsia in women with Inheritable Thrombophilia: the FRUIT-RCT.
Activated Protein C Resistance
Lupus Anticoagulant Interference in Activated Protein C Resistance Testing: In Vitro Phenomenon or In Vivo Pathophysiologic Effect?
Activated Protein C Resistance
Mali acroangiodermatitis in homozygous activated protein C resistance.
Activated Protein C Resistance
Maternal thrombophilias are not associated with early pregnancy loss.
Activated Protein C Resistance
Maximising the diagnostic potential of APTT-based screening assays for activated protein C resistance.
Activated Protein C Resistance
Measurement of activated protein C resistance during menstrual cycle in women with and without the Leiden mutation.
Activated Protein C Resistance
Mechanical prosthetic heart valve thrombosis despite optimal anticoagulation in a patient with congenital thrombophilia (factor V Leiden).
Activated Protein C Resistance
Mechanisms for acquired activated protein C resistance in cancer patients.
Activated Protein C Resistance
Mechanisms of thrombosis in paraproteinemias: the effects of immunomodulatory drugs.
Activated Protein C Resistance
Membrane autoantibodies in systemic lupus erythematosus: a case of autoimmune hemolytic anemia, antiphospholipid antibodies, and transient acquired activated protein C resistance.
Activated Protein C Resistance
Membranous glomerulonephritis in a patient with inherited activated protein C resistance.
Activated Protein C Resistance
Mesenteric arterial thrombosis due to activated protein C resistance (factor V Leiden)
Activated Protein C Resistance
Mesenteric artery occlusion secondary to activated protein C resistance: a life-threatening combination.
Activated Protein C Resistance
Mesenteric vein thrombosis associated with primary cytomegalovirus infection: a case report.
Activated Protein C Resistance
Mesenteric vein thrombosis due to factor V Leiden gene mutation.
Activated Protein C Resistance
Minor allele of the factor V K858R variant protects from venous thrombosis only in non-carriers of factor V Leiden mutation.
Activated Protein C Resistance
Modulation of systemic hemostatic parameters by enoxaparin during gestation in women with thrombophilia and pregnancy loss.
Activated Protein C Resistance
Molecular biology and pathophysiology of APC resistance: current insights and clinical implications.
Activated Protein C Resistance
Molecular characterization of a type I quantitative factor V deficiency in a thrombosis patient that is "pseudo homozygous" for activated protein C resistance.
Activated Protein C Resistance
Molecular mechanisms of activated protein C resistance. Properties of factor V isolated from an individual with homozygosity for the Arg506 to Gln mutation in the factor V gene.
Activated Protein C Resistance
Multi-chamber intracardiac thrombi associated with activated protein C resistance in a patient with dilated cardiomyopathy.
Activated Protein C Resistance
Multicenter evaluation of a kit for activated protein C resistance on various coagulation instruments using plasmas from healthy individuals. The APC Resistance Study Group.
Activated Protein C Resistance
Multilaboratory testing in thrombophilia through the United Kingdom National External Quality Assessment Scheme (Blood Coagulation) Quality Assurance Program.
Activated Protein C Resistance
Multilaboratory testing of thrombophilia: current and past practice in Australasia as assessed through the Royal College of Pathologists of Australasia Quality Assurance Program for Hematology.
Activated Protein C Resistance
Multiple hemostatic abnormalities in young adults with activated protein C resistance and cerebral ischemia.
Activated Protein C Resistance
Mutation at either Arg336 or Arg562 in factor VIII is insufficient for complete resistance to activated protein C (APC)-mediated inactivation: implications for the APC resistance test.
Activated Protein C Resistance
Mutation screening for thrombophilia: two cases with factor V Cambridge without activated protein C resistance.
Activated Protein C Resistance
Mutations and polymorphisms in genes affecting haemostasis components in children with thromboembolic events.
Activated Protein C Resistance
Mutations and Polymorphisms in Genes Affecting Hemostasis Proteins and Homocysteine Metabolism in Children with Arterial Ischemic Stroke.
Activated Protein C Resistance
Mycoplasma pneumonia and pulmonary embolism in a child due to acquired prothrombotic factors.
Activated Protein C Resistance
Myocardial infarction and normal coronary arteries: the experience of the cardiology department of sfax, Tunisia.
Activated Protein C Resistance
Myocardial infarction, Arg 506 to Gln factor V mutation, and activated protein C resistance.
Activated Protein C Resistance
Natural anticoagulant protein levels in Turkish patients with inflammatory bowel disease.
Activated Protein C Resistance
Natural coagulation inhibitory proteins and activated protein C resistance in Turkish patients with inflammatory bowel disease.
Activated Protein C Resistance
Neonatal purpura fulminans in association with factor V R506Q mutation.
Activated Protein C Resistance
Neurological deficit after cerebral angiography and activated protein C resistance.
Activated Protein C Resistance
No association between thrombosis and factor V gene polymorphisms in Chinese Han population.
Activated Protein C Resistance
No correlation between activated protein C resistance and free flap failures in 100 consecutive patients.
Activated Protein C Resistance
Normalization does not improve between-laboratory agreement but may improve specificity of some assays for activated protein C resistance.
Activated Protein C Resistance
Normalization of haemoglobin concentration with recombinant erythropoietin has minimal effect on blood haemostasis.
Activated Protein C Resistance
Obstetric implications of activated protein C resistance and factor V Leiden mutation.
Activated Protein C Resistance
Oral Contraceptives and Venous Thromboembolism: Focus on Testing that May Enable Prediction and Assessment of the Risk.
Activated Protein C Resistance
Paediatric thrombo-embolism: the influence of non-genetic factors and the role of activated protein C resistance and protein C deficiency.
Activated Protein C Resistance
Performance of a novel test to quantify activated protein C resistance in women with a history of pre-eclampsia.
Activated Protein C Resistance
Peripheral retinal neovascularization and retinal vascular occlusion associated with activated protein C resistance.
Activated Protein C Resistance
Phenotype and genotype expression in pseudohomozygous factor VLEIDEN : the need for phenotype analysis.
Activated Protein C Resistance
Phenotypic APC resistance as a marker of hypercoagulability in primitive cerebral lymphoma.
Activated Protein C Resistance
Phenotypic correction of activated protein C resistance following orthotopic liver transplantation.
Activated Protein C Resistance
Phenotypic homozygous activated protein C resistance associated with compound heterozygosity for Arg506Gln (factor V Leiden) and His1299Arg substitutions in factor V.
Activated Protein C Resistance
Phenprocoumon-induced hepatitis delaying precise diagnosis in a thrombophilic patient with activated protein C resistance due to factor V R506Q mutation.
Activated Protein C Resistance
Phlegmasia cerulea dolens in a teenage boy found to have Factor V Leiden.
Activated Protein C Resistance
Physical activity and hemostatic and inflammatory variables in elderly men.
Activated Protein C Resistance
Physiological anticoagulants and activated protein C resistance in childhood stroke.
Activated Protein C Resistance
Pitfalls of protein C assays in patients with activated protein C resistance.
Activated Protein C Resistance
Placental prothrombin mRNA levels in APC resistance (APCR) women with increased placental fibrin deposition.
Activated Protein C Resistance
Placental thrombosis and second trimester miscarriage in association with activated protein C resistance.
Activated Protein C Resistance
Plasma homocysteine and hematological factors in patients with venous thromboembolic diseases in Kuwait.
Activated Protein C Resistance
Plasma homocysteine concentration is not associated with activated protein C resistance in patients investigated for hypercoagulability.
Activated Protein C Resistance
Plasma resistance to activated protein C regulates the activation of coagulation induced by thrombolysis in patients with ischaemic heart disease.
Activated Protein C Resistance
Plasma resistance to activated protein C: an important link between venous thromboembolism and combined oral contraceptives--a short review.
Activated Protein C Resistance
Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden.
Activated Protein C Resistance
Population differences in the frequency of the factor V Leiden variant among people with clinically symptomatic protein C deficiency.
Activated Protein C Resistance
Porcine factor V: cDNA cloning, gene mapping, three-dimensional protein modeling of membrane binding sites and comparative anatomy of domains.
Activated Protein C Resistance
Portal Thrombosis in Cirrhosis: Role of Thrombophilic Disorders.
Activated Protein C Resistance
Postmortem diagnosis of Factor V Leiden from paraffin wax embedded tissue.
Activated Protein C Resistance
Postnatal screening for thrombophilia in women with severe pregnancy complications.
Activated Protein C Resistance
Postpartum cerebral venous thrombosis, congenital protein C deficiency, and activated protein C resistance due to heterozygous factor V Leiden mutation.
Activated Protein C Resistance
Postpartum seizures after epidural analgesia: a patient with a mutation of the factor V Leiden and prothrombin gene.
Activated Protein C Resistance
Practical applications of snake venom toxins in haemostasis.
Activated Protein C Resistance
Prediction of ischemic stroke in young Indians: is thrombophilia profiling a way out?
Activated Protein C Resistance
Predictors of left ventricular thrombus formation in patients with anterior myocardial infarction: role of activated protein C resistance.
Activated Protein C Resistance
Predictors of left ventricular thrombus formation in patients with dilated cardiomyopathy: role of activated protein C resistance.
Activated Protein C Resistance
Preeclampsia is associated with a reduced response to activated protein C.
Activated Protein C Resistance
Pregnancy associated coagulopathies in selected community hospitals in Southwest Nigeria.
Activated Protein C Resistance
Prenatal stroke in a neonate heterozygous for factor V Leiden mutation.
Activated Protein C Resistance
Presumed pre- or perinatal arterial ischemic stroke: risk factors and outcomes.
Activated Protein C Resistance
Prethrombotic disorders in children with arterial ischemic stroke and sinovenous thrombosis.
Activated Protein C Resistance
Prevalence and outcome of activated protein C resistance in patients after peripheral arterial bypass grafts.
Activated Protein C Resistance
Prevalence and patient profile in activated protein C resistance.
Activated Protein C Resistance
Prevalence and role of antithrombin III, protein C and protein S deficiencies and activated protein C resistance in Kosovo women with recurrent pregnancy loss during the first trimester of pregnancy.
Activated Protein C Resistance
Prevalence of activated protein C resistance (Factor V Leiden) in Lagos, Nigeria.
Activated Protein C Resistance
Prevalence of activated protein C resistance among women with recurrent miscarriage.
Activated Protein C Resistance
Prevalence of activated protein C resistance and analysis of clinical profile in thromboembolic patients. A Belgian prospective study.
Activated Protein C Resistance
Prevalence of activated protein C resistance in acute myocardial infarction in Japan.
Activated Protein C Resistance
Prevalence of activated protein C resistance in the Chinese population.
Activated Protein C Resistance
Prevalence of common thrombophilia markers and risk factors in Indian patients with primary venous thrombosis.
Activated Protein C Resistance
Prevalence of Factor V Genetic Variants Associated With Indian APCR Contributing to Thrombotic Risk.
Activated Protein C Resistance
Prevalence of factor V Leiden (APCR) and other inherited thrombophilias in young patients with myocardial infarction and normal coronary arteries.
Activated Protein C Resistance
Prevalence of factor V Leiden and activated protein C resistance in central retinal vein occlusion.
Activated Protein C Resistance
Prevalence of factor V Leiden mutation and other hereditary thrombophilic factors in Egyptian children with portal vein thrombosis: results of a single-center case-control study.
Activated Protein C Resistance
Prevalence of hyperhomocysteinaemia, activated protein C resistance and prothrombin gene mutation in inflammatory bowel disease.
Activated Protein C Resistance
Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease.
Activated Protein C Resistance
Prevalence of phenotypic activated protein C resistance (APCR) in venous thromboembolic patients.
Activated Protein C Resistance
Prevalence of the Factor V E666D Mutation and Its Correlation With Activated Protein C Resistance in the Chinese Population.
Activated Protein C Resistance
Prevalence of the Factor V Leiden Mutation Arg534Gln in Western Region of Saudi Arabia: Functional Alteration and Association Study With Different Populations.
Activated Protein C Resistance
Prevalence of the factor VLeiden mutation among autopsy patients with pulmonary thromboembolic disease using an improved method for factor VLeiden detection.
Activated Protein C Resistance
Primary antiphospholipid syndrome is not associated with activated protein C resistance caused by factor V Arg 506 -->Gln mutation.
Activated Protein C Resistance
Primary Budd-Chiari syndrome in a 3-year-old boy with homozygous factor V Leiden G1691A mutation.
Activated Protein C Resistance
Primary pulmonary artery sarcoma resembling chronic thromboembolic pulmonary disease.
Activated Protein C Resistance
Primary recurrent miscarriages: anti-beta2-glycoprotein I IgG antibodies induce an acquired activated protein C resistance that can be detected by the modified activated protein C resistance test.
Activated Protein C Resistance
Primary thrombophilia in Mexico III: A prospective study of the sticky platelet syndrome.
Activated Protein C Resistance
Primary thrombophilia in Mexico IV: frequency of the Leiden, Cambridge, Hong Kong, Liverpool and HR2 haplotype polymorphisms in the factor V gene of a group of thrombophilic Mexican Mestizo patients.
Activated Protein C Resistance
Primary Thrombophilia in México XI: Activated Protein C Resistance Phenotypes are Multifactorial.
Activated Protein C Resistance
Primary thrombophilia in Mexico. II. Factor V G1691A (Leiden), prothrombin G20210A, and methylenetetrahydrofolate reductase C677T polymorphism in thrombophilic Mexican mestizos.
Activated Protein C Resistance
Primary thrombophilia in Mexico. V. A comprehensive prospective study indicates that most cases are multifactorial.
Activated Protein C Resistance
Primary thrombophilia in Mexico: a single tertiary referral hospital experience.
Activated Protein C Resistance
Pro CR global: an effective screening test for thrombophilia.
Activated Protein C Resistance
Profile of prothrombotic factors in Indian children with ischemic stroke.
Activated Protein C Resistance
Proof of concept of a new scale for the harmonization and the standardization of the ETP-based APC resistance.
Activated Protein C Resistance
Protein C system defects in Indian children with thrombosis.
Activated Protein C Resistance
Protein S deficiency, activated protein C resistance and sticky platelet syndrome in a young woman with bilateral strokes.
Activated Protein C Resistance
Protein S levels modulate the activated protein C resistance phenotype induced by elevated prothrombin levels.
Activated Protein C Resistance
Protein Z levels and central retinal vein or artery occlusion.
Activated Protein C Resistance
Prothrombotic disorders in infants and children with cerebral thromboembolism.
Activated Protein C Resistance
Prothrombotic factors and the risk of acute onset non-cardioembolic stroke in young Asian Indians.
Activated Protein C Resistance
Prothrombotic Factors Have Significant Association with Arterial and Venous Strokes in Indian Tamilians.
Activated Protein C Resistance
Pseudo-homozygous activated protein C resistance due to coinheritance of heterozygous factor V Leiden mutation and type I factor V deficiency. Variable expression when analyzed by different activated protein C resistance functional assays.
Activated Protein C Resistance
Pseudo-protein S deficiency due to activated protein C resistance.
Activated Protein C Resistance
Pseudohomozygosity for activated protein C resistance is a risk factor for venous thrombosis.
Activated Protein C Resistance
Public health approach to activated protein C resistance assay.
Activated Protein C Resistance
Pulmonary embolism and deep venous thrombosis during pregnancy or oral contraceptive use: prevalence of factor V Leiden.
Activated Protein C Resistance
Purpura fulminans in a child with combined heterozygous prothrombin G20210A and factor V Leiden mutations.
Activated Protein C Resistance
Quality standards for sample collection in coagulation testing.
Activated Protein C Resistance
Raised factor VIII is associated with coronary thrombotic events.
Activated Protein C Resistance
Reactions to awareness of activated protein C resistance carriership: a descriptive study of 270 women.
Activated Protein C Resistance
Real-time polymerase chain reaction with fluorescent hybridization probes for the detection of prevalent mutations causing common thrombophilic and iron overload phenotypes.
Activated Protein C Resistance
Recurrent thrombosis after carotid endarterectomy secondary to activated protein C resistance and essential thrombocytosis: A case report.
Activated Protein C Resistance
Recurrent thrombosis in a patient with pseudohomozygous activated protein C resistance and homozygosity for MTHFR gene polymorphism C677T.
Activated Protein C Resistance
Recurrent thrombosis of the superior vena cava associated with activated protein C resistance: imaging findings.
Activated Protein C Resistance
Recurrent thrombotic occlusion of a transjugular intrahepatic portosystemic stent-shunt due to activated protein C resistance.
Activated Protein C Resistance
Recurrent venous thrombosis despite correction of activated protein C resistance following orthotopic liver transplantation.
Activated Protein C Resistance
Reduced Protein C Global Assay Levels in Infertile Women with in vitro Fertilization Failure: A Pilot Study.
Activated Protein C Resistance
Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis.
Activated Protein C Resistance
Relevance of Inherited Thrombophilia Screening in Adult Kidney Transplant Recipients.
Activated Protein C Resistance
Renal vein thrombosis in a newborn with prothrombotic genetic risk factors.
Activated Protein C Resistance
Resistance to activated protein C (APCR) in children with acute lymphoblastic leukaemia--the need for a prospective multicentre study.
Activated Protein C Resistance
Resistance to activated protein C and Arg 506 Gln factor V mutation are uncommon in eastern Asian populations.
Activated Protein C Resistance
Resistance to activated protein C and ischemic arterial disease in a young man.
Activated Protein C Resistance
Resistance to activated protein C and low levels of free protein S in Greek patients with inflammatory bowel disease.
Activated Protein C Resistance
Resistance to activated protein C and low levels of protein S activity in nine thrombophilic families: a correct diagnosis.
Activated Protein C Resistance
Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives.
Activated Protein C Resistance
Resistance to activated protein C caused by a factor V gene mutation.
Activated Protein C Resistance
Resistance to activated protein C in nine thrombophilic families: interference in a protein S functional assay.
Activated Protein C Resistance
Resistance to activated protein C: a major cause of inherited thrombophilia.
Activated Protein C Resistance
Resistance to activated protein C: arterial thrombosis associated with autoimmune features.
Activated Protein C Resistance
Resistance to activated protein C: role in venous and arterial thrombosis.
Activated Protein C Resistance
Resistance to APC and SHBG levels during use of a four-phasic oral contraceptive containing dienogest and estradiol valerate: a randomized controlled trial.
Activated Protein C Resistance
Retinal arterial occlusion in a child with factor V Leiden and thermolabile methylene tetrahydrofolate reductase mutations.
Activated Protein C Resistance
Risk factors and management of patients with upper limb deep vein thrombosis.
Activated Protein C Resistance
Risk factors for thrombophilia in young adults presenting with thrombosis.
Activated Protein C Resistance
Risk factors for thrombosis in nonembolic cerebrovascular disease.
Activated Protein C Resistance
Risk factors in central retinal vein occlusion an activated protein C resistance.
Activated Protein C Resistance
Risk factors in central retinal vein occlusion and activated protein C resistance.
Activated Protein C Resistance
Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency, or activated protein C resistance: a multicenter collaborative family study.
Activated Protein C Resistance
Risk of Venous Thrombosis in Carriers of a Common Mutation in the Homocysteine Regulatory Enzyme Methylenetetrahydrofolate Reductase.
Activated Protein C Resistance
Rivaroxaban Causes Missed Diagnosis of Protein S Deficiency but Not of Activated Protein C Resistance (Factor V Leiden).
Activated Protein C Resistance
Role of activated protein C resistance in left atrial thrombogenesis in patients with mitral stenosis.
Activated Protein C Resistance
Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis.
Activated Protein C Resistance
Role of factor VIII on activated protein C resistance ratio in inflammatory diseases.
Activated Protein C Resistance
Role of hyperhomocystinemia in retinal vascular occlusive disease.
Activated Protein C Resistance
Role of protein S and tissue factor pathway inhibitor in the development of activated protein C resistance early in pregnancy in women with a history of preeclampsia.
Activated Protein C Resistance
Routine coagulation tests are not useful as a screening tool for the FII G20210A polymorphism.
Activated Protein C Resistance
Screening for a prothrombotic diathesis in patients attending family planning clinics.
Activated Protein C Resistance
Screening for abnormalities of the protein C anticoagulant pathway using the ProC Global assay. Results of a European multicenter evaluation.
Activated Protein C Resistance
Screening for activated protein C resistance before oral contraceptive treatment: a pilot study.
Activated Protein C Resistance
Screening with the activated protein C resistance assay yields significant savings in a patient population with low prevalence of factor V leiden.
Activated Protein C Resistance
Search for mutations in the genes for coagulation factors V and VIII with a possible predisposition to activated protein C resistance.
Activated Protein C Resistance
Second-trimester pregnancy loss is associated with activated C resistance.
Activated Protein C Resistance
Sensitivity, specificity and predictive value of modified assays for activated protein C resistance in children.
Activated Protein C Resistance
Severe thrombotic complications associated with activated protein C resistance acquired by orthotopic liver transplantation.
Activated Protein C Resistance
Short-term hemostatic safety of strontium ranelate treatment in elderly women with osteoporosis.
Activated Protein C Resistance
Shortened activated partial thromboplastin time, a hemostatic marker for hypercoagulable state during acute coronary event.
Activated Protein C Resistance
Single inherited thrombophilias and adverse pregnancy outcomes.
Activated Protein C Resistance
Soluble Endothelial Protein C Receptor and Coagulation Parameters as Prognostic Factors in Non-Small Cell Lung Cancer.
Activated Protein C Resistance
Spontaneous central vein thrombosis in a patient with activated protein C resistance and dengue infection: An association or causation?
Activated Protein C Resistance
Spontaneous neonatal renal vein thromboses: Should we treat them all? A report of five cases and a literature review.
Activated Protein C Resistance
Standardization of activated protein C resistance testing: effect of residual platelets in frozen plasmas assessed by commercial and home-made methods.
Activated Protein C Resistance
Stroke in children: inherited and acquired factors and age-related variations in the presentation of 48 paediatric patients.
Activated Protein C Resistance
Study of the homocysteine status in children with chronic renal failure.
Activated Protein C Resistance
Successful liver transplantation in a patient with Budd-Chiari syndrome caused by homozygous factor V Leiden.
Activated Protein C Resistance
Successful Living-Related Renal Allograft in a Recipient With Factor V Leiden Deficiency: A Case Report.
Activated Protein C Resistance
Superficial vein thrombosis, thrombin generation and activated protein C resistance as predictors of thromboembolic events in lupus and antiphospholipid patients. A prospective cohort study.
Activated Protein C Resistance
Systemic corticosteroids for the outpatient treatment of necrobiosis lipoidica in a diabetic patient.
Activated Protein C Resistance
Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden.
Activated Protein C Resistance
Tamoxifen-induced tissue factor pathway inhibitor reduction: a clue for an acquired thrombophilic state?
Activated Protein C Resistance
Testing for heredity hypercoagulability Activated protein C resistance.
Activated Protein C Resistance
Testing for heritable thrombophilia in children at Starship Children's Hospital: An audit of requests between 2004 and 2009.
Activated Protein C Resistance
The addition of idarucizumab to plasma samples containing dabigatran allows the use of routine coagulation assays for the diagnosis of hemostasis disorders.
Activated Protein C Resistance
The adsorption of dabigatran is as efficient as addition of idarucizumab to neutralize the drug in routine coagulation assays.
Activated Protein C Resistance
The association between extrinsic activated protein C resistance and venous thromboembolism in women.
Activated Protein C Resistance
The clinical application of a new specific functional assay to detect the factor V(Leiden) mutation associated with activated protein C resistance.
Activated Protein C Resistance
The concomitant presence of lupus anticoagulant, anticardiolipin and anti-beta2-glycoprotein i antibodies could be associated with acquired activated protein c resistance in non-systemic lupus erythematosus patients.
Activated Protein C Resistance
The diagnosis and clinical manifestations of activated protein C resistance: a case report and review of the literature.
Activated Protein C Resistance
The diagnostic dilemma: dual presentations of clinical mucosal bleeding and venous thrombosis associated with the presence of thrombophilia markers and mild reduction in von Willebrand factor.
Activated Protein C Resistance
The differential association of conjugated equine estrogen and esterified estrogen with activated protein C resistance in postmenopausal women.
Activated Protein C Resistance
The effect of dabigatran and rivarovaban on a prothrombinase-based assay for activated protein C resistance: a preliminary study in subjects heterozygous for factor V Leiden.
Activated Protein C Resistance
The effect of dabigatran on select specialty coagulation assays.
Activated Protein C Resistance
The effect of lupus anticoagulant in the second-generation assay for activated protein C resistance.
Activated Protein C Resistance
The effect of pre-eclampsia on the levels of coagulation and fibrinolysis factors in umbilical cord blood of newborns.
Activated Protein C Resistance
The effect of thrombophylaxis on pregnancy outcome in patients with recurrent pregnancy loss associated with factor V Leiden mutation.
Activated Protein C Resistance
The effects of oral contraceptive usage on thrombin generation and activated protein C resistance in Saudi women, with a possible impact of the body mass index.
Activated Protein C Resistance
The effects of transport temperature and time on routine and specialized coagulation assays.
Activated Protein C Resistance
The elevated markers of hypercoagulability in children with Henoch-Schönlein purpura.
Activated Protein C Resistance
The factor V (FV) gene ASP79HIS polymorphism modulates FV plasma levels and affects the activated protein C resistance phenotype in presence of the FV Leiden mutation.
Activated Protein C Resistance
The factor V Glu1608Lys mutation is recurrent in familial thrombophilia.
Activated Protein C Resistance
The factor V Leiden mutation increases the risk of venous thrombosis in patients with inflammatory bowel disease.
Activated Protein C Resistance
The factor VIII D1241E polymorphism is associated with decreased factor VIII activity and not with activated protein C resistance levels.
Activated Protein C Resistance
The frequency of factor V Leiden and concomitance of factor V Leiden with prothrombin G20210A mutation and methylene tetrahydrofolate reductase C677T gene mutation in healthy population of Denizli, Aegean region of Turkey.
Activated Protein C Resistance
The Glasgow Outcome, APCR and Lipid (GOAL) Pregnancy Study: significance of pregnancy associated activated protein C resistance.
Activated Protein C Resistance
The impact of oral anticoagulant therapy, factor VIII level and quality of factor V-deficient plasma on three commercial methods for activated protein C resistance.
Activated Protein C Resistance
The incidence of activated protein C resistance among patients with deep vein thrombosis and healthy subjects in Osaka.
Activated Protein C Resistance
The influence of factor VIII on measurement of activated protein C resistance.
Activated Protein C Resistance
The Leiden mutation and activated protein C resistance as risk factors for disseminated intravascular coagulation in acutely poisoned patients.
Activated Protein C Resistance
The Normal anticoagulant system and risk of placental abruption: protein C, protein S and resistance to activated protein C.
Activated Protein C Resistance
The phenomenon known as acquired activated protein C resistance.
Activated Protein C Resistance
The polymerase chain reaction with sequence specific primers for the detection of the factor V mutation associated with activated protein C resistance.
Activated Protein C Resistance
The predictability of factor V Leiden (FV:Q(506)) gene mutation via clotting-based diagnosis of activated protein C resistance.
Activated Protein C Resistance
The presence of multiple prothrombotic risk factors is associated with a higher risk of thrombosis in individuals with anticardiolipin antibodies.
Activated Protein C Resistance
The Prevalence of Activated Protein C Resistance and F V Leiden in Healthy Population of Edirne, Turkey.
Activated Protein C Resistance
The prevalence of thrombophilia in patients with chronic venous leg ulceration.
Activated Protein C Resistance
The prevalence of thrombophilia in patients with symptomatic peripheral vascular disease.
Activated Protein C Resistance
The relationship of the factor V Leiden mutation and pregnancy outcomes for mother and fetus.
Activated Protein C Resistance
The role of activated protein C resistance in the pathogenesis of venous thrombosis.
Activated Protein C Resistance
The role of natural anticoagulant deficiencies and factor V Leiden in the development of idiopathic portal vein thrombosis.
Activated Protein C Resistance
The role of thrombophilia and thyroid autoimmunity in unexplained infertility, implantation failure and recurrent spontaneous abortion.
Activated Protein C Resistance
The use of direct oral anticoagulants in inherited thrombophilia.
Activated Protein C Resistance
Third-generation oral contraceptive and deep venous thrombosis: from epidemiologic controversy to new insight in coagulation.
Activated Protein C Resistance
Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera.
Activated Protein C Resistance
Thrombin generation and activated protein C resistance in the absence of factor V Leiden correlates with the risk of recurrent venous thromboembolism in women aged 18-65 years.
Activated Protein C Resistance
Thrombin generation in children with sickle cell Anemia is Higher in the presence of platelets? and ?.
Activated Protein C Resistance
Thromboembolic diseases: biochemical mechanisms and new possibilities of biological diagnosis.
Activated Protein C Resistance
Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations.
Activated Protein C Resistance
Thrombophilia and first arterial ischaemic stroke: a systematic review.
Activated Protein C Resistance
Thrombophilia differences in cerebral venous sinus and lower extremity deep venous thrombosis.
Activated Protein C Resistance
Thrombophilia in Cardiac Surgery-Patients with Symptomatic Factor V Leiden.
Activated Protein C Resistance
Thrombophilia in patients with chronic venous leg ulcers-a study on patients with or without post-thrombotic syndrome.
Activated Protein C Resistance
Thrombophilia investigation in Malaysian women with recurrent pregnancy loss.
Activated Protein C Resistance
Thrombophilia prevalence in patients seeking laparoscopic sleeve gastrectomy: extended chemoprophylaxis may decrease portal vein thrombosis rate.
Activated Protein C Resistance
Thrombophilia: a mechanism of disease in women with adverse pregnancy outcome and thrombotic lesions in the placenta.
Activated Protein C Resistance
Thrombophilia: disorders predisposing to venous thromboembolism.
Activated Protein C Resistance
Thrombophilia: the discovery of activated protein C resistance.
Activated Protein C Resistance
Thrombophilias and pregnancy complications: a case-control study.
Activated Protein C Resistance
Thrombophilic abnormalities of natural anticoagulants in patients with ulcerative colitis.
Activated Protein C Resistance
Thrombophilic factors and their relation to thromboembolic and other clinical manifestations in Behçet's disease.
Activated Protein C Resistance
Thrombophilic factors in chronic thromboembolic pulmonary hypertension.
Activated Protein C Resistance
Thrombophilic factors in Stage V chronic kidney disease patients are largely corrected by renal transplantation.
Activated Protein C Resistance
Thrombophilic mutations in Iranian patients with infertility and recurrent spontaneous abortion.
Activated Protein C Resistance
Thrombophilic mutations in pre-eclampsia and pregnancy-induced hypertension.
Activated Protein C Resistance
Thrombophilic risk factors in epileptic children treated with valproic Acid.
Activated Protein C Resistance
Thrombophilic risk factors in patients with central retinal vein occlusion.
Activated Protein C Resistance
Thrombophilic risk factors in the pathogenesis of non-arteritic anterior ischemic optic neuropathy patients.
Activated Protein C Resistance
Thromboprophylaxis with low molecular mass heparin, 'Fragmin' (dalteparin), during pregnancy--a longitudinal safety study.
Activated Protein C Resistance
Thrombosis and Hemostatic Abnormalities in Hematological Malignancies.
Activated Protein C Resistance
Thrombosis in inflammatory bowel disease: clinical setting, procoagulant profile and factor V Leiden.
Activated Protein C Resistance
Thrombosis in otherwise well children with the factor V Leiden mutation.
Activated Protein C Resistance
Thrombosis involving the major veins with heterozygote factor V Leiden mutation as the only risk factor.
Activated Protein C Resistance
Thrombosis risk in systemic lupus erythematosus: the role of thrombophilic risk factors.
Activated Protein C Resistance
Thrombotic complications in multiple myeloma: a report of three cases and review of the literature.
Activated Protein C Resistance
Thrombotic risk factors and extent of liver fibrosis in chronic viral hepatitis.
Activated Protein C Resistance
Thyroid function, activated protein C resistance and the risk of venous thrombosis in users of hormonal contraceptives.
Activated Protein C Resistance
Tissue Factor Pathway Inhibitor, Activated Protein C Resistance, and Risk of Coronary Heart Disease Due To Combined Estrogen Plus Progestin Therapy.
Activated Protein C Resistance
Tissue Factor Pathway Inhibitor, Activated Protein C Resistance, and Risk of Ischemic Stroke due to Postmenopausal Hormone Therapy.
Activated Protein C Resistance
Transdermal estradiol therapy for prostate cancer reduces thrombophilic activation and protects against thromboembolism.
Activated Protein C Resistance
Two novel factor V null mutations associated with activated protein C resistance phenotype/genotype discrepancy.
Activated Protein C Resistance
Two rare confounding polymorphisms proximal to the factor V Leiden mutation.
Activated Protein C Resistance
Unchanged global fibrinolytic capacity despite increased factor VIIa activity in Behçet's disease: evidence of a prethrombotic state.
Activated Protein C Resistance
Underlying disorders associated with severe early-onset preeclampsia.
Activated Protein C Resistance
Use of a systematic risk analysis method (FMECA) to improve quality in a clinical laboratory procedure.
Activated Protein C Resistance
Use of first nucleotide change technology to determine the frequency of factor V Leiden in a population of Australian blood donors.
Activated Protein C Resistance
Use of modified functional assays for activated protein C resistance in patients with basally prolonged aPTT.
Activated Protein C Resistance
Use of selective factor V Leiden screening in pregnancy to identify candidates for anticoagulants.
Activated Protein C Resistance
Use of the etonogestrel-releasing implant is associated with hypoactivation of the coagulation cascade.
Activated Protein C Resistance
Usefulness of factor V Leiden mutation testing in clinical practice.
Activated Protein C Resistance
Usefulness of screening for congenital or acquired hemostatic abnormalities in women with previous complicated pregnancies.
Activated Protein C Resistance
Utility of the clinical practice of administering thrombophilic screening and antithrombotic prophylaxis with low-molecular-weight heparin to healthy donors treated with G-CSF for mobilization of peripheral blood stem cells.
Activated Protein C Resistance
Utilization of testing for activated protein C resistance in a reference laboratory.
Activated Protein C Resistance
Validation and standardization of the ETP-based activated protein C resistance test for the clinical investigation of steroid contraceptives in women: an unmet clinical and regulatory need.
Activated Protein C Resistance
Variable interference of activated protein C resistance in the measurement of protein S activity by commercial assays.
Activated Protein C Resistance
Vascular graft thrombosis secondary to activated protein C resistance: a case report and literature review.
Activated Protein C Resistance
Vascular surgical society of great britain and ireland: prevalence and significance of thrombophilia in patients with intermittent claudication
Activated Protein C Resistance
Venous sonography for the diagnosis of asymptomatic deep vein thrombosis in patients with cancer undergoing chemotherapy.
Activated Protein C Resistance
Venous thromboembolic disease: risk factors and laboratory investigation.
Activated Protein C Resistance
Venous thromboembolism at a young age in a brother and sister with coinheritance of homozygous 20210A/A prothrombin mutation and heterozygous 1691G/A factor V Leiden mutation.
Activated Protein C Resistance
Venous thromboembolism, factor V Leiden, and methylenetetrahydrofolate reductase in a sickle cell anemia patient.
Activated Protein C Resistance
Venous thrombosis in older people: prevalence of the factor V gene mutation Q506.
Activated Protein C Resistance
Venous thrombosis with oral postmenopausal hormone therapy: Roles of activated protein C resistance and tissue factor pathway inhibitor.
Activated Protein C Resistance
Venous thrombosis: prevalence of prothrombotic defects in north Indian population.
Activated Protein C Resistance
Warfarin induced skin necrosis associated with activated protein C resistance.
Activated Protein C Resistance
[A new cause of familial thrombophilia: resistance to the effect of activated protein C]
Activated Protein C Resistance
[A new cause of hereditary thrombophilia: activated protein c resistance]
Activated Protein C Resistance
[A new cause of hereditary venous thrombosis: activated protein C resistance]
Activated Protein C Resistance
[Abnormalities of haemostasis in myocardial infarction with normal coronary artery]
Activated Protein C Resistance
[Acquired and inherited hypercoagulability among patients with cerebral venous thrombosis]
Activated Protein C Resistance
[Activated C protein resistance manifested by cutaneous necrosis after interferon alpha injection: case report]
Activated Protein C Resistance
[Activated C protein resistance: laboratory study and prevalence of the defect in the Chilean population]
Activated Protein C Resistance
[Activated protein C resistance (APCR) in thromboembolic diseases in Cotonou (Benin)]
Activated Protein C Resistance
[Activated protein C resistance and cardiolipin antibodies in leg ulcers]
Activated Protein C Resistance
[Activated protein C resistance and deep venous thrombosis in pregnancy]
Activated Protein C Resistance
[Activated protein C resistance and factor V Leiden: Clinical interest.]
Activated Protein C Resistance
[Activated protein C resistance and mutation of coagulation factor V]
Activated Protein C Resistance
[Activated protein C resistance and venous thrombophilia: molecular genetic prevalence study in the German population]
Activated Protein C Resistance
[Activated protein C resistance as the cause of recurrent mesenteric venous thrombosis]
Activated Protein C Resistance
[Activated protein C resistance in factor V disease: how high is the risk of thrombosis?]
Activated Protein C Resistance
[Activated protein C resistance in patients with central retinal vein occlusion in comparison to patients with a history of deep-vein thrombosis and a healthy control group]
Activated Protein C Resistance
[Activated protein C resistance in patients with venous leg ulcer]
Activated Protein C Resistance
[Activated protein C resistance of an acquired nature: the potential role of hormonal treatment and of elevated factor VIII plasma levels]
Activated Protein C Resistance
[Activated protein C resistance, Leiden mutation, anticoagulant proteins and fibrinogen levels in patients with deep venous thrombosis]
Activated Protein C Resistance
[Activated protein C resistance--a recently discovered hereditary thrombophilia]
Activated Protein C Resistance
[Activated protein C resistance: role in venous and arterial thrombosis]
Activated Protein C Resistance
[Analysis of activated protein C resistance, factor V coagulation activity and gene polymorphisms in patients with venous thromboembolism]
Activated Protein C Resistance
[Antiphospholipid thrombosis syndrome and acquired activated protein C resistance]
Activated Protein C Resistance
[APC resistance. Resistance against activated Protein C, a frequent cause of congenital thrombosis susceptibility]
Activated Protein C Resistance
[Assessment of risk factors for retinal vein occlusions in patients under 60 years of age]
Activated Protein C Resistance
[Association of tow thrombotic risk factors: factor V Leiden and hyperhomocysteinemia. A case report]
Activated Protein C Resistance
[Benign intracranial hypertension and heterozygosity for factor V Leiden mutation]
Activated Protein C Resistance
[Brain stem ischemia in a boy with resistance to C activated protein and elevated lipoprotein A]
Activated Protein C Resistance
[Cerebral panthrombophlebitis in a paucisymptomatic patient]
Activated Protein C Resistance
[Clinical analysis of 12 cases with venous thromboembolism during pregnancy and puerperium]
Activated Protein C Resistance
[Clinical usefulness of global assays of the anticoagulant pathway of protein C]
Activated Protein C Resistance
[Comparison of three reactants for the detection of activated protein C resistance due to mutation of factor V Leiden during pregnancy]
Activated Protein C Resistance
[Comparison of two groups of 22 women homozygous or heterozygous for factor V Leiden mutation]
Activated Protein C Resistance
[Cutaneous manifestations of activated protein C resistance]
Activated Protein C Resistance
[Diagnosis of activated protein C resistance by chronometric test and molecular biology]
Activated Protein C Resistance
[Diagnosis of thrombophilia based on coagulation and genetic studies]
Activated Protein C Resistance
[Evaluation of hemostasis in venous thromboembolism pathology]
Activated Protein C Resistance
[Factor V Leiden mutation leads to enhanced atherosclerosis in apolipoprotein E deficient mice]
Activated Protein C Resistance
[Frequency of antiphospholipid antibodies and factor V (G1691A), prothrombin (G20210A) gene polimorphism among women with pregnancy complications]
Activated Protein C Resistance
[G20210A transition in the prothrombin gene and venous thromboembolic disease]
Activated Protein C Resistance
[Genetic trombophilia and markers of endotelial activation in patients with preeclampsia]
Activated Protein C Resistance
[Hematological changes and related gene mutation of post-severe acute respiratory syndrome patients with osteonecrosis]
Activated Protein C Resistance
[Hereditary thrombophilia in free microvascular flaps--a case report]
Activated Protein C Resistance
[Hypercoagulable state due to acquired protein C resistance, harbinger of colonic neoplasm?]
Activated Protein C Resistance
[Importance of determination of activated protein C resistance (APC) in gynecology and obstetrics]
Activated Protein C Resistance
[Initial experience in the diagnosis of thrombophilia due to activated protein C resistance]
Activated Protein C Resistance
[Intravenous recombinant tissue plasminogen activator in an 18-week pregnant woman with embolic stroke]
Activated Protein C Resistance
[Laboratory tests for detection of antiphospholipid antibodies]
Activated Protein C Resistance
[Mechanisms and risk factors of venous thromboembolic disease]
Activated Protein C Resistance
[Mesenteric and splenic vein thrombosis in a female patient with essential thrombocytosis and activated protein C resistance]
Activated Protein C Resistance
[Multiple phlebothrombosis following cesarean section due to heterozygous factor V Leiden mutation detected post partum]
Activated Protein C Resistance
[National evaluation of the diagnosis of activated protein C resistance]
Activated Protein C Resistance
[One Chinese case of F V Leiden mutation associated with APC resistance]
Activated Protein C Resistance
[Oral contraceptives and activated protein C resistance: a paradigmatic example of genotype and environment interaction in the development of deep venous thrombosis]
Activated Protein C Resistance
[Paraneoplastic superior vena cava thrombosis disclosing an ovarian tumor]
Activated Protein C Resistance
[Pathophysiology and clinical manifestations in pre-eclampsia]
Activated Protein C Resistance
[Pregnancy outcomes in a patient-heterozygous carrier of R506Q mutation of factor V (Leiden)]
Activated Protein C Resistance
[Prevalence of Factor V Leiden and the G20210A mutation of the prothrombin gene in a random group of patients with thrombotic episodes]
Activated Protein C Resistance
[Prevalence of genetic prothrombotic factors (factor V Leiden and II20210 prothrombin mutation) in glomerular nephropathies with or without thrombosis]
Activated Protein C Resistance
[Prevalence of the activated protein C resistance in indigenous and Black populations of the western Venezuela]
Activated Protein C Resistance
[Primary thrombophilia in México. VI: lack of statistical association among the inherited thrombophilic conditions]
Activated Protein C Resistance
[Pulmonary embolism disclosing activated protein C resistance]
Activated Protein C Resistance
[Pulmonary embolism in a 30 year-old man with chronic hepatitis C during therapy with pegylated interferon-? and ribavirin].
Activated Protein C Resistance
[Recurrent thrombophlebitis and ulcera crurum as manifestations of hereditary blood coagulation disorders and Klinefelter syndrome. Discussion based on 4 case examples]
Activated Protein C Resistance
[Relationship between phenomenon of acquired activated protein C resistance and antiphospholipid antibodies in patients with systemic lupus erythematosus]
Activated Protein C Resistance
[Resistance to activated protein C and pregnancy: thromboprophylaxis with low molecular weight heparin]
Activated Protein C Resistance
[Resistance to activated protein C in venous thromboembolic complications. Incidence and clinical manifestations]
Activated Protein C Resistance
[Resistance to activated protein C, so-called APC resistance: the first two cases in Slovakia]
Activated Protein C Resistance
[Study of activated protein C resistance(APC-R) and FV Leiden in healthy blood donors and patients with thrombosis]
Activated Protein C Resistance
[Study on activated protein C resistance and disordered coagulation in patients with myeloproliferative neoplasms].
Activated Protein C Resistance
[Study on relationship of activated protein C resistance and recurrent spontaneous abortion]
Activated Protein C Resistance
[The contribution of the hematological examination in patients with retinal vein occlusion]
Activated Protein C Resistance
[The role of resistance to C active protein (R-APC) in a pediatric stroke]
Activated Protein C Resistance
[The routine coagulation tests along with activated protein C resistance (APC-R) in population of women applying for oral contraceptives]
Activated Protein C Resistance
[Thrombophilia factors as inducers of retinal vascular occlusion]
Activated Protein C Resistance
[Thrombophilia in systemic lupus erythematosus: A case-control study].
Activated Protein C Resistance
[Thrombophilias in patients with ischemic stroke. Indication and calculated costs for evidence-based diagnostics and treatment]
Activated Protein C Resistance
[Thrombosis of the cerebral venous sinuses: a description of its clinical features, risk factors and treatment in a hospital of Colombia]
Activated Protein C Resistance
[Thrombosis risk in activated protein C resistance deficiency?]
Activated Protein C Resistance
[Type I protein C deficiency caused by a novel protein C gene mutation]
Activated Protein C Resistance
[Venous thromboembolism in connection with physical restraint]
Acute Coronary Syndrome
A new method to measure plasma levels of activated protein C in complex with protein C inhibitor in patients with acute coronary syndromes.
Acute Kidney Injury
Activated protein C ameliorates impaired renal microvascular oxygenation and sodium reabsorption in endotoxemic rats.
Acute Kidney Injury
Activated protein C ameliorates LPS-induced acute kidney injury and downregulates renal INOS and angiotensin 2.
Acute Kidney Injury
Activated Protein C and Acute Kidney Injury: Selective Targeting of PAR-1.
Acute Kidney Injury
Distinct functions of activated protein C differentially attenuate acute kidney injury.
Acute Kidney Injury
Human activated protein C attenuates both hepatic and renal injury caused by hepatic ischemia and reperfusion injury in mice.
Acute Lung Injury
Activated Protein C and Normal Saline Infusion Might Prevent Deleterious Effects of Remote Acute Lung Injury Caused by Intestinal Ischemia-Reperfusion: An Experimental Study in the Rat Model.
Acute Lung Injury
Activated Protein C Attenuates Acute Lung Injury and Apoptosis in a Hyperoxic Animal Model.
Acute Lung Injury
Activated protein C attenuates cardiopulmonary bypass-induced acute lung injury through the regulation of neutrophil activation.
Acute Lung Injury
Activated protein C attenuates intestinal reperfusion-induced acute lung injury: an experimental study in a rat model.
Acute Lung Injury
Activated protein C attenuates ischemia-reperfusion-induced acute lung injury.
Acute Lung Injury
Activated protein C in the treatment of acute lung injury and acute respiratory distress syndrome.
Acute Lung Injury
Activated protein C inhalation: a novel therapeutic strategy for acute lung injury.
Acute Lung Injury
Activated protein C protection from lung inflammation in endotoxin-induced injury.
Acute Lung Injury
Combined recombinant human activated protein C and ceftazidime prevent the onset of acute respiratory distress syndrome in severe sepsis.
Acute Lung Injury
Effect of activated protein C on pulmonary blood flow and cytokine production in experimental acute lung injury.
Acute Lung Injury
Effects of activated protein C on coagulation and fibrinolysis in rabbits with endotoxin induced acute lung injury.
Acute Lung Injury
Effects of recombinant human activated protein C in human models of endotoxin administration.
Acute Lung Injury
Enhancing autophagy with activated protein C and rapamycin protects against sepsis-induced acute lung injury.
Acute Lung Injury
Heme oxygenase-1 modulates thrombomodulin and activated protein c levels to attenuate lung injury in cecal ligation and puncture-induced acute lung injury mice.
Acute Lung Injury
Impact of introducing multiple evidence-based clinical practice protocols in a medical intensive care unit: a retrospective cohort study.
Acute Lung Injury
Inhalation of activated protein C inhibits endotoxin-induced pulmonary inflammation in mice independent of neutrophil recruitment.
Acute Lung Injury
Inhaled activated protein C: a new therapy for the prevention of ventilator-induced lung injury?
Acute Lung Injury
Pharmacotherapy of acute lung injury and the acute respiratory distress syndrome.
Acute Lung Injury
Positive end-expiratory pressure, prone positioning, and activated protein C: a critical review of meta-analyses.
Acute Lung Injury
Randomized clinical trial of activated protein C for the treatment of acute lung injury.
Acute Lung Injury
Recently published papers: Pseudomonas, brain and bowel injury and novel cardiac therapies.
Acute Lung Injury
Recombinant human activated protein C attenuates cardiovascular and microcirculatory dysfunction in acute lung injury and septic shock.
Acute Lung Injury
Recombinant human activated protein C improves pulmonary function in ovine acute lung injury resulting from smoke inhalation and sepsis.
Acute Lung Injury
Recombinant human activated protein C in acute lung injury: what is the role of bronchial circulation?
Acute Lung Injury
Recombinant human activated protein C in experimental models of acute lung injury: the timing is critical!
Acute Lung Injury
Role of coagulation pathways and treatment with activated protein C in hyperoxic lung injury.
Acute Lung Injury
Struggle for implementation of new strategies in intensive care medicine: anticoagulation, insulin, and lower tidal volumes.
Acute Lung Injury
Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock.
Acute Lung Injury
[Protocol of the management of patients with severe sepsis and septic shock].
Acute Radiation Syndrome
Sex-dependent effects of genetic upregulation of activated protein C on delayed effects of acute radiation exposure in the mouse heart, small intestine, and skin.
Adenocarcinoma of Lung
Receptor of activated protein C promotes metastasis and correlates with clinical outcome in lung adenocarcinoma.
Adrenal Insufficiency
Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008.
Adrenal Insufficiency
Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.
Alzheimer Disease
Increased Levels of Coagulation Factor XI in Plasma Are Related to Alzheimer's Disease Diagnosis.
Anaphylaxis
Activated protein C concentrate reverses purpura fulminans in severe genetic protein C deficiency.
Anemia
Membrane autoantibodies in systemic lupus erythematosus: a case of autoimmune hemolytic anemia, antiphospholipid antibodies, and transient acquired activated protein C resistance.
Anemia, Hemolytic, Autoimmune
Membrane autoantibodies in systemic lupus erythematosus: a case of autoimmune hemolytic anemia, antiphospholipid antibodies, and transient acquired activated protein C resistance.
Anemia, Iron-Deficiency
Iron-deficiency anaemia in childhood: a risk factor for severe venous thrombosis?
Anemia, Sickle Cell
Red blood cells from patients with homozygous sickle cell disease provide a catalytic surface for factor Va inactivation by activated protein C.
Anemia, Sickle Cell
The role of hypercoagulability in the development of osteonecrosis of the femoral head.
Angioedemas, Hereditary
Cutaneous necrosis in pregnancy secondary to activated protein C resistance in hereditary angioedema.
Antiphospholipid Syndrome
Activated protein C resistance phenotype and genotype in patients with primary antiphospholipid syndrome.
Antiphospholipid Syndrome
Anti-Domain I ?2-Glycoprotein I Antibodies and Activated Protein C Resistance Predict Thrombosis in Antiphospholipid Syndrome: TAC(I)T Study.
Antiphospholipid Syndrome
Antiphospholipid syndrome and factor V Leiden. Three cases with recurrent venous thrombosis.
Antiphospholipid Syndrome
Association of primary antiphospholipid syndrome with inherited activated protein C resistance.
Antiphospholipid Syndrome
Detection of acquired resistance to activated protein C associated with antiphospholipid antibodies using a novel clotting assay.
Antiphospholipid Syndrome
Inherited activated protein C resistance in a patient with familial primary antiphospholipid syndrome.
Antiphospholipid Syndrome
Inhibition of APC anticoagulant activity on oxidized phospholipid by anti-{beta}2-glycoprotein I monoclonal antibodies.
Antiphospholipid Syndrome
Myocardial infarction and normal coronary arteries: the experience of the cardiology department of sfax, Tunisia.
Antiphospholipid Syndrome
Prevalence of activated protein C resistance in acute myocardial infarction in Japan.
Antiphospholipid Syndrome
Primary antiphospholipid syndrome is not associated with activated protein C resistance caused by factor V Arg 506 -->Gln mutation.
Antiphospholipid Syndrome
Sensitivity to activated protein C in patients with deep vein thrombosis during early puerperium period.
Antiphospholipid Syndrome
Some antiphospholipid antibodies recognize conformational epitopes shared by beta2-glycoprotein I and the homologous catalytic domains of several serine proteases.
Antiphospholipid Syndrome
The inhibition of protein C anticoagulant activity by anti-?2-glycoprotein I (?2GPI) antibodies isolated from patients with antiphospholipid syndrome by chromatography methods.
Antiphospholipid Syndrome
[Hereditary thrombophilia in free microvascular flaps--a case report]
Antithrombin III Deficiency
Flow cytometric analysis of autonomous growth of erythroid precursors in liquid culture detects occult polycythemia vera in the Budd-Chiari syndrome.
Antithrombin III Deficiency
Guidelines for the management of thrombophilia. Department of Haematology, The Royal London Hospital, Whitechapel, London, UK.
Antithrombin III Deficiency
Ischemic stroke subtypes and thrombophilia in young and elderly Brazilian stroke patients admitted to a rehabilitation hospital.
Antithrombin III Deficiency
Prevalence of activated protein C resistance in acute myocardial infarction in Japan.
Antithrombin III Deficiency
Resistance to activated protein C: arterial thrombosis associated with autoimmune features.
Antithrombin III Deficiency
Risk factors for thrombophilia in young adults presenting with thrombosis.
Antithrombin III Deficiency
The relationship of the factor V Leiden mutation and pregnancy outcomes for mother and fetus.
Antithrombin III Deficiency
Thrombophilia is common in women with idiopathic pregnancy loss and is associated with late pregnancy wastage.
Antithrombin III Deficiency
Thrombophilia prevalence in patients seeking laparoscopic sleeve gastrectomy: extended chemoprophylaxis may decrease portal vein thrombosis rate.
Antithrombin III Deficiency
Thrombophilic factors in chronic thromboembolic pulmonary hypertension.
Antithrombin III Deficiency
Underlying disorders associated with severe early-onset preeclampsia.
Antithrombin III Deficiency
[Thrombosis of the cerebral venous sinuses: a description of its clinical features, risk factors and treatment in a hospital of Colombia]
Arrhythmias, Cardiac
Activated protein c resistance (APC) and inherited factor V (FV) mis-sense mutation in patients with venous and arterial thrombosis in a haematology clinic.
Arterial Occlusive Diseases
Diminished response to activated protein C is not correlated with severity of peripheral arterial occlusive disease.
Arteriosclerosis
The VITA Project: heritability of resistance to activated protein C. Vincenza Thrombophilia and Arteriosclerosis.
Arthritis
Activated protein C targets immune cells and rheumatoid synovial fibroblasts to prevent inflammatory arthritis in mice.
Arthritis, Rheumatoid
Activated protein C targets immune cells and rheumatoid synovial fibroblasts to prevent inflammatory arthritis in mice.
Arthritis, Rheumatoid
Differential regulation of matrix metalloproteinase 2 and matrix metalloproteinase 9 by activated protein C: relevance to inflammation in rheumatoid arthritis.
Arthritis, Rheumatoid
Elevation of activated protein C in synovial joints in rheumatoid arthritis and its correlation with matrix metalloproteinase 2.
Arthritis, Rheumatoid
Endothelial protein C receptor is overexpressed in rheumatoid arthritic (RA) synovium and mediates the anti-inflammatory effects of activated protein C in RA monocytes.
Arthritis, Rheumatoid
From coagulation to inflammation: novel avenues for treating rheumatoid arthritis with activated protein C.
Arthritis, Rheumatoid
Increased levels of serum histone H4 and activated protein C in patients with active rheumatoid arthritis.
Asthma
Activated protein C inhibits neutrophil migration in allergic asthma: a randomised trial.
Atherosclerosis
Activated protein C reverses epigenetically sustained p66Shc expression in plaque-associated macrophages in diabetes.
Atherosclerosis
Anticoagulant responses to thrombin are enhanced during regression of atherosclerosis in monkeys.
Atherosclerosis
Emerging risk factors for stroke: Patent foramen ovale, proximal aortic atherosclerosis, antiphospholipid antibodies, and activated protein C resistance.
Atherosclerosis
Impaired anticoagulant response to infusion of thrombin in atherosclerotic monkeys associated with acquired defects in the protein C system.
Atherosclerosis
Poor response to activated protein C as a prominent risk predictor of advanced atherosclerosis and arterial disease.
Atherosclerosis
The VITA project: phenotypic resistance to activated protein C and FV Leiden mutation in the general population. Vicenza Thrombophilia and Atherosclerosis.
Atherosclerosis
[Factor V Leiden mutation leads to enhanced atherosclerosis in apolipoprotein E deficient mice]
Atrial Fibrillation
Rivaroxaban as an effective alternative to warfarin in a patient with atrial fibrillation, thrombophilia, and left atrial appendage thrombus: a case report.
Autoimmune Diseases
Hypercoagulable states in renal transplant candidates: impact of anticoagulation upon incidence of renal allograft thrombosis.
Autoimmune Diseases
The Immunoregulatory Activities of Activated Protein C in Inflammatory Disease.
Bacterial Infections
Effects of intravenous infusion of highly purified vitamin B2 on lipopolysaccharide-induced shock and bacterial infection in mice.
Blood Coagulation Disorders
[A newly discovered blood coagulation disorder. Resistance to activated protein C as a cause of thrombosis]
Brain Edema
Roles of inflammation and the activated protein C pathway in the brain edema associated with cerebral venous sinus thrombosis.
Brain Infarction
Functional recovery after embolic stroke in rodents by activated protein C.
Brain Injuries
Activated protein C prevents glutamate- and thrombin-induced activation of nuclear factor-kappaB in cultured hippocampal neurons.
Brain Injuries
Evaluation of 3K3A-Activated Protein C to Treat Neonatal Hypoxic Ischemic Brain Injury in the Spiny Mouse.
Brain Injuries
Neonatal brain injury and systemic inflammation: modulation by activated protein C ex vivo.
Brain Ischemia
Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage.
Brain Ischemia
High dose infusion of activated protein C (rhAPC) fails to improve neuronal damage and cognitive deficit after global cerebral ischemia in rats.
Brain Ischemia
Multiple hemostatic abnormalities in young adults with activated protein C resistance and cerebral ischemia.
Breast Neoplasms
Activated protein C enhances cell motility of endothelial cells and MDA-MB-231 breast cancer cells by intracellular signal transduction.
Breast Neoplasms
Activated protein C promotes breast cancer cell migration through interactions with EPCR and PAR-1.
Breast Neoplasms
An innovative immunosensor for ultrasensitive detection of breast cancer specific carbohydrate (CA 15-3) in unprocessed human plasma and MCF-7 breast cancer cell lysates using gold nanospear electrochemically assembled onto thiolated graphene quantum dots.
Breast Neoplasms
Antiphopholipid antibodies and functional activated protein C resistance in patients with breast cancer during anthracycline-based chemotherapy administered through an intravenous port-catheter device.
Breast Neoplasms
Determinants of acquired activated protein C resistance and D-dimer in breast cancer.
Breast Neoplasms
Functional impairment of activated protein C in breast cancer - relationship to survival outcomes.
Breast Neoplasms
Immunosensing of breast cancer tumor protein CA 15-3 (carbohydrate antigen 15.3) using a novel nano-bioink: A new platform for screening of proteins in human biofluids by pen-on-paper technology.
Breast Neoplasms
Significant correlation between salivary and serum Ca 15-3 in healthy women and breast cancer patients.
Breast Neoplasms
Ultrasensitive immunoassay of tumor protein CA 15.3 in MCF-7 breast cancer cell lysates and unprocessed human plasma using gold nanoparticles doped on the structure of mesoporous silica.
Budd-Chiari Syndrome
Acute Budd-Chiari syndrome treated by liver transplantation in a woman homozygous for factor V Leiden.
Budd-Chiari Syndrome
Acute Budd-Chiari syndrome with fulminant hepatic failure in a pregnant woman with factor V Leiden mutation.
Budd-Chiari Syndrome
Budd-Chiari syndrome during nephrotic relapse in a patient with resistance to activated protein C clotting inhibitor.
Budd-Chiari Syndrome
Liver transplantation in a patient with Budd-Chiari syndrome secondary to factor V Leiden mutation.
Carcinoma
Massive infiltration of bone marrow in colon carcinoma after treatment with activated protein C.
Carcinoma, Hepatocellular
Full-length human tissue factor pathway inhibitor inhibits human activated protein C in the presence of heparin.
Cardiac Papillary Fibroelastoma
Ischemic stroke associated with activated protein C resistance and aortic valvular papillary fibroelastoma.
Cardiomyopathy, Dilated
Multi-chamber intracardiac thrombi associated with activated protein C resistance in a patient with dilated cardiomyopathy.
Cardiomyopathy, Dilated
Predictors of left ventricular thrombus formation in patients with dilated cardiomyopathy: role of activated protein C resistance.
Cardiovascular Diseases
Membranous glomerulonephritis in a patient with inherited activated protein C resistance.
Cardiovascular Diseases
The cross-sectional association between vasomotor symptoms and hemostatic parameter levels in postmenopausal women.
Carotid Artery Diseases
Inverse correlation between activated protein C generation and carotid atherosclerosis in Type 2 diabetic patients.
Cavernous Sinus Thrombosis
Acute proptosis in relation to activated protein C resistance: a case report.
Central Nervous System Vascular Malformations
Association of resistance to activated protein C and dural arteriovenous fistulas.
Central Nervous System Vascular Malformations
Incidental discovery of a dural arteriovenous fistula in a patient with activated protein C resistance.
Cerebral Infarction
The factor V Leiden mutation (R506Q) is not a major risk factor for migrainous cerebral infarction.
Cerebral Palsy
Factor V Leiden mutation: an unrecognized cause of hemiplegic cerebral palsy, neonatal stroke, and placental thrombosis.
Cerebrovascular Disorders
Activated protein C resistance due to a factor V mutation associated with familial ischemic stroke.
Cerebrovascular Disorders
Cerebrovascular disease risk factors: neuroradiologic findings in patients with activated protein C resistance.
Cerebrovascular Disorders
Factor V Leiden mutation: an unrecognized cause of hemiplegic cerebral palsy, neonatal stroke, and placental thrombosis.
Cerebrovascular Disorders
Reduced response to activated protein C is associated with increased risk for cerebrovascular disease.
Chagas Disease
Human acute Chagas disease: changes in factor VII, activated protein C and hepatic enzymes from patients of oral outbreaks in Pará State (Brazilian Amazon).
Choroidal Neovascularization
Activated Protein C (APC) and 3K3A-APC-Induced Regression of Choroidal Neovascularization (CNV) Is Accompanied by Vascular Endothelial Growth Factor (VEGF) Reduction.
Chronic Limb-Threatening Ischemia
APC resistance due to Factor V Leiden is not related to baseline inflammatory mediators or survival up to 10 years in patients with critical limb ischemia.
Coinfection
Severe sepsis due to severe falciparum malaria and leptospirosis co-infection treated with activated protein C.
Coinfection
Successful treatment of septic shock and respiratory failure due to leptospirosis and scrub typhus coinfection with penicillin, levofloxacin, and activated protein C.
Colitis, Ischemic
Ischemic colitis and acquired resistance to activated protein C in a woman using oral contraceptives.
Colitis, Ischemic
Ischemic colitis, pulmonary embolism, and right atrial thrombosis in a patient with inherited resistance to activated protein C.
Colitis, Ulcerative
Thrombophilic abnormalities of natural anticoagulants in patients with ulcerative colitis.
Colorectal Neoplasms
Association between increased tumor necrosis factor alpha levels and acquired activated protein C resistance in patients with metastatic colorectal cancer.
Colorectal Neoplasms
Massive infiltration of bone marrow in colon carcinoma after treatment with activated protein C.
Colorectal Neoplasms
Resistance to activated protein C, factor V leiden and the prothrombin G20210A variant in patients with colorectal cancer.
Communicable Diseases
Anti-apoptotic effect of activated protein C on lipopolysaccharide-stimulated human umbilical vein endothelial cells is associated with the inhibition of the caspase-3 pathway.
Communicable Diseases
Recombinant human activated protein C in the treatment of severe sepsis: an evidence-based review.
Confusion
[Potential benefits of non-anti-infective treatments of septic shock: a critical analysis of literature]
Congenital Abnormalities
Laboratory screening of thrombophilia. Evaluation of the diagnostic efficacy of a global test to detect congenital deficiencies of the protein C anticoagulant pathway.
Congenital Abnormalities
Resistance to activated protein C due to a factor V gene mutation The most common inherited risk factor of thrombosis.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Venous thrombosis and procoagulant factors in high-risk neuroblastoma.
Coronary Artery Disease
Association of the R485K polymorphism of the factor V gene with poor response to activated protein C and increased risk of coronary artery disease in the Chinese population.
Coronary Artery Disease
Evidence against heterozygous coagulation factor V 1691 G-->A mutation with resistance to activated protein C being a risk factor for coronary artery disease and myocardial infarction.
Coronary Artery Disease
Mutation in coagulation factor V associated with resistance to activated protein C in patients with coronary artery disease.
Coronary Artery Disease
No Prognostic Importance of Resistance to Activated Protein C in Unstable Coronary Artery Disease Despite Signs of Thrombin Activation.
Coronary Artery Disease
Prospective cross-sectional study of haemostatic factors in patients with and without coronary artery disease.
Coronary Artery Disease
Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock.
Coronary Artery Disease
Thrombin inhibitors suppress the thrombin-thrombomodulin-mediated generation of activated protein C.
Coronary Artery Disease
[Protocol of the management of patients with severe sepsis and septic shock].
Coronary Disease
Activated protein C ratio, plasma tissue factor activity and activated factor VII in Chinese patients with coronary heart disease.
Coronary Disease
Activated protein C resistance and Japanese NIDDM patients with coronary heart disease.
Coronary Disease
Tissue Factor Pathway Inhibitor, Activated Protein C Resistance, and Risk of Coronary Heart Disease Due To Combined Estrogen Plus Progestin Therapy.
Coronary Thrombosis
Early identification of acute myocardial infarction by activated protein C--protein C inhibitor complex.
COVID-19
COVID-19 hypothesis: Activated protein C for therapy of virus-induced pathologic thromboinflammation.
COVID-19
Old drug, new Trick? The rationale for the treatment of COVID-19 with activated protein C.
Craniocerebral Trauma
Coagulopathy and the role of recombinant human activated protein C in sepsis and following polytrauma.
Craniocerebral Trauma
Controversial treatment of a victim of severe head injury complicated by septic shock and acute respiratory distress syndrome.
Crohn Disease
An investigation of the association of the factor V Leiden mutation and inflammatory bowel disease.
Crohn Disease
Resistance to activated protein C is a risk factor for fibrostenosis in Crohn's disease.
Cytomegalovirus Infections
The importance of detecting cytomegalovirus infections in studies evaluating new therapies for severe sepsis.
Death, Sudden, Cardiac
Decreased activated protein C levels as a clinical predictor in patients with ST-elevation myocardial infarction.
Deficiency Diseases
Evidence of normal functional levels of activated protein C inhibitor in combined Factor V/VIII deficiency disease.
Dehydration
Fetal stroke and congenital parvovirus B19 infection complicated by activated protein C resistance.
Dementia
Response to activated protein C in subjects with and without dementia. The Dutch Vascular Factors in Dementia Study.
Dengue
Spontaneous central vein thrombosis in a patient with activated protein C resistance and dengue infection: An association or causation?
Dengue
Systemic host inflammatory and coagulation response in the Dengue virus primo-infection.
Diabetes Complications
Qualitative and quantitative studies of autoantibodies to phospholipids in diabetes mellitus.
Diabetes Mellitus
Activated protein C reverses epigenetically sustained p66Shc expression in plaque-associated macrophages in diabetes.
Diabetes Mellitus, Type 1
Enhanced anticoagulant response to activated protein C in patients with IDDM.
Diabetes Mellitus, Type 1
Lupus anticoagulant positivity in insulin dependent diabetic patients: an additional risk factor in the pathogenesis of diabetic retinopathy?
Diabetes Mellitus, Type 2
A family history of type 2 diabetes is associated with lower sensitivity to activated protein C in overweight and obese premenopausal women.
Diabetes Mellitus, Type 2
Activated protein C resistance and Japanese NIDDM patients with coronary heart disease.
Diabetes Mellitus, Type 2
Decreased activated protein C levels are inversely associated with the urinary albumin excretion rate in patients with type 2 diabetes.
Diabetic Nephropathies
Activated protein C ameliorates diabetic nephropathy by epigenetically inhibiting the redox enzyme p66Shc.
Diabetic Nephropathies
Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis.
Diabetic Nephropathies
Decreased activated protein C levels are inversely associated with the urinary albumin excretion rate in patients with type 2 diabetes.
Diabetic Nephropathies
Exogenous activated protein C inhibits the progression of diabetic nephropathy.
Diabetic Nephropathies
Podocyte Integrin-?3 and Activated Protein C Coordinately Restrict RhoA Signaling and Ameliorate Diabetic Nephropathy.
Diabetic Nephropathies
Protease-activated receptor-1 deficiency protects against streptozotocin-induced diabetic nephropathy in mice.
Diabetic Nephropathies
Signal integration at the PI3K-p85-XBP1 hub endows coagulation protease activated protein C with insulin-like function.
Disseminated Intravascular Coagulation
A comparative double-blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation.
Disseminated Intravascular Coagulation
Activated protein C does not increase in the early phase of trauma with disseminated intravascular coagulation: comparison with acute coagulopathy of trauma-shock.
Disseminated Intravascular Coagulation
Activated protein C is effective for disseminated intravascular coagulation associated with placental abruption.
Disseminated Intravascular Coagulation
Assessment of the Interplay between Blood and Skin Vascular Abnormalities in Adult Purpura Fulminans.
Disseminated Intravascular Coagulation
Circulating activated protein C levels are not increased in septic patients treated with recombinant human soluble thrombomodulin.
Disseminated Intravascular Coagulation
Comparison of hemorrhagic effect of heparin and human activated protein C with use of Thrombostat 4000.
Disseminated Intravascular Coagulation
Different antithrombotic properties of factor Xa inhibitor and thrombin inhibitor in rat thrombosis models.
Disseminated Intravascular Coagulation
Effect of activated protein C on impaired fibrinolysis in rats with obstructive jaundice.
Disseminated Intravascular Coagulation
Microvascular thrombosis in pediatric multiple organ failure: Is it a therapeutic target?
Disseminated Intravascular Coagulation
Plasma levels of activated protein C-protein C inhibitor complex in patients with hypercoagulable states.
Disseminated Intravascular Coagulation
Plasma soluble fibrin monomer complex is a useful predictor of disseminated intravascular coagulation in neonatal sepsis.
Disseminated Intravascular Coagulation
Pregnancy associated coagulopathies in selected community hospitals in Southwest Nigeria.
Disseminated Intravascular Coagulation
Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation.
Disseminated Intravascular Coagulation
Recombinant human activated protein C in the treatment of severe sepsis: an evidence-based review.
Disseminated Intravascular Coagulation
Recombinant thrombomodulin and activated protein C in the treatment of disseminated intravascular coagulation.
Disseminated Intravascular Coagulation
Study of protein C, protein S, and antithrombin III in newborns with sepsis.
Disseminated Intravascular Coagulation
The effect of activated protein C in the experimental disseminated intravascular coagulation model formed by lipopolysaccharide infusion.
Disseminated Intravascular Coagulation
The Leiden mutation and activated protein C resistance as risk factors for disseminated intravascular coagulation in acutely poisoned patients.
Disseminated Intravascular Coagulation
Thrombomodulin accelerates activated protein C production and inhibits thrombin generation in the plasma of disseminated intravascular coagulation patients.
Disseminated Intravascular Coagulation
Treatment of patients with disseminated intravascular coagulation by protein C.
Disseminated Intravascular Coagulation
[Blood plasma resistance to activated protein C as a risk factor of disseminated intravascular coagulation in acute-poisoned patients]
Disseminated Intravascular Coagulation
[Diagnosis and correction of thrombohemorrhagic complications in cardiosurgical patients in the early postoperative period].
Eclampsia
Evaluation of natural coagulation inhibitor levels in various hypertensive states of pregnancy.
Eisenmenger Complex
Dual endothelin-1 receptor antagonism attenuates platelet-mediated derangements of blood coagulation in Eisenmenger syndrome.
Embolic Stroke
Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage.
Embolism
A case report of a new pulmonary embolism occurring in a patient receiving continuous infusion of recombinant activated protein C.
Embolism
Does activated protein C resistance increase the risk of systematic embolism in non rheumatic atrial fibrillation?
Embolism
Intracardiac thrombus causing systemic embolism in a child with idiopathic ventricular tachycardia and heterozygous activated protein C resistance.
Embolism
Mycoplasma pneumonia and pulmonary embolism in a child due to acquired prothrombotic factors.
Embolism
Puerperal streptococcal toxic shock syndrome treated with recombinant human activated protein C and intravenous immunoglobulin.
Encephalomyelitis
Activated Protein C Attenuates Experimental Autoimmune Encephalomyelitis Progression by Enhancing Vascular Integrity and Suppressing Microglial Activation.
Encephalomyelitis
Inhibition of endogenous activated protein C attenuates experimental autoimmune encephalomyelitis by inducing myeloid-derived suppressor cells.
Encephalomyelitis
Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets.
Encephalomyelitis
Thrombin mutant W215A/E217A treatment improves neurological outcome and attenuates central nervous system damage in experimental autoimmune encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
Activated Protein C Attenuates Experimental Autoimmune Encephalomyelitis Progression by Enhancing Vascular Integrity and Suppressing Microglial Activation.
Encephalomyelitis, Autoimmune, Experimental
Inhibition of endogenous activated protein C attenuates experimental autoimmune encephalomyelitis by inducing myeloid-derived suppressor cells.
Encephalomyelitis, Autoimmune, Experimental
Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets.
Encephalomyelitis, Autoimmune, Experimental
Thrombin mutant W215A/E217A treatment improves neurological outcome and attenuates central nervous system damage in experimental autoimmune encephalomyelitis.
Endocarditis
Safety evaluation of Lactobacillus delbrueckii subsp. lactis UO 004, a probiotic bacterium.
Endotoxemia
Activated protein C ameliorates impaired renal microvascular oxygenation and sodium reabsorption in endotoxemic rats.
Endotoxemia
Activated protein C improves pial microcirculation in experimental endotoxemia in rats.
Endotoxemia
Activated protein C improves the visceral microcirculation by attenuating the leukocyte-endothelial interaction in a rat lipopolysaccharide model.
Endotoxemia
Activated protein C reduces tissue hypoxia, inflammation, and apoptosis in traumatized skeletal muscle during endotoxemia.
Endotoxemia
Activated protein C targets CD8+ dendritic cells to reduce the mortality of endotoxemia in mice.
Endotoxemia
Age-dependent vulnerability to endotoxemia is associated with reduction of anti-coagulant factors activated protein C and thrombomodulin.
Endotoxemia
Cardiovascular protective role for activated protein C during endotoxemia in rats.
Endotoxemia
Characterization of a novel human protein C inhibitor (PCI) gene transgenic mouse useful for studying the role of PCI in physiological and pathological conditions.
Endotoxemia
Effects of activated protein C on the mesenteric microcirculation and cytokine release during experimental endotoxemia: [Effets de la proteine C activee sur la microcirculation mesenterique et la liberation de cytokines durant une endotoxemie experimentale].
Endotoxemia
Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C.
Endotoxemia
Increased coagulation and suppressed generation of activated protein C in aged mice during intra-abdominal sepsis.
Endotoxemia
Microhemodynamic and cellular mechanisms of activated protein C action during endotoxemia.
Endotoxemia
Recombinant human activated protein C (rhAPC; drotrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxemia.
Endotoxemia
Recombinant human activated protein C attenuates endotoxin-induced lung injury in awake sheep.
Endotoxemia
Recombinant human activated protein C improves endotoxemia-induced endothelial dysfunction: A blood free model in isolated mouse arteries.
Endotoxemia
Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-gamma, or phorbol ester.
Endotoxemia
The effect of activated protein C on plasma cytokine levels in a porcine model of acute endotoxemia.
Endotoxemia
The effects of supra-normal protein C levels on markers of coagulation, fibrinolysis and inflammation in a human model of endotoxemia.
Endotoxemia
The efficacy of activated protein C in murine endotoxemia is dependent on integrin CD11b.
Enterocolitis, Necrotizing
Activated protein C reduces intestinal injury in an experimental model of necrotizing enterocolitis.
Enterocolitis, Necrotizing
Resistance to activated protein C in newborns with necrotizing enterocolitis.
Erythema Infectiosum
Fetal stroke and congenital parvovirus B19 infection complicated by activated protein C resistance.
Escherichia coli Infections
Effect of recombinant human activated protein C on the bactericidal activity of human monocytes and modulation of pro-inflammatory cytokines in the presence of antimicrobial agents.
Fabry Disease
Allograft loss in renal transplant recipients with Fabry's disease and activated protein C resistance.
Factor V Deficiency
Association of severe haemophilia A and factor V Leiden: report of three cases.
Factor V Deficiency
Molecular characterization of a type I quantitative factor V deficiency in a thrombosis patient that is "pseudo homozygous" for activated protein C resistance.
Factor V Deficiency
Pseudo-homozygous activated protein C resistance due to coinheritance of heterozygous factor V Leiden mutation and type I factor V deficiency. Variable expression when analyzed by different activated protein C resistance functional assays.
Factor V Deficiency
The factor V Glu1608Lys mutation is recurrent in familial thrombophilia.
Fasciitis, Necrotizing
[Monitoring of plasma disappearance rate of indocyanine green in a patient with necrotizing fasciitis and septic shock]
Fatty Liver
Complications of acute fatty liver of pregnancy treated with activated protein C.
Fetal Death
High prevalence of activated protein C resistance due to factor V leiden mutation in cases of intrauterine fetal death.
Fetal Growth Retardation
Activated protein C prevents development of phosphatidylserine-induced intrauterine growth restriction in mice.
Foramen Ovale, Patent
Emerging risk factors for stroke: Patent foramen ovale, proximal aortic atherosclerosis, antiphospholipid antibodies, and activated protein C resistance.
Gastrointestinal Neoplasms
Hypercoagulable state in patients with advanced gastrointestinal cancer: evidence for an acquired resistance to activated protein C.
Genetic Diseases, Inborn
Familial thrombophilia: clinical and molecular analysis of Swedish families with inherited resistance to activated protein C or protein S deficiency.
Glaucoma
[Assessment of risk factors for retinal vein occlusions in patients under 60 years of age]
Glomerulonephritis
[Prevalence of genetic prothrombotic factors (factor V Leiden and II20210 prothrombin mutation) in glomerular nephropathies with or without thrombosis]
Glomerulonephritis, Membranous
Association of membranous nephropathy with familial resistance to activated protein C.
Glomerulonephritis, Membranous
Membranous glomerulonephritis in a patient with inherited activated protein C resistance.
Graft vs Host Disease
Activated protein C ameliorates chronic graft-versus-host disease by PAR1-dependent biased cell signaling on T cells.
Hearing Loss, Noise-Induced
Activated protein C rescues the cochlea from noise-induced hearing loss.
Heart Arrest
Effects of activated protein C on post cardiac arrest microcirculation: an in vivo microscopy study.
Heart Defects, Congenital
Low arterial saturation is associated with increased sensitivity to activated protein C in children with congenital heart disease.
Heart Diseases
Plasma resistance to activated protein C regulates the activation of coagulation induced by thrombolysis in patients with ischaemic heart disease.
Heart Diseases
Thromboembolism and resistance to activated protein C in children with underlying cardiac disease.
Heart Failure
The Cardioprotective Signaling Activity of Activated Protein C in Heart Failure and Ischemic Heart Diseases.
Heart Failure
[Can we afford the costs of progress in intensive care medicine? A plea for a candid debate]
Hematologic Diseases
The use of recombinant human activated protein C (rhAPC) in the treatment of severe sepsis in immunosuppressed patients in the course of hematological diseases.
Hematologic Neoplasms
Activated protein C resistance as measured by residual factor V after Russell's viper venom and activated protein C treatment analyzed as a continuous variable in multiple myeloma and normal controls.
Hematologic Neoplasms
Increased acquired activated protein C resistance in unselected patients with hematological malignancies.
Hemoglobinopathies
The role of hypercoagulability in the development of osteonecrosis of the femoral head.
Hemophilia A
Activated protein C inhibitor for correction of thrombin generation in hemophilia A blood and plasma1.
Hemophilia A
Design, synthesis, and SAR of a series of activated protein C (APC) inhibitors with selectivity against thrombin for the treatment of haemophilia.
Hemophilia A
Emicizumab-mediated haemostatic function in patients with haemophilia A is down-regulated by activated protein C through inactivation of activated factor V.
Hemophilia A
Endogenous activated protein C signaling is critical to protection of mice from lipopolysaccaride-induced septic shock.
Hemophilia A
Factor VIIa interaction with EPCR modulates the hemostatic effect of rFVIIa in hemophilia therapy: Mode of its action.
Hemophilia A
Modulation of the activated protein C pathway in severe haemophilia A patients: The effects of thrombomodulin and a factor V-stabilizing fab.
Hemophilia A
Mutations associated with hemophilia A in the 558-565 loop of the factor VIIIa A2 subunit alter the catalytic activity of the factor Xase complex.
Hemophilia A
Peptidomimetic inhibitors for activated protein C: implications for hemophilia management.
Hemophilia A
Targeted inhibition of activated protein C by a non-active-site inhibitory antibody to treat hemophilia.
Hemophilia A
The plasma concentration of activated protein C appears normal in patients with haemophilia.
Hemorrhagic Fever, Ebola
Recombinant Human Activated Protein C for the Postexposure Treatment of Ebola Hemorrhagic Fever.
Hepatitis
Phenprocoumon-induced hepatitis delaying precise diagnosis in a thrombophilic patient with activated protein C resistance due to factor V R506Q mutation.
HIV Infections
Defects in assembly explain reduced antiviral activity of the G249D polymorphism in human TRIM5?.
Homocystinuria
Coexistence of hereditary homocystinuria and factor V Leiden--effect on thrombosis.
Hydrocephalus
Activated protein C resistance and false type 2 protein C deficiency detected after multiple shunt failures in a patient with hydrocephalus.
Hyperalgesia
Thrombomodulin alfa prevents oxaliplatin-induced neuropathic symptoms through activation of thrombin-activatable fibrinolysis inhibitor and protein C without affecting anti-tumor activity.
Hypercholesterolemia
Activated protein C resistance is a risk factor for central retinal vein occlusion.
Hyperglycemia
Evidence-based management of critically ill patients: analysis and implementation.
Hyperglycemia
Impact of introducing multiple evidence-based clinical practice protocols in a medical intensive care unit: a retrospective cohort study.
Hyperhomocysteinemia
Antiphospholipid antibodies and thrombosis: association with acquired activated protein C resistance in venous thrombosis and with hyperhomocysteinemia in arterial thrombosis.
Hyperhomocysteinemia
Clinical and ethnic characteristics of stroke in an Israeli population: a study in a community hospital population.
Hyperhomocysteinemia
Cutaneous necrosis revealing the coexistence of an antiphospholipid syndrome with acquired protein S deficiency, factor V Leiden and hyperhomocysteinemia.
Hyperhomocysteinemia
High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia.
Hyperhomocysteinemia
Inherited and acquired thrombophilia: pregnancy outcome and treatment.
Hyperhomocysteinemia
Ischemic stroke subtypes and thrombophilia in young and elderly Brazilian stroke patients admitted to a rehabilitation hospital.
Hyperhomocysteinemia
Pathology consultation on the laboratory evaluation of thrombophilia: when, how, and why.
Hyperhomocysteinemia
Prothrombin gene mutation G20210A, homocysteine, antiphospholipid antibodies and other hypercoagulable states in ocular thrombosis.
Hyperhomocysteinemia
Thrombophilic abnormalities and recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatment.
Hypersensitivity
Activated protein C modulates the proinflammatory activity of dendritic cells.
Hypertension
Evaluation of natural coagulation inhibitor levels in various hypertensive states of pregnancy.
Hypertension
Resistance to activated protein C and FV leiden mutation in patients with a history of acute myocardial infarction or primary hypertension.
Hypertension, Pregnancy-Induced
Activated protein C resistance shows an association with pregnancy-induced hypertension.
Hyperventilation
Recently published papers: Pseudomonas, brain and bowel injury and novel cardiac therapies.
Hypotension
Activated protein C prevents endotoxin-induced hypotension in rats by inhibiting excessive production of nitric oxide.
Hypotension
Activated protein C suppresses adrenomedullin and ameliorates lipopolysaccharide-induced hypotension.
Hypotension
High dose infusion of activated protein C (rhAPC) fails to improve neuronal damage and cognitive deficit after global cerebral ischemia in rats.
Hypotension
Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008.
Hypotension
Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.
Hypotension
Vascular hyporesponsiveness to vasopressors in septic shock: from bench to bedside.
Idiopathic Pulmonary Fibrosis
[Protein C system in patients with idiopathic pulmonary fibrosis - preliminary report.]
Infections
Clinical experience with drotrecogin alfa in treating gram-positive and -negative pathogens in patients with severe sepsis.
Infections
Critical role of activated protein C in early coagulopathy and later organ failure, infection and death in trauma patients.
Infections
Effect of recombinant human activated protein C on the bactericidal activity of human monocytes and modulation of pro-inflammatory cytokines in the presence of antimicrobial agents.
Infections
Efficacy of therapy with recombinant human activated protein C of critically ill surgical patients with infection complicated by septic shock and multiple organ dysfunction syndrome.
Infections
Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis.
Infections
Fetal stroke and congenital parvovirus B19 infection complicated by activated protein C resistance.
Infections
Future perspectives on regulating pro-and anti-inflammatory responses in sepsis.
Infections
Inhalation of activated protein C inhibits endotoxin-induced pulmonary inflammation in mice independent of neutrophil recruitment.
Infections
Old drug, new Trick? The rationale for the treatment of COVID-19 with activated protein C.
Infections
Recombinant human activated protein C treatment of septic shock syndrome in a patient at 18th week of gestation: a case report.
Infections
Relationship between the inflammation and coagulation pathways in patients with severe sepsis: implications for therapy with activated protein C.
Infections
Spontaneous central vein thrombosis in a patient with activated protein C resistance and dengue infection: An association or causation?
Infections
Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008.
Infections
Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.
Infections
Systemic host inflammatory and coagulation response in the Dengue virus primo-infection.
Infections
Treatment of severe sepsis secondary to mycobacterium avium-intracellulare with recombinant human activated protein C.
Infections
Voltage-Dependent Anion Channel Protein 2 (VDAC2) and Receptor of Activated Protein C Kinase 1 (RACK1) Act as Functional Receptors for Lymphocystis Disease Virus Infection.
Infections
[Can we afford the costs of progress in intensive care medicine? A plea for a candid debate]
Infections
[New therapy strategies for treatment of severe sepsis and septic shock in intensive care unit of clinical centre in Kragujevac]
Inflammatory Bowel Diseases
Activated protein C resistance in pediatric inflammatory bowel disease.
Inflammatory Bowel Diseases
Activated protein C resistance, thrombophilia, and inflammatory bowel disease.
Inflammatory Bowel Diseases
Effects of dermatan sulfate derivatives on platelet surface P-selectin expression and protein C activity in blood of inflammatory bowel disease patients.
Inflammatory Bowel Diseases
Natural coagulation inhibitory proteins and activated protein C resistance in Turkish patients with inflammatory bowel disease.
Inflammatory Bowel Diseases
Prevalence of hyperhomocysteinaemia, activated protein C resistance and prothrombin gene mutation in inflammatory bowel disease.
Inflammatory Bowel Diseases
Resistance to activated protein C and low levels of free protein S in Greek patients with inflammatory bowel disease.
Inflammatory Bowel Diseases
Thromboembolism and resistance to activated protein C in patients with inflammatory bowel disease.
Influenza, Human
Activated protein C ameliorates coagulopathy but does not influence outcome in lethal H1N1 influenza: a controlled laboratory study.
Influenza, Human
Effects on coagulation and fibrinolysis induced by influenza in mice with a reduced capacity to generate activated protein C and a deficiency in plasminogen activator inhibitor type 1.
Influenza, Human
Nebulized activated protein C in a paediatric patient with severe acute respiratory distress syndrome secondary to H1N1 influenza.
Intracranial Aneurysm
Incidental discovery of a dural arteriovenous fistula in a patient with activated protein C resistance.
Intracranial Hemorrhage, Traumatic
Successful treatment of severe sepsis with recombinant human activated protein C in a patient with traumatic intracranial hemorrhage.
Intracranial Hemorrhages
Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage.
Intracranial Hemorrhages
Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis.
Intracranial Hemorrhages
Prevalence of serious bleeding events and intracranial hemorrhage in patients receiving activated protein C: a systematic review and meta-analysis.
Intracranial Hemorrhages
Study of protein C, protein S, and antithrombin III in newborns with sepsis.
Iron Deficiencies
Iron-deficiency anaemia in childhood: a risk factor for severe venous thrombosis?
Ischemic Attack, Transient
Prognosis after Cryptogenic Cerebral Ischemia in Patients with Coagulopathies.
Ischemic Attack, Transient
Resistance to activated protein C in adults with a history of juvenile transient ischemic attacks.
Ischemic Stroke
?-arrestin-2 in PAR-1-biased signaling has a crucial role in endothelial function via PDGF-? in stroke.
Ischemic Stroke
A hypercoagulable state in activated protein C resistant patients with ischemic stroke.
Ischemic Stroke
Activated protein C analog promotes neurogenesis and improves neurological outcome after focal ischemic stroke in mice via protease activated receptor 1.
Ischemic Stroke
Activated protein C analog protects from ischemic stroke and extends the therapeutic window of tissue-type plasminogen activator in aged female mice and hypertensive rats.
Ischemic Stroke
Activated Protein C Attenuates Experimental Autoimmune Encephalomyelitis Progression by Enhancing Vascular Integrity and Suppressing Microglial Activation.
Ischemic Stroke
Activated protein C resistance and acute ischaemic stroke: relation to stroke causation and age.
Ischemic Stroke
Activated protein C resistance due to a factor V mutation associated with familial ischemic stroke.
Ischemic Stroke
Activated protein C resistance in ischemic stroke not due to factor V arginine506-->glutamine mutation.
Ischemic Stroke
Activated protein C resistance in young African American patients with ischemic stroke.
Ischemic Stroke
An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tissue plasminogen activator for ischemic stroke in rodents.
Ischemic Stroke
Anti-inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke.
Ischemic Stroke
Can adjunctive therapies augment the efficacy of endovascular thrombolysis? A potential role for activated protein C.
Ischemic Stroke
Ethnic differences in markers of thrombophilia: implications for the investigation of ischemic stroke in multiethnic populations: the South London Ethnicity and Stroke Study.
Ischemic Stroke
Extensive venous and arterial thrombosis associated with an inhibitor to activated protein C.
Ischemic Stroke
Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke.
Ischemic Stroke
Frequency of resistance to activated protein C due to factor V mutation in young patients with ischemic stroke.
Ischemic Stroke
FV-ARG-506-GLN-Mutation-associated resistance to activated protein C in ischemic stroke.
Ischemic Stroke
Influence of the 3K3A-activated protein C variant on the plasma clot lysis activity of tPA and of tPA on the variant's anticoagulant activity.
Ischemic Stroke
Ischemic stroke associated with activated protein C resistance and aortic valvular papillary fibroelastoma.
Ischemic Stroke
Ischemic stroke in the elderly. Role of the common factor V mutation causing resistance to activated protein C.
Ischemic Stroke
Ischemic stroke in young patients with activated protein C resistance. A report of three cases belonging to three different kindreds.
Ischemic Stroke
Neurotoxicity of the anticoagulant-selective E149A-activated protein C variant after focal ischemic stroke in mice.
Ischemic Stroke
NF-?B-dependent and -independent pathways in the protective effects of activated protein C in hippocampal and cortical neurons at excitotoxicity.
Ischemic Stroke
NON-activated protein C as post-treatment after spinal cord compression injury in rats.
Ischemic Stroke
Physiological cerebrovascular remodeling in response to chronic mild hypoxia: A role for activated protein C.
Ischemic Stroke
Preclinical Safety and Pharmacokinetic Profile of 3K3A-APC, a Novel, Modified Activated Protein C for Ischemic Stroke.
Ischemic Stroke
Prognosis after Cryptogenic Cerebral Ischemia in Patients with Coagulopathies.
Ischemic Stroke
Protective effects of non-anticoagulant activated protein C variant (D36A/L38D/A39V) in a murine model of ischaemic stroke.
Ischemic Stroke
Prothrombotic Factors Have Significant Association with Arterial and Venous Strokes in Indian Tamilians.
Ischemic Stroke
Recombinant murine-activated protein C is neuroprotective in a murine ischemic stroke model.
Ischemic Stroke
Thrombin mutant W215A/E217A treatment improves neurological outcome and reduces cerebral infarct size in a mouse model of ischemic stroke.
Ischemic Stroke
Tissue Factor Pathway Inhibitor, Activated Protein C Resistance, and Risk of Ischemic Stroke due to Postmenopausal Hormone Therapy.
Ischemic Stroke
[Thrombophilias in patients with ischemic stroke. Indication and calculated costs for evidence-based diagnostics and treatment]
Kidney Failure, Chronic
Hypercoagulable states in renal transplant candidates: impact of anticoagulation upon incidence of renal allograft thrombosis.
Kidney Failure, Chronic
Increased activated protein C: protein C inhibitor complex and decreased protein C inhibitor levels in patients with chronic renal failure on maintenance hemodialysis.
Kidney Failure, Chronic
Safety and dose-finding study of activated protein C (drotrecogin alfa activated) as an anticoagulant in end-stage renal disease patients treated with hemodialysis.
Leg Ulcer
A prospective coagulation study including resistance to activated protein C and mutations in factors V and II in venous leg ulcers.
Leg Ulcer
Activated protein C resistance and anticardiolipin antibodies in patients with venous leg ulcers.
Leg Ulcer
Activated protein C resistance caused by factor V gene mutation: common coagulation defect in chronic venous leg ulcers?
Leg Ulcer
Coagulation factor V gene mutation associated with activated protein C resistance leading to recurrent thrombosis, leg ulcers, and lymphedema: successful treatment with intermittent compression.
Leg Ulcer
Resistance to activated protein C due to factor V Leiden mutation: high prevalence in patients with post-thrombotic leg ulcers.
Leg Ulcer
Treatment of chronic diabetic lower leg ulcers with activated protein C: a randomised placebo-controlled, double-blind pilot clinical trial.
Legg-Calve-Perthes Disease
Absence of congenital prethrombotic disorders in children with Legg-Perthes disease.
Legg-Calve-Perthes Disease
The role of inherited thrombotic disorders in the etiology of Legg-Calvé-Perthes disease.
Legg-Calve-Perthes Disease
The role of protein C, protein S, and resistance to activated protein C in Legg-Perthes disease.
Leptospirosis
Severe sepsis due to severe falciparum malaria and leptospirosis co-infection treated with activated protein C.
Leptospirosis
Successful treatment of septic shock and respiratory failure due to leptospirosis and scrub typhus coinfection with penicillin, levofloxacin, and activated protein C.
Leukemia
Activated protein C suppresses tissue factor expression on U937 cells in the endothelial protein C receptor-dependent manner.
Leukemia
The use of recombinant human activated protein C (rhAPC) in the treatment of severe sepsis in immunosuppressed patients in the course of hematological diseases.
Leukemia
Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia.
Leukemia, Hairy Cell
The use of recombinant human activated protein C (rhAPC) in the treatment of severe sepsis in immunosuppressed patients in the course of hematological diseases.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Activated Protein C Resistance in Polycythemia Vera.
Liver Cirrhosis
Clinical characteristics and outcomes of sepsis-related vs non-sepsis-related ARDS.
Liver Diseases
Activated protein C prevents multiple organ injury following extensive hepatectomy in cirrhotic rats.
Liver Diseases
Increased bleeding risk associated with the use of recombinant human activated protein C in patients with advanced liver disease.
Liver Failure, Acute
Acute Budd-Chiari syndrome with fulminant hepatic failure in a pregnant woman with factor V Leiden mutation.
Lung Diseases
Activated Protein C Attenuates Systemic Lupus Erythematosus and Lupus Nephritis in MRL-Fas(lpr) Mice.
Lung Injury
Activated protein C ameliorates coagulopathy but does not influence outcome in lethal H1N1 influenza: a controlled laboratory study.
Lung Injury
Activated protein C inhibits lung injury induced by LPS via downregulating MAPK signaling.
Lung Injury
Current view on alveolar coagulation and fibrinolysis in acute inflammatory and chronic interstitial lung diseases.
Lung Injury
Cytoprotective-selective Activated Protein C Attenuates P. aeruginosa-induced Lung Injury in Mice.
Lung Injury
Heme oxygenase-1 modulates thrombomodulin and activated protein c levels to attenuate lung injury in cecal ligation and puncture-induced acute lung injury mice.
Lung Injury
Inhaled activated protein C attenuates lung injury induced by aerosolized endotoxin in mice.
Lung Injury
Inhaled aerosolized recombinant human activated protein C ameliorates endotoxin-induced lung injury in anesthetized sheep.
Lung Injury
Intravenous administration of activated protein C in Pseudomonas-induced lung injury: impact on lung fluid balance and the inflammatory response.
Lung Injury
Nebulized anticoagulants for acute lung injury - a systematic review of preclinical and clinical investigations.
Lung Injury
Pulmonary coagulopathy as a new target in lung injury--a review of available pre-clinical models.
Lung Injury
Recombinant human activated protein C ameliorates oleic acid-induced lung injury in awake sheep.
Lung Injury
Recombinant human activated protein C attenuates endotoxin-induced lung injury in awake sheep.
Lung Injury
Recombinant human activated protein C in acute lung injury: what is the role of bronchial circulation?
Lung Injury
Role of coagulation pathways and treatment with activated protein C in hyperoxic lung injury.
Lung Injury
Treatment of sepsis-induced acquired protein C deficiency reverses Angiotensin-converting enzyme-2 inhibition and decreases pulmonary inflammatory response.
Lung Neoplasms
The functional properties of a truncated form of endothelial cell protein C receptor generated by alternative splicing.
Lupus Erythematosus, Systemic
Acquired activated protein C resistance is associated with IgG antibodies to protein S in patients with systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Acquired activated protein C resistance is associated with lupus anticoagulants and thrombotic events in pediatric patients with systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Acquired activated protein C resistance is associated with the co-existence of anti-prothrombin antibodies and lupus anticoagulant activity in patients with systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Acquired activated protein C resistance, high tissue factor expression, and hyper-homocysteinemia in systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Activated Protein C Attenuates Systemic Lupus Erythematosus and Lupus Nephritis in MRL-Fas(lpr) Mice.
Lupus Erythematosus, Systemic
Clinical significance of acquired activated protein C resistance in patients with systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Low levels of activated protein C in patients with systemic lupus erythematosus do not relate to lupus anticoagulants but to low levels of factor II.
Lupus Erythematosus, Systemic
Membrane autoantibodies in systemic lupus erythematosus: a case of autoimmune hemolytic anemia, antiphospholipid antibodies, and transient acquired activated protein C resistance.
Lupus Erythematosus, Systemic
Resistance to activated protein C in systemic lupus erythematosus patients with antiphospholipid antibodies.
Lupus Erythematosus, Systemic
The role of hypercoagulability in the development of osteonecrosis of the femoral head.
Lupus Erythematosus, Systemic
[Relationship between phenomenon of acquired activated protein C resistance and antiphospholipid antibodies in patients with systemic lupus erythematosus]
Lupus Nephritis
Activated Protein C Attenuates Systemic Lupus Erythematosus and Lupus Nephritis in MRL-Fas(lpr) Mice.
Lymphedema
Coagulation factor V gene mutation associated with activated protein C resistance leading to recurrent thrombosis, leg ulcers, and lymphedema: successful treatment with intermittent compression.
Lymphohistiocytosis, Hemophagocytic
Differences between adult and pediatric septic shock.
Lymphoma
Phenotypic APC resistance as a marker of hypercoagulability in primitive cerebral lymphoma.
Macular Edema
Activated Protein C for Ischemic Central Retinal Vein Occlusion: One-Year Results.
Malaria
Activated protein C protects vascular endothelial cells from apoptosis in malaria and in sepsis.
Malaria
Severe adult malaria is associated with specific PfEMP1 adhesion types and high parasite biomass.
Malaria
Severe sepsis due to severe falciparum malaria and leptospirosis co-infection treated with activated protein C.
Malaria
[Activated protein C (Xigris) during severe imported malaria: look at benefit/risk ratio]
Malaria
[Is there a place for activated protein C (Xigris) in the treatment of severe imported malaria in the adult?]
Malaria, Falciparum
The use of activated protein C in severe Plasmodium falciparum malaria.
Melanoma
Low recurrence rate after deep calf-vein thrombosis with 6 weeks of oral anticoagulation.
Melanoma
Proteolytic activation of tissue plasminogen activator by plasma and tissue enzymes.
Melioidosis
Overexpression of Activated Protein C is Detrimental During Severe Experimental Gram-Negative Sepsis (Melioidosis)*
Melioidosis
Successful treatment of life-threatening melioidosis with activated protein C and meropenem.
Meningitis, Bacterial
Subarachnoid haemorrhage following activated protein C for bacterial meningitis.
Mesenteric Ischemia
Activated protein C resistance associated with lupus anticoagulants is a high risk in acute mesenteric venous thrombosis.
Mesenteric Ischemia
[Activated protein C resistance as the cause of recurrent mesenteric venous thrombosis]
Mesenteric Ischemia
[Upper mesenteric venous thrombosis revealing familial resistance to activated protein C]
Mitral Valve Stenosis
Role of activated protein C resistance in left atrial thrombogenesis in patients with mitral stenosis.
Monoclonal Gammopathy of Undetermined Significance
Plasma Thrombin Generation and Sensitivity to Activated Protein C Among Patients With Myeloma and Monoclonal Gammopathy of Undetermined Significance.
Multiple Myeloma
Acquired activated protein C resistance and thrombosis in multiple myeloma patients.
Multiple Myeloma
Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism.
Multiple Myeloma
Activated protein C resistance as measured by residual factor V after Russell's viper venom and activated protein C treatment analyzed as a continuous variable in multiple myeloma and normal controls.
Multiple Myeloma
Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications.
Multiple Myeloma
Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations.
Multiple Sclerosis
Activated protein C: possible therapeutic implications for multiple sclerosis.
Multiple Sclerosis
The effects of thrombomodulin and activated protein C on the pathogenesis of multiple sclerosis.
Myocardial Infarction
A new method to measure plasma levels of activated protein C in complex with protein C inhibitor in patients with acute coronary syndromes.
Myocardial Infarction
Activated protein C levels and outcome in patients with cardiogenic shock complicating acute myocardial infarction.
Myocardial Infarction
Association of plasma levels of activated protein C with recanalization of the infarct-related coronary artery after thrombolytic therapy in acute myocardial infarction.
Myocardial Infarction
Circulating activated protein C is reduced in young survivors of myocardial infarction and inversely correlates with the severity of coronary lesions.
Myocardial Infarction
Decreased activated protein C levels as a clinical predictor in patients with ST-elevation myocardial infarction.
Myocardial Infarction
Decreased protein C inhibitor after percutaneous transluminal coronary angioplasty in patients with acute myocardial infarction.
Myocardial Infarction
Effect of activated protein C on plasma plasminogen activator inhibitor activity in patients with acute myocardial infarction treated with alteplase: comparison with unfractionated heparin.
Myocardial Infarction
Endothelial protein C receptor polymorphisms and risk of myocardial infarction.
Myocardial Infarction
Evaluation of activated protein C on canine infarct size in a nonthrombotic model of myocardial reperfusion injury.
Myocardial Infarction
Evidence against heterozygous coagulation factor V 1691 G-->A mutation with resistance to activated protein C being a risk factor for coronary artery disease and myocardial infarction.
Myocardial Infarction
Myocardial infarction associated with homozygous resistance to activated protein C.
Myocardial Infarction
Myocardial infarction in a 35-year-old man with homocysteinemia, high plasminogen activator inhibitor activity, and resistance to activated protein C.
Myocardial Infarction
Myocardial infarction, Arg 506 to Gln factor V mutation, and activated protein C resistance.
Myocardial Infarction
Plasma levels of activated protein C-protein C inhibitor complex in patients with hypercoagulable states.
Myocardial Infarction
Predictors of left ventricular thrombus formation in patients with anterior myocardial infarction: role of activated protein C resistance.
Myocardial Infarction
Prevalence of activated protein C resistance in acute myocardial infarction in Japan.
Myocardial Infarction
Prevalence of resistance against activated protein C resulting from factor V Leiden is significantly increased in myocardial infarction: investigation of 507 patients with myocardial infarction.
Myocardial Infarction
Resistance to activated protein C and FV leiden mutation in patients with a history of acute myocardial infarction or primary hypertension.
Myocardial Infarction
Resistance to activated protein C and risk of premature myocardial infarction.
Myocardial Infarction
Resistance to activated protein C: role in venous and arterial thrombosis.
Myocardial Infarction
Risk of myocardial infarction related to factor V Leiden mutation: a meta-analysis.
Myocardial Infarction
[Activated protein C resistance: role in venous and arterial thrombosis]
Myocardial Infarction
[Evaluation of resistance to activated protein C in myocardial infarction patients]
Myocardial Infarction
[Resistance to activated protein C in a patient with multiple myocardial infarctions and stroke--a case report]
Myocardial Ischemia
The Cardioprotective Signaling Activity of Activated Protein C in Heart Failure and Ischemic Heart Diseases.
Myocardial Reperfusion Injury
Evaluation of activated protein C on canine infarct size in a nonthrombotic model of myocardial reperfusion injury.
Myocarditis
Successful use of extracorporeal membrane oxygenation and drotrecogin alpha in patients with acute life-threatening myocarditis.
Necrobiosis Lipoidica
Systemic corticosteroids for the outpatient treatment of necrobiosis lipoidica in a diabetic patient.
Neonatal Sepsis
Study of protein C, protein S, and antithrombin III in newborns with sepsis.
Neoplasm Metastasis
Association between protein C levels and mortality in patients with advanced prostate, lung and pancreatic cancer.
Neoplasm Metastasis
Receptor of activated protein C promotes metastasis and correlates with clinical outcome in lung adenocarcinoma.
Neoplasm Metastasis
Role of activated protein C and its receptor in inhibition of tumor metastasis.
Neoplasms
Acquired activated protein C resistance and thrombosis in multiple myeloma patients.
Neoplasms
Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism.
Neoplasms
Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism.
Neoplasms
Activated protein C attenuates cardiopulmonary bypass-induced acute lung injury through the regulation of neutrophil activation.
Neoplasms
Activated protein C decreases tumor necrosis factor related apoptosis-inducing ligand by an EPCR- independent mechanism involving Egr-1/Erk-1/2 activation.
Neoplasms
Activated protein C improves ischemic flap survival and modulates proangiogenic and antiinflammatory gene expression.
Neoplasms
Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kappaB (NF-kappaB) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line.
Neoplasms
Activated protein C inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kappa B and activator protein-1 in human monocytes.
Neoplasms
Activated Protein C Inhibits Proliferation and Tumour Necrosis Factor ?-stimulated Activation of p38, JNK and Akt in Rheumatoid Synovial Fibroblasts.
Neoplasms
Activated protein C inhibits tumor necrosis factor and macrophage migration inhibitory factor production in monocytes.
Neoplasms
Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production.
Neoplasms
Activated protein C upregulates ovarian cancer cell migration and promotes unclottability of the cancer cell microenvironment.
Neoplasms
An innovative immunosensor for ultrasensitive detection of breast cancer specific carbohydrate (CA 15-3) in unprocessed human plasma and MCF-7 breast cancer cell lysates using gold nanospear electrochemically assembled onto thiolated graphene quantum dots.
Neoplasms
Association between increased tumor necrosis factor alpha levels and acquired activated protein C resistance in patients with metastatic colorectal cancer.
Neoplasms
Clinical characteristics and outcomes of sepsis-related vs non-sepsis-related ARDS.
Neoplasms
Complement activation and plasma levels of C4b-binding protein in critical limb ischemia patients.
Neoplasms
Determination of coagulation inhibitor levels and resistance to activated protein C in patients undergoing gastric surgery for benign and malignant disorders.
Neoplasms
Development and biological evaluation of ??mTc-sulfonamide derivatives for in vivo visualization of CA IX as surrogate tumor hypoxia markers.
Neoplasms
Drotrecogin alfa (activated) does not affect intracellular production of interleukin-6 and tumor necrosis factor-alpha in endotoxin-stimulated human monocytes.
Neoplasms
Early changes of a novel APC-dependent thrombin generation assay during chemotherapy independently predict venous thromboembolism in cancer patients-a pilot study.
Neoplasms
Emodin improves alveolar hypercoagulation and inhibits pulmonary inflammation in LPS-provoked ARDS in mice via NF-?B inactivation.
Neoplasms
Endogenous activated protein C is essential for immune-mediated cancer cell elimination from the circulation.
Neoplasms
Endogenous activated protein C limits cancer cell extravasation through sphingosine-1-phosphate receptor 1-mediated vascular endothelial barrier enhancement.
Neoplasms
Enhanced induction of heme oxygenase-1 suppresses thrombus formation and affects the protein C system in sepsis.
Neoplasms
EPCR promotes MGC803 human gastric cancer cell tumor angiogenesis in vitro through activating ERK1/2 and AKT in a PAR1-dependent manner.
Neoplasms
Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis.
Neoplasms
Heme oxygenase 1 modulates thrombomodulin and endothelial protein C receptor levels to attenuate septic kidney injury.
Neoplasms
Hypercoagulable state in patients with advanced gastrointestinal cancer: evidence for an acquired resistance to activated protein C.
Neoplasms
Immunosensing of breast cancer tumor protein CA 15-3 (carbohydrate antigen 15.3) using a novel nano-bioink: A new platform for screening of proteins in human biofluids by pen-on-paper technology.
Neoplasms
Impact of chemotherapy on activated protein C-dependent thrombin generation-Association with VTE occurrence.
Neoplasms
Inactivation of factor Va by activated protein C on selected human tumor cell lines.
Neoplasms
Increased acquired activated protein C resistance in unselected patients with hematological malignancies.
Neoplasms
Increased D-dimer levels correlate with binding of activated protein C, but not tissue factor expression, on peripheral blood monocytes in cancer patients.
Neoplasms
Inflammatory mediators are associated with 1-year mortality in critical limb ischemia.
Neoplasms
Paper based immunosensing of ovarian cancer tumor protein CA 125 using novel nano-ink: A new platform for efficient diagnosis of cancer and biomedical analysis using microfluidic paper-based analytical devices (?PAD).
Neoplasms
Patterns of markers of inflammation, coagulation and vasoconstriction during folllow-up of abdominal aortic aneurysms.
Neoplasms
PO-14 - Tumour expression of coagulation proteases of the aPC pathway - a role in the pathogenesis of gynaecological cancers?
Neoplasms
Primary pulmonary artery sarcoma resembling chronic thromboembolic pulmonary disease.
Neoplasms
Production and control of coagulation proteins for factor X activation in human endothelial cells and fibroblasts.
Neoplasms
Prospective evaluation of patients hospitalized with venous thromboembolism: comparison between cancer and non-cancer patients.
Neoplasms
RACK1 is indispensable for porcine reproductive and respiratory syndrome virus replication and NF-?B activation in Marc-145 cells.
Neoplasms
Recombinant human activated protein C upregulates cyclooxygenase-2 expression in endothelial cells via binding to endothelial cell protein C receptor and activation of protease-activated receptor-1.
Neoplasms
Role of activated protein C in facilitating basement membrane invasion by tumor cells.
Neoplasms
Structure of the carbonic anhydrase VI (CA6) gene: evidence for two distinct groups within the alpha-CA gene family.
Neoplasms
Ultrasensitive immunoassay of tumor protein CA 15.3 in MCF-7 breast cancer cell lysates and unprocessed human plasma using gold nanoparticles doped on the structure of mesoporous silica.
Neoplasms
[Study on activated protein C resistance and disordered coagulation in patients with myeloproliferative neoplasms].
Nephrotic Syndrome
A case of deep vein thrombosis in idiopathic nephrotic syndrome with resistance to activated protein C.
Nephrotic Syndrome
Resistance to activated protein C as an underlying cause of recurrent venous thrombosis during relapsing nephrotic syndrome.
Nephrotic Syndrome
The factor V Leiden mutation and risk of renal vein thrombosis in patients with nephrotic syndrome.
Nervous System Diseases
Endothelial protein C receptor-assisted transport of activated protein C across the mouse blood-brain barrier.
Neuralgia
Exogenous estrogen may exacerbate thrombophilia, impair bone healing and contribute to development of chronic facial pain.
Neurodegenerative Diseases
High dose infusion of activated protein C (rhAPC) fails to improve neuronal damage and cognitive deficit after global cerebral ischemia in rats.
Neuroinflammatory Diseases
Activated protein C prevents glutamate- and thrombin-induced activation of nuclear factor-kappaB in cultured hippocampal neurons.
Non-alcoholic Fatty Liver Disease
Association between thrombotic risk factors and extent of fibrosis in patients with non-alcoholic fatty liver diseases.
Oligohydramnios
Longitudinal evaluation of activated protein C resistance among normal pregnancies of Hispanic women.
Optic Nerve Diseases
Activated protein C resistance in anterior ischaemic optic neuropathy.
Optic Neuropathy, Ischemic
Anterior ischemic optic neuropathy and activated protein C resistance. A case report and review of the literature.
Optic Neuropathy, Ischemic
[Thrombophilic disorders associated with non-arteritic anterior ischaemic optic neuropathy in patients < 60 years of age]
Osteoarthritis
Matrix metalloproteinase (MMP)-2, MMP-9 and MMP-13 are activated by Activated Protein C (APC) in human osteoarthritic cartilage chondrocytes.
Osteonecrosis
Exogenous estrogen may exacerbate thrombophilia, impair bone healing and contribute to development of chronic facial pain.
Osteonecrosis
Heritable thrombophilia-hypofibrinolysis and osteonecrosis of the femoral head.
Osteonecrosis
Heterozygosity for the Leiden mutation of the factor V gene, a common pathoetiology for osteonecrosis of the jaw, with thrombophilia augmented by exogenous estrogens.
Osteonecrosis
Long term anticoagulation (4-16 years) stops progression of idiopathic hip osteonecrosis associated with familial thrombophilia.
Ovarian Hyperstimulation Syndrome
Activated protein C and the ovarian hyperstimulation syndrome: Possible therapeutic implications.
Ovarian Hyperstimulation Syndrome
Use of recombinant human activated protein C in treatment of severe sepsis in a pregnant patient with fully symptomatic ovarian hyperstimulation syndrome.
Ovarian Neoplasms
Activated protein C upregulates ovarian cancer cell migration and promotes unclottability of the cancer cell microenvironment.
Ovarian Neoplasms
Identification of key genes for guiding chemotherapeutic management in ovarian cancer using translational bioinformatics.
Ovarian Neoplasms
Paper based immunosensing of ovarian cancer tumor protein CA 125 using novel nano-ink: A new platform for efficient diagnosis of cancer and biomedical analysis using microfluidic paper-based analytical devices (?PAD).
Ovarian Neoplasms
Procoagulant activity in high grade serous ovarian cancer patients following neoadjuvant chemotherapy-The role of the activated protein C pathway.
Overweight
A family history of type 2 diabetes is associated with lower sensitivity to activated protein C in overweight and obese premenopausal women.
Pancreatitis
Activated Protein C Does Not Alleviate the Course of Systemic Inflammation in the APCAP Trial.
Pancreatitis
Activated Protein C Improves the Severity of Severe Acute Pancreatitis via Up-Regulating the Expressions of Endothelial Cell Protein C Receptor and Thrombomodulin.
Pancreatitis
Activated protein C in severe acute pancreatitis without sepsis? Not just yet ...
Pancreatitis
Activated protein C retards recovery from coagulopathy in severe acute pancreatitis.
Pancreatitis
Activated protein C, an anticoagulant polypeptide, ameliorates severe acute pancreatitis via regulation of mitogen-activated protein kinases.
Pancreatitis
Activated Protein C-Protein C Inhibitor Complex, Activation Peptide of Carboxypeptidase B and C-Reactive Protein as Predictors of Severe Acute Pancreatitis.
Pancreatitis
Administration of human recombinant activated protein C is not associated with pancreatic parenchymal haemorrhage in L-arginine-induced experimental acute pancreatitis.
Pancreatitis
Correction: The effect of activated protein C on experimental acute necrotizing pancreatitis.
Pancreatitis
Decreased inflammation and improved survival with recombinant human activated protein C treatment in experimental acute pancreatitis.
Pancreatitis
Recombinant human activated protein C (Xigris) attenuates murine cerulein-induced acute pancreatitis via regulation of nuclear factor ?B and apoptotic pathways.
Pancreatitis
Recombinant human activated protein C as a disease modifier in severe acute pancreatitis: systematic review of current evidence.
Pancreatitis
The effect of activated protein C on experimental acute necrotizing pancreatitis.
Pancreatitis
Twenty-four hour infusion of human recombinant activated protein C (Xigris) early in severe acute pancreatitis: The XIG-AP 1 trial.
Pancreatitis
Upregulated but insufficient generation of activated protein C is associated with development of multiorgan failure in severe acute pancreatitis.
Pancreatitis
Use of activated protein C has no avail in the early phase of acute pancreatitis.
Pancreatitis
[Pathogenesis and treatment of hemocoagulation disorders in an acute necrotic pancreatitis]
Pancreatitis, Acute Necrotizing
Correction: The effect of activated protein C on experimental acute necrotizing pancreatitis.
Pancreatitis, Acute Necrotizing
The effect of activated protein C on experimental acute necrotizing pancreatitis.
Pancreatitis, Acute Necrotizing
Use of activated protein C has no avail in the early phase of acute pancreatitis.
Pancreatitis, Graft
Use of Drotrecogin Alpha (Recombinant Human Activated Protein C, rhAPC) in the Treatment of Severe Sepsis Induced by Graft Pancreatitis After Simultaneous Pancreas and Kidney Transplantation: A Case Report.
Paraproteinemias
Mechanisms of thrombosis in paraproteinemias: the effects of immunomodulatory drugs.
Paraproteinemias
Plasma Thrombin Generation and Sensitivity to Activated Protein C Among Patients With Myeloma and Monoclonal Gammopathy of Undetermined Significance.
Paraproteinemias
Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations.
Peripheral Vascular Diseases
Activated protein C resistance in patients with peripheral vascular disease.
Peripheral Vascular Diseases
Activated protein C resistance, factor V Leiden and peripheral vascular disease.
Peripheral Vascular Diseases
Activated protein C resistance: prevalence and implications in peripheral vascular disease.
Peripheral Vascular Diseases
The prevalence of thrombophilia in patients with symptomatic peripheral vascular disease.
Peritonitis
Effect of activated protein C on secretory activity of rat peritoneal mast cells.
Peritonitis
Peritoneal lavage with activated protein C alters compartmentalized coagulation and fibrinolysis and improves survival in polymicrobial peritonitis.
Peritonitis
Treatment of severe sepsis secondary to mycobacterium avium-intracellulare with recombinant human activated protein C.
plasmin deficiency
Combined heterozygous plasminogen deficiency and factor V Leiden defect in the same kindred.
Pneumonia
A thrombomodulin mutation that impairs activated protein C generation results in uncontrolled lung inflammation during murine tuberculosis.
Pneumonia
Activated protein C inhibits the expression of platelet-derived growth factor in the lung.
Pneumonia
Activated protein C protection from lung inflammation in endotoxin-induced injury.
Pneumonia
CURB-65, PSI, and APACHE II to assess mortality risk in patients with severe sepsis and community acquired pneumonia in PROWESS.
Pneumonia
Effect of activated protein C on pulmonary blood flow and cytokine production in experimental acute lung injury.
Pneumonia
Inhalation of activated protein C inhibits endotoxin-induced pulmonary inflammation in mice independent of neutrophil recruitment.
Pneumonia
Inhaled activated protein C attenuates lung injury induced by aerosolized endotoxin in mice.
Pneumonia
Inhaled activated protein C: a new therapy for the prevention of ventilator-induced lung injury?
Pneumonia
Intravenous administration of activated protein C in Pseudomonas-induced lung injury: impact on lung fluid balance and the inflammatory response.
Pneumonia
Nebulized anticoagulants limit coagulopathy but not inflammation in pseudomonas aeruginosa-induced pneumonia in rats.
Pneumonia
Nebulized antithrombin limits bacterial outgrowth and lung injury in Streptococcus pneumoniae pneumonia in rats.
Pneumonia
Recombinant human activated protein C inhibits local and systemic activation of coagulation without influencing inflammation during Pseudomonas aeruginosa pneumonia in rats.
Pneumonia
Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis.
Pneumonia
Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study.
Pneumonia
Successful treatment of life-threatening melioidosis with activated protein C and meropenem.
Pneumonia
The use of recombinant human activated protein C (rhAPC) in the treatment of severe sepsis in immunosuppressed patients in the course of hematological diseases.
Pneumonia
[18F]fluorodeoxyglucose positron emission tomography for lung antiinflammatory response evaluation.
Pneumonia, Bacterial
COVID-19 hypothesis: Activated protein C for therapy of virus-induced pathologic thromboinflammation.
Pneumonia, Pneumococcal
Overexpression of activated protein C hampers bacterial dissemination during pneumococcal pneumonia.
Pneumonia, Pneumococcal
Recombinant activated protein C attenuates coagulopathy and inflammation when administered early in murine pneumococcal pneumonia.
Pneumonia, Pneumococcal
The cytoprotective effects of endogenous activated protein C reduce activation of coagulation during murine pneumococcal pneumonia and sepsis.
Pneumonia, Pneumococcal
Therapeutic recombinant murine activated protein C attenuates pulmonary coagulopathy and improves survival in murine pneumococcal pneumonia.
Polycystic Ovary Syndrome
Are women with polycystic ovary syndrome resistant to activated protein C?
Polycystic Ovary Syndrome
Beneficial effect of metformin on pregnancy outcome in women with polycystic ovary syndrome is not associated with major changes in C-reactive protein levels or indices of coagulation.
Polycythemia Vera
Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis.
Polycythemia Vera
Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera.
Postphlebitic Syndrome
[Resistance to activated protein C disclosed by postphlebitic disease. Two cases]
Pre-Eclampsia
A comparative study of the protein C system in mother's blood, cord blood and amniotic fluid.
Pre-Eclampsia
Activated protein C as disease-modifying therapy in antenatal preeclampsia: An open-label, single arm safety and efficacy trial.
Pre-Eclampsia
Activated protein C in normal human pregnancy and pregnancies complicated by severe preeclampsia: a therapeutic opportunity?
Pre-Eclampsia
Changes of resistance to activated protein C in the course of pregnancy and prevalence of factor V mutation.
Pre-Eclampsia
Complexes of activated protein C with alpha 1-antitrypsin in normal pregnancy and in severe preeclampsia.
Pre-Eclampsia
Enhanced coagulation activation in preeclampsia: the role of APC resistance, microparticles and other plasma constituents.
Pre-Eclampsia
Evaluation of natural coagulation inhibitor levels in various hypertensive states of pregnancy.
Pre-Eclampsia
High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia.
Pre-Eclampsia
Overall haemostasis potential assays performed in thrombophilic plasma: the effect of preactivating protein C and antithrombin.
Pre-Eclampsia
Performance of a novel test to quantify activated protein C resistance in women with a history of pre-eclampsia.
Pre-Eclampsia
Role of protein S and tissue factor pathway inhibitor in the development of activated protein C resistance early in pregnancy in women with a history of preeclampsia.
Pre-Eclampsia
The Glasgow Outcome, APCR and Lipid (GOAL) Pregnancy Study: significance of pregnancy associated activated protein C resistance.
Pre-Eclampsia
[Genetic trombophilia and markers of endotelial activation in patients with preeclampsia]
Pre-Eclampsia
[Occurrence of gene mutations in factor V Leiden, prothrombin and methylenetetrahydrofolate reductase in patients with pre-eclampsia]
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The use of recombinant human activated protein C (rhAPC) in the treatment of severe sepsis in immunosuppressed patients in the course of hematological diseases.
Pregnancy Complications
Postnatal screening for thrombophilia in women with severe pregnancy complications.
protein c (activated) deficiency
Cardiopulmonary bypass for a coronary artery bypass graft patient with heterozygous protein C deficiency and protein S deficiency.
protein c (activated) deficiency
Protein C pathway impairment in nonsymptomatic cigarette smokers.
Protein C Deficiency
A case of purpura fulminans is caused by homozygous delta8857 mutation (protein C-nagoya) and successfully treated with activated protein C concentrate.
Protein C Deficiency
A molecular model of the serine protease domain of activated protein C: application to the study of missense mutations causing protein C deficiency.
Protein C Deficiency
A preliminary pilot study of treatment of thrombophilia and hypofibrinolysis and amelioration of the pain of osteonecrosis of the jaws.
Protein C Deficiency
Activated protein C concentrate reverses purpura fulminans in severe genetic protein C deficiency.
Protein C Deficiency
Activated protein C concentrate treatment for skin necrosis under warfarin treatment in severe genetic protein C deficiency combined with prothrombin mutation and factor V Leiden.
Protein C Deficiency
Activated protein C concentrate: a new tool for the treatment of acute thromboembolism in patients with congenital protein C deficiency.
Protein C Deficiency
Activated protein C resistance and false type 2 protein C deficiency detected after multiple shunt failures in a patient with hydrocephalus.
Protein C Deficiency
Apparent different thrombotic tendency in patients with factor V Leiden and protein C deficiency due to selection of patients.
Protein C Deficiency
Association between prothrombin gene polymorphisms and hereditary thrombophilia in Xinjiang Kazakhs population.
Protein C Deficiency
Cardiopulmonary bypass for a coronary artery bypass graft patient with heterozygous protein C deficiency and protein S deficiency.
Protein C Deficiency
Clinical and ethnic characteristics of stroke in an Israeli population: a study in a community hospital population.
Protein C Deficiency
Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis.
Protein C Deficiency
Effect of thrombophylaxis on uterine and fetal circulation in pregnant women with a history of pregnancy complications.
Protein C Deficiency
Evaluation of a global screening assay for the investigation of the protein C anticoagulant pathway.
Protein C Deficiency
Flow cytometric analysis of autonomous growth of erythroid precursors in liquid culture detects occult polycythemia vera in the Budd-Chiari syndrome.
Protein C Deficiency
Fulminant sepsis/meningitis due to Haemophilus influenzae in a protein C-deficient heterozygote treated with activated protein C therapy.
Protein C Deficiency
High coagulation factor VIII and von Willebrand factor in patients with lymphoma and leukemia.
Protein C Deficiency
How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review.
Protein C Deficiency
Hypercoagulability test strategies in the protein C and protein S pathway.
Protein C Deficiency
Incidence of thrombophilia and venous thrombosis in transsexuals under cross-sex hormone therapy.
Protein C Deficiency
Ischemic stroke subtypes and thrombophilia in young and elderly Brazilian stroke patients admitted to a rehabilitation hospital.
Protein C Deficiency
Laboratory screening of thrombophilia. Evaluation of the diagnostic efficacy of a global test to detect congenital deficiencies of the protein C anticoagulant pathway.
Protein C Deficiency
Mesenteric vein thrombosis associated with primary cytomegalovirus infection: a case report.
Protein C Deficiency
Myocardial infarction and normal coronary arteries: the experience of the cardiology department of sfax, Tunisia.
Protein C Deficiency
Paediatric thrombo-embolism: the influence of non-genetic factors and the role of activated protein C resistance and protein C deficiency.
Protein C Deficiency
Plasma hypercoagulability in the presence of thrombomodulin but not of activated protein C in patients with cirrhosis.
Protein C Deficiency
Population differences in the frequency of the factor V Leiden variant among people with clinically symptomatic protein C deficiency.
Protein C Deficiency
Postpartum cerebral venous thrombosis, congenital protein C deficiency, and activated protein C resistance due to heterozygous factor V Leiden mutation.
Protein C Deficiency
Primary thrombophilia in Mexico. II. Factor V G1691A (Leiden), prothrombin G20210A, and methylenetetrahydrofolate reductase C677T polymorphism in thrombophilic Mexican mestizos.
Protein C Deficiency
ProC Global: the first functional screening assay for the complete protein C pathway.
Protein C Deficiency
Protein C antigen levels in major abdominal surgery: relationships to deep vein thrombosis, malignancy and treatment with stanozolol.
Protein C Deficiency
Relevance of Inherited Thrombophilia Screening in Adult Kidney Transplant Recipients.
Protein C Deficiency
Resistance to activated protein C mimicking dysfunctional protein C: diagnostic approach.
Protein C Deficiency
Severe protein C deficiency is associated with organ dysfunction in patients with severe sepsis.
Protein C Deficiency
Six missense mutations associated with type I and type II protein C deficiency and implications obtained from molecular modelling.
Protein C Deficiency
Successful management of a pregnant woman with heterozygous protein C deficiency using activated protein C concentrate.
Protein C Deficiency
Successful treatment of deep vein thrombosis in homozygous protein C deficiency with activated protein C.
Protein C Deficiency
The relationship of the factor V Leiden mutation and pregnancy outcomes for mother and fetus.
Protein C Deficiency
Thrombophilia differences in cerebral venous sinus and lower extremity deep venous thrombosis.
Protein C Deficiency
Thrombophilia in patients with chronic venous leg ulcers-a study on patients with or without post-thrombotic syndrome.
Protein C Deficiency
Thrombophilia prevalence in patients seeking laparoscopic sleeve gastrectomy: extended chemoprophylaxis may decrease portal vein thrombosis rate.
Protein C Deficiency
Thrombophilic factors in chronic thromboembolic pulmonary hypertension.
Protein C Deficiency
Vascular surgical society of great britain and ireland: prevalence and significance of thrombophilia in patients with intermittent claudication
Protein C Deficiency
[Perioperative management of a patient with purpura fulminans syndrome due to protein C deficiency]
Protein C Deficiency
[Pulmonary embolism in patients using estrogen-progestagen contraceptives]
Protein C Deficiency
[Thrombosis of the cerebral venous sinuses: a description of its clinical features, risk factors and treatment in a hospital of Colombia]
Protein Deficiency
Activated protein C resistance and anticoagulant proteins in young adults with central retinal vein occlusion.
Protein Deficiency
Lack of Association between Recurrent Pregnancy Loss and Inherited Thrombophilia in a Group of Colombian Patients.
Protein S Deficiency
A novel thrombomodulin gene mutation in a patient suffering from sagittal sinus thrombosis.
Protein S Deficiency
Activated protein C resistance and deficiencies of antithrombin III, protein C or protein S and the risk of thromboembolic disease in users of oral contraceptives.
Protein S Deficiency
Association between prothrombin gene polymorphisms and hereditary thrombophilia in Xinjiang Kazakhs population.
Protein S Deficiency
Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis.
Protein S Deficiency
Effect of thrombophylaxis on uterine and fetal circulation in pregnant women with a history of pregnancy complications.
Protein S Deficiency
Elevated levels of prothrombin activation fragment 1 + 2 in plasma from patients with heterozygous Arg506 to Gln mutation in the factor V gene (APC-resistance) and/or inherited protein S deficiency.
Protein S Deficiency
Familial thrombophilia: clinical and molecular analysis of Swedish families with inherited resistance to activated protein C or protein S deficiency.
Protein S Deficiency
Flow cytometric analysis of autonomous growth of erythroid precursors in liquid culture detects occult polycythemia vera in the Budd-Chiari syndrome.
Protein S Deficiency
Further evidence that activated protein C resistance can be misdiagnosed as inherited functional protein S deficiency.
Protein S Deficiency
Genetic abnormalities of the protein C system: shared risk factors in young adults with migraine with aura and with ischemic stroke?
Protein S Deficiency
Guidelines for the management of thrombophilia. Department of Haematology, The Royal London Hospital, Whitechapel, London, UK.
Protein S Deficiency
How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review.
Protein S Deficiency
Hypercoagulability test strategies in the protein C and protein S pathway.
Protein S Deficiency
Inherited defects of the protein C anticoagulant system in childhood thrombo-embolism.
Protein S Deficiency
Inherited thrombophilia: memorandum from a joint WHO/International Society on Thrombosis and Haemostasis meeting.
Protein S Deficiency
Ischemic colitis revisited: a prospective study identifying hypercoagulability as a risk factor.
Protein S Deficiency
Ischemic stroke subtypes and thrombophilia in young and elderly Brazilian stroke patients admitted to a rehabilitation hospital.
Protein S Deficiency
Low-Molecular-Weight Heparin Added to Aspirin in the Prevention of Recurrent Early-Onset Preeclampsia in women with Inheritable Thrombophilia: the FRUIT-RCT.
Protein S Deficiency
Maternal and paternal thrombophilia: risk factors for perinatal mortality.
Protein S Deficiency
N-Terminal domain linkage modulates the folding properties of protein S epidermal growth factor-like modules.
Protein S Deficiency
No correlation between activated protein C resistance and free flap failures in 100 consecutive patients.
Protein S Deficiency
Plasma hypercoagulability in the presence of thrombomodulin but not of activated protein C in patients with cirrhosis.
Protein S Deficiency
Prevalence and role of antithrombin III, protein C and protein S deficiencies and activated protein C resistance in Kosovo women with recurrent pregnancy loss during the first trimester of pregnancy.
Protein S Deficiency
Primary thrombophilia in Mexico. II. Factor V G1691A (Leiden), prothrombin G20210A, and methylenetetrahydrofolate reductase C677T polymorphism in thrombophilic Mexican mestizos.
Protein S Deficiency
ProC Global: the first functional screening assay for the complete protein C pathway.
Protein S Deficiency
Protein S deficiency, activated protein C resistance and sticky platelet syndrome in a young woman with bilateral strokes.
Protein S Deficiency
Protein S Tokushima: abnormal molecule with a substitution of Glu for Lys-155 in the second epidermal growth factor-like domain of protein S.
Protein S Deficiency
Relevance of Inherited Thrombophilia Screening in Adult Kidney Transplant Recipients.
Protein S Deficiency
Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency, or activated protein C resistance: a multicenter collaborative family study.
Protein S Deficiency
Rivaroxaban Causes Missed Diagnosis of Protein S Deficiency but Not of Activated Protein C Resistance (Factor V Leiden).
Protein S Deficiency
The prevalence of thrombophilia in patients with chronic venous leg ulceration.
Protein S Deficiency
The relationship of the factor V Leiden mutation and pregnancy outcomes for mother and fetus.
Protein S Deficiency
The role of hypercoagulability in the development of osteonecrosis of the femoral head.
Protein S Deficiency
Thrombophilia in patients with chronic venous leg ulcers-a study on patients with or without post-thrombotic syndrome.
Protein S Deficiency
Thrombophilia prevalence in patients seeking laparoscopic sleeve gastrectomy: extended chemoprophylaxis may decrease portal vein thrombosis rate.
Protein S Deficiency
Thrombophilic abnormalities and recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatment.
Protein S Deficiency
Thrombophilic factors in chronic thromboembolic pulmonary hypertension.
Protein S Deficiency
Vascular surgical society of great britain and ireland: prevalence and significance of thrombophilia in patients with intermittent claudication
Protein S Deficiency
[Clinical usefulness of global assays of the anticoagulant pathway of protein C]
Protein S Deficiency
[Congenital deficiencies of natural anticoagulant systems responsible for recurrent thromboembolism]
Protein S Deficiency
[Thrombophilia in a family with resistance to activated protein C and protein S deficiency]
Pulmonary Edema
Intravenous administration of activated protein C in Pseudomonas-induced lung injury: impact on lung fluid balance and the inflammatory response.
Pulmonary Embolism
A case report of a new pulmonary embolism occurring in a patient receiving continuous infusion of recombinant activated protein C.
Pulmonary Embolism
Activated protein C resistance is uncommon in sudden death due to pulmonary embolism.
Pulmonary Embolism
Combined thrombophilic risk factors and essential thrombocythemia in patient with recurrent venous thromboembolic episodes-thirty-three-year follow-up.
Pulmonary Embolism
Concurrent administration of heparin and activated protein C in a patient with pulmonary embolism and severe sepsis with positive outcome.
Pulmonary Embolism
Drotrecogin alpha: a rational approach to the treatment of submassive pulmonary embolism?
Pulmonary Embolism
Endogenous plasma activated protein C levels and the effect of enoxaparin and drotrecogin alfa (activated) on markers of coagulation activation and fibrinolysis in pulmonary embolism.
Pulmonary Embolism
Increased activated protein C-protein C inhibitor complex levels in patients with pulmonary embolism.
Pulmonary Embolism
Iron-deficiency anaemia in childhood: a risk factor for severe venous thrombosis?
Pulmonary Embolism
Ischemic colitis, pulmonary embolism, and right atrial thrombosis in a patient with inherited resistance to activated protein C.
Pulmonary Embolism
Life threatening pulmonary embolus in a factor V Leiden carrier on oral contraceptives: a case report.
Pulmonary Embolism
Low prevalence of factor V:Q506 in 41 patients with isolated pulmonary embolism.
Pulmonary Embolism
Plasma levels of activated protein C-protein C inhibitor complex in patients with hypercoagulable states.
Pulmonary Embolism
Prevalence of the factor VLeiden mutation among autopsy patients with pulmonary thromboembolic disease using an improved method for factor VLeiden detection.
Pulmonary Embolism
Pulmonary embolism and deep venous thrombosis during pregnancy or oral contraceptive use: prevalence of factor V Leiden.
Pulmonary Embolism
Resistance to activated protein C in an unselected population of patients with pulmonary embolism.
Pulmonary Embolism
Screening for a prothrombotic diathesis in patients attending family planning clinics.
Pulmonary Embolism
Sensitivity to activated protein C in patients with deep vein thrombosis during early puerperium period.
Pulmonary Embolism
Three-year evaluation of late breast reconstruction with a free transverse rectus abdominis musculocutaneous flap in a county hospital in Sweden: a retrospective study.
Pulmonary Embolism
Thrombotic tendency in 75 symptomatic, unrelated patients with APC resistance.
Pulmonary Embolism
[Activated protein C resistance and deep venous thrombosis in pregnancy]
Pulmonary Embolism
[Pulmonary thromboembolism in a female with resistance to activated protein C]
Pulmonary Fibrosis
High endogenous activated protein C levels attenuates bleomycin-induced pulmonary fibrosis.
Pulmonary Fibrosis
Increased Mortality during Bleomycin-induced Pulmonary Fibrosis due to Low Endogenous Activated Protein C Levels.
Pulmonary Fibrosis
Reply: Increased Mortality during Bleomycin-induced Pulmonary Fibrosis due to Low Endogenous Activated Protein C Levels.
Purpura Fulminans
A case of purpura fulminans is caused by homozygous delta8857 mutation (protein C-nagoya) and successfully treated with activated protein C concentrate.
Purpura Fulminans
Activated protein C concentrate reverses purpura fulminans in severe genetic protein C deficiency.
Purpura Fulminans
Fulminant sepsis/meningitis due to Haemophilus influenzae in a protein C-deficient heterozygote treated with activated protein C therapy.
Purpura Fulminans
Massive soft tissue infections: necrotizing fasciitis and purpura fulminans.
Purpura Fulminans
Plasma exchange as a source of protein C for acute onset protein C pathway failure.
Purpura Fulminans
Pneumococcal purpura fulminans successfully treated with activated protein C.
Purpura Fulminans
Protein C/activated protein C pathway: overview of clinical trial results in severe sepsis.
Purpura Fulminans
Treatment of acute infectious purpura fulminans with activated protein C.
Purpura Fulminans
[Recombinant human activated protein C in the treatment of children with meningococcal purpura fulminans]
Purpura, Thrombotic Thrombocytopenic
Plasma levels of activated protein C-protein C inhibitor complex in patients with hypercoagulable states.
Pyoderma Gangrenosum
Use of dermal injection of activated protein C for treatment of large chronic wounds secondary to pyoderma gangrenosum.
Renal Insufficiency
Tissue factor coagulation pathway and blood cells activation state in renal insufficiency.
Reperfusion Injury
A Friend in Need: Activated Protein C Stabilizes YB-1 during Renal Ischemia Reperfusion Injury.
Reperfusion Injury
Activated Protein C Ameliorates Renal Ischemia-Reperfusion Injury by Restricting Y-Box Binding Protein-1 Ubiquitination.
Reperfusion Injury
Activated protein C attenuates acute ischaemia reperfusion injury in skeletal muscle.
Reperfusion Injury
Activated protein C improves left ventricular remodelling after ischemia-reperfusion injury in rats.
Reperfusion Injury
Activated Protein C in Ischemia-Reperfusion Injury After Experimental Lung Transplantation.
Reperfusion Injury
Activated protein C in the cardioplegic solution on a porcine model of coronary ischemia-reperfusion has deleterious hemodynamic effects.
Reperfusion Injury
Activated protein C prevents deleterious effects of remote reperfusion injury caused by intestinal ischemia on wound healing in the left colonic anastomoses: an experimental study in the murine model.
Reperfusion Injury
Activated protein C prevents methylglyoxal-induced endoplasmic reticulum stress and cardiomyocyte apoptosis via regulation of the AMP-activated protein kinase signaling pathway.
Reperfusion Injury
Activated protein C protects myocardium via activation of anti-apoptotic pathways of survival in ischemia-reperfused rat heart.
Reperfusion Injury
Activated protein C: an emerging therapeutic agent in the prevention of ischemia-reperfusion injury.
Reperfusion Injury
Comparative Study on the Cytoprotective Effects of Activated Protein C Treatment in Nonsteatotic and Steatotic Livers under Ischemia-Reperfusion Injury.
Reperfusion Injury
Cytoprotective activated protein C averts Nlrp3 inflammasome induced ischemia reperfusion injury via mTORC1 inhibition.
Reperfusion Injury
Human activated protein C attenuates both hepatic and renal injury caused by hepatic ischemia and reperfusion injury in mice.
Reperfusion Injury
Microcirculatory alterations in ischemia-reperfusion injury and sepsis: effects of activated protein C and thrombin inhibition.
Reperfusion Injury
Neuroprotective effects of activated protein C through induction of insulin-like growth factor-1 (IGF-1), IGF-1 receptor, and its downstream signal phosphorylated serine-threonine kinase after spinal cord ischemia in rabbits.
Reperfusion Injury
The Effect of Activated Protein C on Attenuation of Ischemia-Reperfusion Injury in a Rat Muscle Flap Model.
Respiratory Distress Syndrome
Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats.
Respiratory Distress Syndrome
Activated protein C attenuates pulmonary coagulopathy in patients with acute respiratory distress syndrome.
Respiratory Distress Syndrome
Activated Protein C has No Effect on Pulmonary Capillary Endothelial Function in Septic Patients with Acute Respiratory Distress Syndrome: Association of Endothelial Dysfunction with Mortality.
Respiratory Distress Syndrome
Activated protein C in the treatment of acute lung injury and acute respiratory distress syndrome.
Respiratory Distress Syndrome
Activated protein C nebulization in severe late acute respiratory distress syndrome.
Respiratory Distress Syndrome
Alveolar dead-space response to activated protein C in acute respiratory distress syndrome.
Respiratory Distress Syndrome
Combined recombinant human activated protein C and ceftazidime prevent the onset of acute respiratory distress syndrome in severe sepsis.
Respiratory Distress Syndrome
Combined use of extracorporeal membrane oxygenation and activated protein C for severe acute respiratory distress syndrome and septic shock.
Respiratory Distress Syndrome
Gonococcal septic shock, acute respiratory distress syndrome, and multisystem organ failure: a case report.
Respiratory Distress Syndrome
Inhalation of activated protein C: A possible new adjunctive intervention in acute respiratory distress syndrome.
Respiratory Distress Syndrome
Nebulized activated protein C in a paediatric patient with severe acute respiratory distress syndrome secondary to H1N1 influenza.
Respiratory Distress Syndrome
Pharmacotherapy of acute lung injury and the acute respiratory distress syndrome.
Respiratory Distress Syndrome
Positive end-expiratory pressure, prone positioning, and activated protein C: a critical review of meta-analyses.
Respiratory Distress Syndrome
Recombinant human activated protein C in the treatment of acute respiratory distress syndrome: a randomized clinical trial.
Respiratory Distress Syndrome
Recombinant human activated protein C in the treatment of severe sepsis: an evidence-based review.
Respiratory Distress Syndrome
Successful treatment of life-threatening melioidosis with activated protein C and meropenem.
Respiratory Distress Syndrome
Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock.
Respiratory Distress Syndrome
Toronto Critical Care Medicine Symposium, 18-20 October 2001, Canada: research breakthroughs are not enough.
Respiratory Distress Syndrome
Which Multicenter Randomized Controlled Trials in Critical Care Medicine Have Shown Reduced Mortality? A Systematic Review.
Respiratory Distress Syndrome
[New therapeutic strategies in severe sepsis and septic shock]
Respiratory Distress Syndrome
[Protocol of the management of patients with severe sepsis and septic shock].
Respiratory Insufficiency
Successful treatment of septic shock and respiratory failure due to leptospirosis and scrub typhus coinfection with penicillin, levofloxacin, and activated protein C.
Respiratory Insufficiency
Use of activated protein C (drotrecogin alfa) in a patient with sepsis and respiratory failure on ultra high frequency jet ventilation.
Respiratory Insufficiency
Use of Drotrecogin Alpha (Recombinant Human Activated Protein C, rhAPC) in the Treatment of Severe Sepsis Induced by Graft Pancreatitis After Simultaneous Pancreas and Kidney Transplantation: A Case Report.
Retinal Artery Occlusion
Central retinal artery occlusion in a patient homozygous for factor V Leiden.
Retinal Artery Occlusion
Central retinal artery occlusion in a young child secondary to resistance to activated protein C.
Retinal Neovascularization
Peripheral retinal neovascularization and retinal vascular occlusion associated with activated protein C resistance.
Retinal Vein Occlusion
Activated Protein C for Ischemic Central Retinal Vein Occlusion: One-Year Results.
Retinal Vein Occlusion
Activated protein C resistance and anticoagulant proteins in young adults with central retinal vein occlusion.
Retinal Vein Occlusion
Activated protein C resistance in patients with central retinal vein occlusion.
Retinal Vein Occlusion
Activated protein C resistance in young adults with central retinal vein occlusion.
Retinal Vein Occlusion
Activated protein C resistance is a risk factor for central retinal vein occlusion.
Retinal Vein Occlusion
Activated protein C resistance, factor V Leiden, and central retinal vein occlusion in young adults.
Retinal Vein Occlusion
Activated protein C resistance--low incidence in glaucomatous optic disc haemorrhage and central retinal vein occlusion.
Retinal Vein Occlusion
Blood viscosity, coagulation, and activated protein C resistance in central retinal vein occlusion: a population controlled study.
Retinal Vein Occlusion
Central retinal vein thrombosis associated with resistance to activated protein C.
Retinal Vein Occlusion
Diagnosis of activated protein C resistance in retinal vein occlusion.
Retinal Vein Occlusion
Factor V Leiden, activated protein C resistance, and retinal vein occlusion.
Retinal Vein Occlusion
High prevalence of resistance to APC in young patients with retinal vein occlusion.
Retinal Vein Occlusion
Long-term outcomes of intravitreal activated protein C injection for ischemic central retinal vein occlusion: an extension trial.
Retinal Vein Occlusion
Prevalence of factor V Leiden and activated protein C resistance in central retinal vein occlusion.
Retinal Vein Occlusion
Reperfusion of large ischemic areas associated with central retinal vein occlusion: a potential novel treatment with activated protein C.
Retinal Vein Occlusion
Risk factors in central retinal vein occlusion an activated protein C resistance.
Retinal Vein Occlusion
Risk factors in central retinal vein occlusion and activated protein C resistance.
Retinal Vein Occlusion
Screening for resistance to activated protein C and the mutant gene for factor V:Q506 in patients with central retinal vein occlusion.
Retinal Vein Occlusion
The prevalence of activated protein C (APC) resistance and factor V Leiden is significantly higher in patients with retinal vein occlusion without general risk factors. Case-control study and meta-analysis.
Retinal Vein Occlusion
[Activated protein C resistance in patients with central retinal vein occlusion in comparison to patients with a history of deep-vein thrombosis and a healthy control group]
Sagittal Sinus Thrombosis
Activated protein C resistance (factor V Leiden) associated with thrombosis in pregnancy.
Sarcoma, Kaposi
[Activated C protein resistance manifested by cutaneous necrosis after interferon alpha injection: case report]
Scleroderma, Systemic
High prevalence of activated protein C resistance in patients with systemic sclerosis.
Scrub Typhus
Successful treatment of septic shock and respiratory failure due to leptospirosis and scrub typhus coinfection with penicillin, levofloxacin, and activated protein C.
Sepsis
A clinically applicable porcine model of septic and ischemia/reperfusion-induced shock and multiple organ injury.
Sepsis
A long-term follow-up study investigating health-related quality of life and resource use in survivors of severe sepsis: comparison of recombinant human activated protein C with standard care.
Sepsis
A meta-analysis of controlled trials of recombinant human activated protein C therapy in patients with sepsis.
Sepsis
Activated protein C and hospital mortality in septic shock: a propensity-matched analysis.
Sepsis
Activated Protein C Attenuates Systemic Lupus Erythematosus and Lupus Nephritis in MRL-Fas(lpr) Mice.
Sepsis
Activated protein C generation is greatly decreased in plasma from newborns compared to adults in the presence or absence of endothelium.
Sepsis
Activated Protein C Improves Macro and Microvascular Reactivity in Human Severe Sepsis and Septic Shock.
Sepsis
Activated protein C improves survival in severe sepsis patients with elevated troponin.
Sepsis
Activated protein C in sepsis: emerging insights regarding its mechanism of action and clinical effectiveness.
Sepsis
Activated protein C induces the release of microparticle-associated endothelial protein C receptor.
Sepsis
Activated protein C inhibits chemotaxis and interleukin-6 release by human neutrophils without affecting other neutrophil functions.
Sepsis
Activated protein C inhibits high mobility group box 1 signaling in endothelial cells.
Sepsis
Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kappaB (NF-kappaB) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line.
Sepsis
Activated protein C inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kappa B and activator protein-1 in human monocytes.
Sepsis
Activated protein C inhibits local coagulation after intrapulmonary delivery of endotoxin in humans.
Sepsis
Activated protein C inhibits tumor necrosis factor and macrophage migration inhibitory factor production in monocytes.
Sepsis
Activated protein C levels and outcome in patients with cardiogenic shock complicating acute myocardial infarction.
Sepsis
Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation.
Sepsis
Activated protein C modulates chemokine response and tissue injury in experimental sepsis.
Sepsis
Activated protein C modulates inflammation, apoptosis and tissue factor procoagulant activity by regulating endoplasmic reticulum calcium depletion in blood monocytes.
Sepsis
Activated protein C mutant with minimal anticoagulant activity, normal cytoprotective activity, and preservation of thrombin activable fibrinolysis inhibitor-dependent cytoprotective functions.
Sepsis
Activated protein C protects vascular endothelial cells from apoptosis in malaria and in sepsis.
Sepsis
Activated protein C restores hepatic microcirculation during sepsis by modulating vasoregulator expression.
Sepsis
Activated protein C signals through the thrombin receptor PAR1 in endothelial cells.
Sepsis
Activated protein C targets CD8+ dendritic cells to reduce the mortality of endotoxemia in mice.
Sepsis
Activated protein C up-regulates IL-10 and inhibits tissue factor in blood monocytes.
Sepsis
Activated protein C utilizes the angiopoietin/Tie2 axis to promote endothelial barrier function.
Sepsis
Activated protein C variants with normal cytoprotective but reduced anticoagulant activity.
Sepsis
Activated protein C was cost-effective for prolonging survival in a subgroup of patients with severe sepsis.
Sepsis
Activated recombinant human protein C does not attenuate recruitment of neutrophils in rat models of acute inflammation.
Sepsis
Activated recombinant protein C in septic shock early after liver transplantation: a case report.
Sepsis
Additive effects of anticoagulants: recombinant human activated protein C and heparin or melagatran, in tissue factor-activated umbilical-cord plasma.
Sepsis
Adjunctive corticosteroid therapy in pediatric severe sepsis: Observations from the RESOLVE study*
Sepsis
Advances in the understanding of clinical manifestations and therapy of severe sepsis: an update for critical care nurses.
Sepsis
Adventure of Recombinant Human Activated Protein C in Sepsis and New Treatment Hopes on the Horizon.
Sepsis
Adverse outcomes associated with the use of drotrecogin alfa (activated) in patients with severe sepsis and baseline bleeding precautions.
Sepsis
alpha(1)-Proteinase inhibitor mutants with specificity for plasma kallikrein and C1s but not C1.
Sepsis
Alterations in the human lung proteome with lipopolysaccharide and activated protein C.
Sepsis
Alveolar dead-space response to activated protein C in acute respiratory distress syndrome.
Sepsis
An algorithmic computerised order entry approach to assist in the prescribing of new therapeutic agents: case study of activated protein C at an academic medical centre.
Sepsis
Anticoagulant factor concentrates in disseminated intravascular coagulation: rationale for use and clinical experience.
Sepsis
Anticoagulant therapy for sepsis-associated disseminated intravascular coagulation: the view from Japan.
Sepsis
Anticoagulant therapy in acute lung injury: a useful tool without proper operating instruction?
Sepsis
Antimalarial artesunate protects sepsis model mice against heat-killed Escherichia coli challenge by decreasing TLR4, TLR9 mRNA expressions and transcription factor NF-kappa B activation.
Sepsis
Bench to bedside: HMGB1-a novel proinflammatory cytokine and potential therapeutic target for septic patients in the emergency department.
Sepsis
Bench-to-bedside review: the role of activated protein C in maintaining endothelial tight junction function and its relationship to organ injury.
Sepsis
Best evidence in anesthetic practice: prevention: recombinant human activated protein C reduces mortality in severe sepsis.
Sepsis
Canadian Association of General Surgeons Evidence Based Reviews in Surgery. 8. Efficacy and safety of recombinant human activated protein C for severe sepsis.
Sepsis
Catastrophic antiphospholipid syndrome and Kikuchi-Fujimoto disease: the first case reported.
Sepsis
Clinical and laboratory effects of recombinant human activated protein C in the treatment of a patient with sepsis-induced multiple organ failure.
Sepsis
Clinical experience with drotrecogin alfa in treating gram-positive and -negative pathogens in patients with severe sepsis.
Sepsis
Clinical expert round table discussion (session 3) at the Margaux Conference on Critical Illness: the role of activated protein C in severe sepsis.
Sepsis
Coagulation in severe sepsis: a central role for thrombomodulin and activated protein C.
Sepsis
Coagulopathy and the role of recombinant human activated protein C in sepsis and following polytrauma.
Sepsis
Combined recombinant human activated protein C and ceftazidime prevent the onset of acute respiratory distress syndrome in severe sepsis.
Sepsis
Compliance With a Sepsis Bundle and Its Effect on Intensive Care Unit Mortality in Surgical Septic Shock Patients.
Sepsis
Concurrent administration of heparin and activated protein C in a patient with pulmonary embolism and severe sepsis with positive outcome.
Sepsis
Controversial treatment of a victim of severe head injury complicated by septic shock and acute respiratory distress syndrome.
Sepsis
Copper inhibits activated protein C: protective effect of human albumin and an analogue of its high-affinity copper-binding site, d-DAHK.
Sepsis
Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis with multiple organ failure.
Sepsis
Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis.
Sepsis
Critical issues in hematology: anemia, thrombocytopenia, coagulopathy, and blood product transfusions in critically ill patients.
Sepsis
CURB-65, PSI, and APACHE II to assess mortality risk in patients with severe sepsis and community acquired pneumonia in PROWESS.
Sepsis
Current advances in sepsis and septic shock with particular emphasis on the role of insulin.
Sepsis
Current concepts in the role of the host response in Neisseria meningitidis septic shock.
Sepsis
Decreased inflammation and improved survival with recombinant human activated protein C treatment in experimental acute pancreatitis.
Sepsis
Disseminated Intravascular Coagulation: An Update on Pathogenesis, Diagnosis, and Therapeutic Strategies.
Sepsis
Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis.
Sepsis
Drotrecogin alfa (activated) did not reduce mortality at 28 or 90 days in patients with septic shock.
Sepsis
Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis.
Sepsis
Drotrecogin alfa (activated) inhibits NF-kappa B activation and MIP-1-alpha release from isolated mononuclear cells of patients with severe sepsis.
Sepsis
Drotrecogin alfa (activated): a pharmacoeconomic review of its use in severe sepsis.
Sepsis
Drotrecogin Alfa (Activated): does current evidence support treatment for any patients with severe sepsis?
Sepsis
Drotrecogin alfa (recombinant human activated protein C) for the treatment of severe sepsis.
Sepsis
Drotrecogin alfa activated (recombinant human activated protein C) in combination with heparin or melagatran: effects on prothrombin time and activated partial thromboplastin time.
Sepsis
Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.
Sepsis
Early goal-directed therapy, corticosteroid, and recombinant human activated protein C for the treatment of severe sepsis and septic shock in the emergency department.
Sepsis
Effect of drotrecogin alfa (activated) on human endothelial cell permeability and Rho kinase signaling.
Sepsis
Effect of factor V Leiden polymorphism in severe sepsis and on treatment with recombinant human activated protein C.
Sepsis
Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression.
Sepsis
Effectiveness of human recombinant activated protein C for severe sepsis and septic shock in adult and pediatric patients: randomized clinical trial versus nonrandomized study.
Sepsis
Effectiveness of treatments for severe sepsis: data from the bundle implementation programs.
Sepsis
Effects of activated protein C on coagulation and fibrinolysis in rabbits with endotoxin induced acute lung injury.
Sepsis
Effects of activated protein C on post cardiac arrest microcirculation: an in vivo microscopy study.
Sepsis
Effects of activated protein C on the mesenteric microcirculation and cytokine release during experimental endotoxemia: [Effets de la proteine C activee sur la microcirculation mesenterique et la liberation de cytokines durant une endotoxemie experimentale].
Sepsis
Effects of recombinant human activated protein C in human models of endotoxin administration.
Sepsis
Effects of recombinant human activated protein C on the coagulation system: a study with rotational thromboelastometry.
Sepsis
Efficacy and effectiveness of recombinant human activated protein C in severe sepsis of adults.
Sepsis
Elevated plasma concentrations of IL-6 and elevated APACHE II score predict acute kidney injury in patients with severe sepsis.
Sepsis
Elevated plasma matrix metalloproteinases and their tissue inhibitors in patients with severe sepsis.
Sepsis
Endogenous activated protein C signaling is critical to protection of mice from lipopolysaccaride-induced septic shock.
Sepsis
Endogenous EPCR/aPC-PAR1 signaling prevents inflammation-induced vascular leakage and lethality.
Sepsis
Endogenous platelet factor 4 stimulates activated protein C generation in vivo and improves survival after thrombin or lipopolysaccharide challenge.
Sepsis
Endothelium and disordered fibrin turnover in the injured lung: newly recognized pathways.
Sepsis
Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C.
Sepsis
Engineering the proteolytic specificity of activated protein C improves its pharmacological properties.
Sepsis
Ethyl pyruvate exerts combined anti-inflammatory and anticoagulant effects on human monocytic cells.
Sepsis
Evaluating the use of recombinant human activated protein C in adult severe sepsis: results of the Surviving Sepsis Campaign.
Sepsis
Evaluation of recombinant activated protein C for severe sepsis at a tertiary academic medical center.
Sepsis
Evaluation of the cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom.
Sepsis
Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis.
Sepsis
Fulminant sepsis/meningitis due to Haemophilus influenzae in a protein C-deficient heterozygote treated with activated protein C therapy.
Sepsis
Future research directions in acute lung injury: summary of a National Heart, Lung, and Blood Institute working group.
Sepsis
Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis.
Sepsis
Growing insights into the potential benefits and risks of activated protein C administration in sepsis: a review of preclinical and clinical studies.
Sepsis
Guidance on patient identification and administration of recombinant human activated protein C for the treatment of severe sepsis.
Sepsis
Guidelines for the diagnosis and management of disseminated intravascular coagulation.
Sepsis
Hemodynamic effects of recombinant human activated protein C in patients with septic shock.
Sepsis
Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial.
Sepsis
How to ENHANCE our knowledge of activated protein C during pediatric sepsis trials: pediatric versus adult trials.
Sepsis
Human recombinant activated protein C for severe sepsis.
Sepsis
Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients.
Sepsis
Identifying patients with severe sepsis who should not be treated with drotrecogin alfa (activated).
Sepsis
Increased coagulation and suppressed generation of activated protein C in aged mice during intra-abdominal sepsis.
Sepsis
Kinetics of immune parameters in a patient with sepsis caused by Streptococcus pyogenes treated with activated protein C.
Sepsis
Levels of protein C activity and clinical factors in early phase of pediatric septic shock may be associated with the risk of death.
Sepsis
Limited generation of activated protein C during infusion of the protein C activator thrombin analog W215A/E217A in primates.
Sepsis
Low plasma protein C values predict mortality in low birth weight neonates with septicemia.
Sepsis
Massive infiltration of bone marrow in colon carcinoma after treatment with activated protein C.
Sepsis
Mechanisms of human complement factor B induction in sepsis and inhibition by activated protein C.
Sepsis
Mediators of systemic inflammatory response syndrome and the role of recombinant activated protein C in sepsis syndrome.
Sepsis
Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis.
Sepsis
Microcirculatory alterations in ischemia-reperfusion injury and sepsis: effects of activated protein C and thrombin inhibition.
Sepsis
Microcirculatory disorders in sepsis and transplantation: therapy with natural coagulatory inhibitors antithrombin and activated protein C.
Sepsis
Microhemodynamic and cellular mechanisms of activated protein C action during endotoxemia.
Sepsis
Neurological outcome and inflammation after cardiac arrest--effects of protein C in rats.
Sepsis
New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated).
Sepsis
New therapeutic options for patients with sepsis and disseminated intravascular coagulation.
Sepsis
Non-hematopoietic EPCR regulates the coagulation and inflammatory responses during endotoxemia.
Sepsis
Only activated protein C treatment and not protein C has demonstrated an improvement in survival in severe sepsis.
Sepsis
Optimum treatment of severe sepsis and septic shock: evidence in support of the recommendations.
Sepsis
Overexpression of activated protein C hampers bacterial dissemination during pneumococcal pneumonia.
Sepsis
Overexpression of Activated Protein C is Detrimental During Severe Experimental Gram-Negative Sepsis (Melioidosis)*
Sepsis
PAR1 agonists stimulate APC-like endothelial cytoprotection and confer resistance to thromboinflammatory injury.
Sepsis
PAR1 biased signaling is required for activated protein C in vivo benefits in sepsis and stroke.
Sepsis
Pasteurella multocida septic shock following liver transplantation treated with drotrecogin alpha (activated).
Sepsis
Pathogenesis and treatment of disseminated intravascular coagulation in the septic patient.
Sepsis
Patients with severe sepsis vary markedly in their ability to generate activated protein C.
Sepsis
Peritoneal lavage with activated protein C alters compartmentalized coagulation and fibrinolysis and improves survival in polymicrobial peritonitis.
Sepsis
Pharmacist intervention in activated protein C therapy for severe sepsis: influence on health and economic outcomes.
Sepsis
Plasma protein C levels in immunocompromised septic patients are significantly lower than immunocompetent septic patients: a prospective cohort study.
Sepsis
Plasma soluble fibrin monomer complex is a useful predictor of disseminated intravascular coagulation in neonatal sepsis.
Sepsis
Positive end-expiratory pressure, prone positioning, and activated protein C: a critical review of meta-analyses.
Sepsis
Prevalence of serious bleeding events and intracranial hemorrhage in patients receiving activated protein C: a systematic review and meta-analysis.
Sepsis
Prognostic value of plasma N-terminal pro-brain natriuretic peptide in patients with severe sepsis.
Sepsis
Protection of vascular barrier integrity by activated protein C in murine models depends on protease-activated receptor-1.
Sepsis
Protective cross talk between activated protein C and TNF signaling in vascular endothelial cells: implication of EPCR, noncanonical NF-{kappa}B, and ERK1/2 MAP kinases.
Sepsis
Protein C -1641A/-1654C haplotype is associated with organ dysfunction and the fatal outcome of severe sepsis in Chinese Han population.
Sepsis
Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation.
Sepsis
Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome.
Sepsis
Protein C/activated protein C pathway: overview of clinical trial results in severe sepsis.
Sepsis
Protein S modulates the anticoagulant action of recombinant human activated protein C: a comparison between neonates and adults.
Sepsis
Rapid and beneficial hemodynamic effects of activated protein C in septic shock patients.
Sepsis
Reassessing recombinant human activated protein C for sepsis: time for a new randomized controlled trial.
Sepsis
Recombinant activated protein C attenuates coagulopathy and inflammation when administered early in murine pneumococcal pneumonia.
Sepsis
Recombinant activated protein C in sepsis: endothelium protection or endothelium therapy?
Sepsis
Recombinant activated protein C induces dose-dependent changes in inflammatory mediators, tissue damage, and apoptosis in in vivo rat model of sepsis.
Sepsis
Recombinant activated protein C treatment improves tissue perfusion and oxygenation in septic patients measured by near-infrared spectroscopy.
Sepsis
Recombinant activated protein C usage in Scotland: a comparison with published guidelines and a survey of attitudes.
Sepsis
Recombinant factor VII (activated) for haemorrhagic complications of severe sepsis treated with recombinant protein C (activated).
Sepsis
Recombinant human activated protein C (rhAPC; drotrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxemia.
Sepsis
Recombinant human activated protein C and strict glycemic control in sepsis: mutually exclusive strategies?
Sepsis
Recombinant human activated protein C as a disease modifier in severe acute pancreatitis: systematic review of current evidence.
Sepsis
Recombinant human activated protein C as a therapy for severe sepsis: lessons learned?
Sepsis
Recombinant human activated protein C attenuates endotoxin-induced lung injury in awake sheep.
Sepsis
Recombinant human activated protein C for severe sepsis.
Sepsis
Recombinant Human Activated Protein C for the Postexposure Treatment of Ebola Hemorrhagic Fever.
Sepsis
Recombinant human activated protein C for the treatment of severe sepsis and septic shock: a study protocol for incorporating observational evidence using a Bayesian approach.
Sepsis
Recombinant human activated protein C for the treatment of severe sepsis: is there a role in pediatrics?
Sepsis
Recombinant human activated protein C improves pulmonary function in ovine acute lung injury resulting from smoke inhalation and sepsis.
Sepsis
Recombinant human activated protein C in acute lung injury: what is the role of bronchial circulation?
Sepsis
Recombinant human activated protein C in sepsis: inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trials.
Sepsis
Recombinant human activated protein C in the treatment of severe sepsis: an evidence-based review.
Sepsis
Recombinant human activated protein C inhibits integrin-mediated neutrophil migration.
Sepsis
Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis.
Sepsis
Recombinant human activated protein C resets thrombin generation in patients with severe sepsis - a case control study.
Sepsis
Recombinant human activated protein C upregulates the release of soluble fractalkine from human endothelial cells.
Sepsis
Recombinant human activated protein C, drotrecogin alfa (activated): a novel therapy for severe sepsis.
Sepsis
Recombinant human activated protein C, heparin and melagatran in umbilical cord versus adult plasma.
Sepsis
Recombinant human activated protein C: a system modulator of vascular function for treatment of severe sepsis.
Sepsis
Recombinant human activated protein C: current insights into its mechanism of action.
Sepsis
Redirection of the reaction between activated protein C and a serpin to the substrate pathway.
Sepsis
Relationship between the inflammation and coagulation pathways in patients with severe sepsis: implications for therapy with activated protein C.
Sepsis
Results of severe sepsis treatment program using recombinant human activated protein C in Poland.
Sepsis
rhAPC reduces the endothelial cell permeability via a decrease of contractile tensions induced by endothelial cells.
Sepsis
Role of Activated Protein C on Wound Healing Process in Left Colonic Anastomoses in the Presence of Intra-abdominal Sepsis Induced by Cecal Ligation and Puncture: An Experimental Study in the Rat.
Sepsis
Role of coagulation pathways and treatment with activated protein C in hyperoxic lung injury.
Sepsis
Role of human recombinant activated protein C and low dose corticosteroid therapy in sepsis.
Sepsis
Role of the tissue factor pathway in the pathogenesis and management of multiple organ failure.
Sepsis
Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis.
Sepsis
Safety and efficacy of recombinant activated protein C for severe sepsis in abdominal organ recipients.
Sepsis
Safety of drotrecogin alfa (activated) in severe sepsis: Data from adult clinical trials and observational studies.
Sepsis
Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis.
Sepsis
Septic shock and multiple organ failure after hematopoietic stem cell transplantation: treatment with recombinant human activated protein C.
Sepsis
Septic shock caused by Streptococcus pneumoniae in a post-splenectomy patient successfully treated with recombinant human activated protein C.
Sepsis
Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study.
Sepsis
Severe protein C deficiency is associated with organ dysfunction in patients with severe sepsis.
Sepsis
Severe sepsis due to severe falciparum malaria and leptospirosis co-infection treated with activated protein C.
Sepsis
Soluble thrombomodulin, plasma-derived unactivated protein C, and recombinant human activated protein C in sepsis.
Sepsis
Standardization of Severe Sepsis Management: A Survey of Methodologies in Academic and Community Settings.
Sepsis
Struggle for implementation of new strategies in intensive care medicine: anticoagulation, insulin, and lower tidal volumes.
Sepsis
Substantiating the concerns about recombinant human activated protein C use in sepsis.
Sepsis
Successful treatment of severe sepsis with recombinant activated protein C during the third trimester of pregnancy.
Sepsis
Successful treatment of severe sepsis with recombinant human activated protein C in a patient with traumatic intracranial hemorrhage.
Sepsis
Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock.
Sepsis
Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008.
Sepsis
Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.
Sepsis
Systemic and organ dysfunction response during infusion of recombinant human activated protein C (rhAPC) in severe sepsis and septic shock.
Sepsis
Systemic host inflammatory and coagulation response in the Dengue virus primo-infection.
Sepsis
Tenecteplase for ST-elevation myocardial infarction in a patient treated with drotrecogin alfa (activated) for severe sepsis: a case report.
Sepsis
The 26th Congress of the Scandinavian Society of Anaesthesiology and Intensive Care Medicine, Tromso, Norway, 13-17 June 2001.
Sepsis
The anticoagulant action of recombinant human activated protein C (rhAPC, Drotrecogin alpha activated): comparison between cord and adult plasma.
Sepsis
The clinical and functional relevance of microparticles induced by activated protein C treatment in sepsis.
Sepsis
The cytoprotective effects of endogenous activated protein C reduce activation of coagulation during murine pneumococcal pneumonia and sepsis.
Sepsis
The effect of plasma-derived activated protein C on leukocyte cell-death and vascular endothelial damage.
Sepsis
The efficacy of activated protein C for the treatment of sepsis: incorporating observational evidence with a Bayesian approach.
Sepsis
The efficacy of activated protein C in murine endotoxemia is dependent on integrin CD11b.
Sepsis
The epidemiology of severe sepsis syndrome and its treatment with recombinant human activated protein C.
Sepsis
The implementation of new therapies for severe sepsis: some questions raised by "early goal-directed therapy, corticosteroid, and recombinant human activated protein c for the treatment of severe sepsis and septic shock in the emergency department".
Sepsis
The loss of homeostasis in hemostasis: new approaches in treating and understanding acute disseminated intravascular coagulation in critically ill patients*.
Sepsis
The Next Generation of Sepsis Clinical Trial Designs: What Is Next After the Demise of Recombinant Human Activated Protein C?
Sepsis
The normal role of Activated Protein C in maintaining homeostasis and its relevance to critical illness.
Sepsis
The therapeutic challenge of Gram-negative sepsis: prolonging the lifespan of a scarce resource.
Sepsis
The use of activated protein C (drotrecogin alfa (activated)) in the treatment of severe sepsis.
Sepsis
The use of drotrecogin alfa (activated) in severe sepsis during acute pancreatitis - two case studies.
Sepsis
The use of drotrecogin alfa (activated) in solid organ transplant patients: a case series.
Sepsis
The use of drotrecogin alfa recombinant activated protein C for severe sepsis in the critically burned patient: A new treatment approach.
Sepsis
The use of recombinant human activated protein C (rhAPC) in the treatment of severe sepsis in immunosuppressed patients in the course of hematological diseases.
Sepsis
The withdrawal of Activated Protein C from the use in patients with severe sepsis and DIC [Amendment to the BCSH guideline on disseminated intravascular coagulation].
Sepsis
Therapeutic recombinant murine activated protein C attenuates pulmonary coagulopathy and improves survival in murine pneumococcal pneumonia.
Sepsis
Toronto Critical Care Medicine Symposium, 18-20 October 2001, Canada: research breakthroughs are not enough.
Sepsis
Tracking the microbes in sepsis: advancements in treatment bring challenges for microbial epidemiology.
Sepsis
Transcriptome analysis revealed unique genes as targets for the anti-inflammatory action of activated protein C in human macrophages.
Sepsis
Treatment of sepsis-induced acquired protein C deficiency reverses Angiotensin-converting enzyme-2 inhibition and decreases pulmonary inflammatory response.
Sepsis
Treatment of severe sepsis secondary to mycobacterium avium-intracellulare with recombinant human activated protein C.
Sepsis
Treatment of severe sepsis: where next? Current and future treatment approaches after the introduction of drotrecogin alfa.
Sepsis
Treatment with recombinant human activated protein C obviates additional anticoagulation during continuous venovenous hemofiltration in patients with severe sepsis.
Sepsis
Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569].
Sepsis
Updates on role of human recombinant activated protein C in patients with sepsis and severe sepsis: Changed scenario after PROWESS SHOCK trial.
Sepsis
Use of activated protein C (drotrecogin alfa) in a patient with sepsis and respiratory failure on ultra high frequency jet ventilation.
Sepsis
Use of Drotrecogin Alpha (Recombinant Human Activated Protein C, rhAPC) in the Treatment of Severe Sepsis Induced by Graft Pancreatitis After Simultaneous Pancreas and Kidney Transplantation: A Case Report.
Sepsis
Use of recombinant human activated protein C in nonmenstrual staphylococcal toxic shock syndrome.
Sepsis
Use of recombinant human activated protein C in patients with severe sepsis: a French retrospective multicentre study.
Sepsis
Use of recombinant human activated protein C in treatment of severe sepsis in a pregnant patient with fully symptomatic ovarian hyperstimulation syndrome.
Sepsis
Using transcutaneous oxygen pressure measurements as selection criteria for activated protein C use.
Sepsis
Vibrio vulnificus sepsis successfully treated with antibiotics, surgical debridement, and recombinant human activated protein C.
Sepsis
When is critical care medicine cost-effective? A systematic review of the cost-effectiveness literature.
Sepsis
Which Multicenter Randomized Controlled Trials in Critical Care Medicine Have Shown Reduced Mortality? A Systematic Review.
Sepsis
Why activated protein C was not successful in severe sepsis and septic shock: are we still tilting at windmills?
Sepsis
Why are clinicians not embracing the results from pivotal clinical trials in severe sepsis? A bayesian analysis.
Sepsis
[Activated protein C, a protein at the crossroads between coagulation and inflammation].
Sepsis
[Activated protein C, coagulation, inflammation and treatment of severe sepsis]
Sepsis
[Application of recombinant human activated protein C with blood product administration and deep vein thrombosis in severe sepsis]
Sepsis
[Can we afford the costs of progress in intensive care medicine? A plea for a candid debate]
Sepsis
[Diagnosis and correction of thrombohemorrhagic complications in cardiosurgical patients in the early postoperative period].
Sepsis
[Expensive modern therapy options in intensive care medicine in Germany-- are they being used? Results of a questionnaire]
Sepsis
[Highlighting the potential of heparin in the treatment of sepsis in view of failure of KyberSept and OPTIMIST projects]
Sepsis
[Human recombinant activated protein C in patients with severe sepsis and septic shock]
Sepsis
[Multiple organ failure. Mechanisms, clinical manifestations and treatment strategies]
Sepsis
[Peptide-agonist of protease-activated receptor (PAR 1), similar to activated protein C, promotesproliferation in keratinocytes and wound healing of epithelial layer.]
Sepsis
[Potential benefits of non-anti-infective treatments of septic shock: a critical analysis of literature]
Sepsis
[Recombinant activated protein C: from evidence to clinical practice. Clinical practice guidelines for the use of activated proteins C in the treatment of severe sepsis]
Sepsis
[Replacement therapy with protein C for meningococcal sepsis and fulminant purpura in pediatric patients]
Sepsis
[Role of coagulation in acute pulmonary lesion physiopathology. Parallelism with sepsis.]
Sepsis
[Surgical patient with severe sepsis: activated protein C and Surviving Sepsis Campaign]
Sepsis
[Use of protein C concentrate in adult patients with severe sepsis and septic shock]
Sepsis
[Use of recombinant human activated protein C in severe sepsis in patient with a pericardial hemorrhagic collection after a recent cardiac surgery]
Shock, Cardiogenic
Activated protein C levels and outcome in patients with cardiogenic shock complicating acute myocardial infarction.
Shock, Septic
Activated protein C and hospital mortality in septic shock: a propensity-matched analysis.
Shock, Septic
Activated protein C concentrate for the treatment of meningococcal endotoxin shock in rabbits.
Shock, Septic
Activated protein C downregulates p38 mitogen-activated protein kinase and improves clinical parameters in an in-vivo model of septic shock.
Shock, Septic
Activated protein C for the treatment of fulminant meningococcal septicaemia.
Shock, Septic
Activated protein C improves lipopolysaccharide-induced cardiovascular dysfunction by decreasing tissular inflammation and oxidative stress.
Shock, Septic
Activated protein C improves LPS-induced cardiovascular dysfunction by decreasing tissular inflammation and oxidative stress.
Shock, Septic
Activated Protein C Improves Macro and Microvascular Reactivity in Human Severe Sepsis and Septic Shock.
Shock, Septic
Activated protein C in patients with septic shock: a consecutive case series.
Shock, Septic
An early favorable outcome of streptococcal toxic shock syndrome may require a combination of antimicrobial and intravenous gamma globulin therapy together with activated protein C.
Shock, Septic
Authors' reply to Thomas et al.'s "Comment on 'Early treatment with activated protein C for meningococcal septic shock: case report and literature review' by Hasin et al.".
Shock, Septic
Beneficial effects of recombinant human activated protein C in a ewe model of septic shock.
Shock, Septic
Clinical and laboratory effects of recombinant human activated protein C in the treatment of a patient with sepsis-induced multiple organ failure.
Shock, Septic
Combined use of extracorporeal membrane oxygenation and activated protein C for severe acute respiratory distress syndrome and septic shock.
Shock, Septic
Comment on "Early treatment with activated protein C for meningococcal septic shock: case report and literature review" by Hasin et al.
Shock, Septic
Comparative effects of recombinant human activated protein C and dexamethasone in experimental septic shock.
Shock, Septic
Compliance With a Sepsis Bundle and Its Effect on Intensive Care Unit Mortality in Surgical Septic Shock Patients.
Shock, Septic
Cost Analysis of Adjunctive Hydrocortisone Therapy for Septic Shock: U.S. Payer Perspective.
Shock, Septic
Current advances in sepsis and septic shock with particular emphasis on the role of insulin.
Shock, Septic
Current role of activated protein C therapy for severe sepsis and septic shock.
Shock, Septic
Design and conduct of the activated protein C and corticosteroids for human septic shock (APROCCHSS) trial.
Shock, Septic
Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock.
Shock, Septic
Dexamethasone and recombinant human activated protein C improve myocardial function and efficiency during experimental septic shock.
Shock, Septic
Drotrecogin alfa (activated) did not reduce mortality at 28 or 90 days in patients with septic shock.
Shock, Septic
Early goal-directed therapy, corticosteroid, and recombinant human activated protein C for the treatment of severe sepsis and septic shock in the emergency department.
Shock, Septic
Early suspension of activated protein C treatment in septic patients after shock reversal.
Shock, Septic
Early treatment with activated protein C for meningococcal septic shock: case report and literature review.
Shock, Septic
Editors' comments on a new trial of activated protein C for persistent septic shock.
Shock, Septic
Effect of protein C and activated protein C on alveolar fibrin deposition and turnover in a piglet model of septic shock.
Shock, Septic
Effect of recombinant activated protein C and low-dose heparin on neutrophil-endothelial cell interactions in septic shock.
Shock, Septic
Effectiveness of human recombinant activated protein C for severe sepsis and septic shock in adult and pediatric patients: randomized clinical trial versus nonrandomized study.
Shock, Septic
Effects of a novel anticoagulant compound (TV7130) in an ovine model of septic shock.
Shock, Septic
Efficacy of therapy with recombinant human activated protein C of critically ill surgical patients with infection complicated by septic shock and multiple organ dysfunction syndrome.
Shock, Septic
Endogenous activated protein C signaling is critical to protection of mice from lipopolysaccaride-induced septic shock.
Shock, Septic
Erratum to: Design and conduct of the activated protein C and corticosteroids for human septic shock (APROCCHSS) trial.
Shock, Septic
Gonococcal septic shock, acute respiratory distress syndrome, and multisystem organ failure: a case report.
Shock, Septic
Hemodynamic effects of recombinant human activated protein C in patients with septic shock.
Shock, Septic
Hemodynamic resuscitation in septic shock: cardiovascular support and adjunctive therapy.
Shock, Septic
Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients.
Shock, Septic
Hydrocortisone Compared with Placebo in Patients with Septic Shock Satisfying the Sepsis-3 Diagnostic Criteria and APROCCHSS Study Inclusion Criteria: A Post Hoc Analysis of the ADRENAL Trial.
Shock, Septic
Implementation of an evidence-based "standard operating procedure" and outcome in septic shock*
Shock, Septic
Incidence, treatment, and outcome of severe sepsis in ICU-treated adults in Finland: the Finnsepsis study.
Shock, Septic
Low utilisation of unactivated protein C in a patient with meningococcal septic shock and disseminated intravascular coagulation.
Shock, Septic
MicroRNA expression following activated protein C treatment during septic shock.
Shock, Septic
Negative regulation of inducible nitric-oxide synthase expression mediated through transforming growth factor-beta-dependent modulation of transcription factor TCF11.
Shock, Septic
Optimum treatment of severe sepsis and septic shock: evidence in support of the recommendations.
Shock, Septic
Puerperal streptococcal toxic shock syndrome treated with recombinant human activated protein C and intravenous immunoglobulin.
Shock, Septic
Rapid and beneficial hemodynamic effects of activated protein C in septic shock patients.
Shock, Septic
Recombinant activated protein C treatment improves tissue perfusion and oxygenation in septic patients measured by near-infrared spectroscopy.
Shock, Septic
Recombinant human activated protein C attenuates cardiovascular and microcirculatory dysfunction in acute lung injury and septic shock.
Shock, Septic
Recombinant Human Activated Protein C for Adults with Septic Shock: a Randomized Controlled Trial.
Shock, Septic
Recombinant human activated protein C for the treatment of severe sepsis and septic shock: a study protocol for incorporating observational evidence using a Bayesian approach.
Shock, Septic
Recombinant human activated protein C treatment of septic shock syndrome in a patient at 18th week of gestation: a case report.
Shock, Septic
Septic shock and multiple organ failure after hematopoietic stem cell transplantation: treatment with recombinant human activated protein C.
Shock, Septic
Septic shock caused by Streptococcus pneumoniae in a post-splenectomy patient successfully treated with recombinant human activated protein C.
Shock, Septic
Successful treatment of life-threatening melioidosis with activated protein C and meropenem.
Shock, Septic
Successful treatment of septic shock and respiratory failure due to leptospirosis and scrub typhus coinfection with penicillin, levofloxacin, and activated protein C.
Shock, Septic
Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock.
Shock, Septic
Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008.
Shock, Septic
Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.
Shock, Septic
Systemic and organ dysfunction response during infusion of recombinant human activated protein C (rhAPC) in severe sepsis and septic shock.
Shock, Septic
The evolution of activated protein C plasma levels in septic shock and its association with mortality: A prospective observational study.
Shock, Septic
The implementation of new therapies for severe sepsis: some questions raised by "early goal-directed therapy, corticosteroid, and recombinant human activated protein c for the treatment of severe sepsis and septic shock in the emergency department".
Shock, Septic
The Next Generation of Sepsis Clinical Trial Designs: What Is Next After the Demise of Recombinant Human Activated Protein C?
Shock, Septic
The nexus between systemic inflammation and disordered coagulation in sepsis.
Shock, Septic
The role of glucocorticoids as adjunctive treatment for sepsis in the modern era.
Shock, Septic
The use of recombinant human activated protein C (drotrecogin alpha) in solid organ transplant recipients: case series and review of the literature.
Shock, Septic
Thrombomodulin as an intravascular safeguard against inflammatory and thrombotic diseases.
Shock, Septic
Urgent care in gynaecology: resuscitation and management of sepsis and acute blood loss.
Shock, Septic
Use of activated protein C in liver transplantation patients with septic shock.
Shock, Septic
Use of Drotrecogin Alpha (Recombinant Human Activated Protein C, rhAPC) in the Treatment of Severe Sepsis Induced by Graft Pancreatitis After Simultaneous Pancreas and Kidney Transplantation: A Case Report.
Shock, Septic
Use of recombinant human activated protein C in nonmenstrual staphylococcal toxic shock syndrome.
Shock, Septic
Why activated protein C was not successful in severe sepsis and septic shock: are we still tilting at windmills?
Shock, Septic
[Human recombinant activated protein C in patients with severe sepsis and septic shock]
Shock, Septic
[Potential benefits of non-anti-infective treatments of septic shock: a critical analysis of literature]
Shock, Septic
[Protocol of the management of patients with severe sepsis and septic shock].
Shock, Septic
[Toxic shock syndrome consecutive to the presence of vaginal tampon for menstruation regressive after early haemodynamic optimization and activated protein C infusion]
Shock, Septic
[Use of protein C concentrate in adult patients with severe sepsis and septic shock]
Sinus Thrombosis, Intracranial
Activated protein C resistance and factor V Leiden mutation are risk factors for cerebral sinus thrombosis.
Sinus Thrombosis, Intracranial
Cerebral sinus thrombosis in a young adult with activated protein C resistance and homosysteinaemia.
Sinus Thrombosis, Intracranial
Dural puncture and activated protein C resistance: risk factors for cerebral venous sinus thrombosis.
Sinus Thrombosis, Intracranial
Dural sinus thrombosis associated with activated protein C resistance: MR imaging findings and proband identification.
Sinus Thrombosis, Intracranial
Iron-deficiency anaemia in childhood: a risk factor for severe venous thrombosis?
Sinus Thrombosis, Intracranial
Roles of inflammation and the activated protein C pathway in the brain edema associated with cerebral venous sinus thrombosis.
Skin Diseases
Activated Protein C Attenuates Systemic Lupus Erythematosus and Lupus Nephritis in MRL-Fas(lpr) Mice.
Skin Diseases
Novel Functions of the Anticoagulant Activated Protein C in Maintaining Skin Barrier Integrity to Impact on Skin Disease.
Skin Ulcer
Use of dermal injection of activated protein C for treatment of large chronic wounds secondary to pyoderma gangrenosum.
Spinal Cord Injuries
Activated protein C reduces the ischemia/reperfusion-induced spinal cord injury in rats by inhibiting neutrophil activation.
Spinal Cord Injuries
Activated protein C reduces the severity of compression-induced spinal cord injury in rats by inhibiting activation of leukocytes.
Spinal Cord Injuries
Neonatal brain injury and systemic inflammation: modulation by activated protein C ex vivo.
Spinal Cord Injuries
Neurological outcome and inflammation after cardiac arrest--effects of protein C in rats.
Spinal Cord Injuries
Neuroprotective effects of recombinant thrombomodulin in controlled contusion spinal cord injury implicates thrombin signaling.
Spinal Cord Injuries
NON-activated protein C as post-treatment after spinal cord compression injury in rats.
Spinal Cord Injuries
Protease-Activated Receptor-1 Supports Locomotor Recovery by Biased Agonist Activated Protein C after Contusive Spinal Cord Injury.
Spinal Cord Injuries
Retraction. Activated protein C reduces the severity of compression-induced spinal cord injury in rats by inhibiting activation of leukocytes.
Spinal Cord Injuries
The long-term effects of pre-treatment with activated protein C in a rat model of compression-induced spinal cord injury.
Spinal Cord Ischemia
Neuroprotective effects of activated protein C through induction of insulin-like growth factor-1 (IGF-1), IGF-1 receptor, and its downstream signal phosphorylated serine-threonine kinase after spinal cord ischemia in rabbits.
Stillbirth
How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review.
Stroke
Activated protein c can be used as a prophylactic as well as a therapeutic agent for heat stroke in rodents.
Stroke
Activated protein C is neuroprotective and mediates new blood vessel formation and neurogenesis after controlled cortical impact.
Stroke
Activated protein C resistance (factor V Leiden) associated with thrombosis in pregnancy.
Stroke
Activated protein C resistance and acute ischaemic stroke: relation to stroke causation and age.
Stroke
Activated Protein C Resistance Does Not Increase Risk for Recurrent Stroke or Death in Stroke Patients.
Stroke
Activated protein C resistance in young African American patients with ischemic stroke.
Stroke
Causal relationship of susceptibility genes to ischemic stroke: comparison to ischemic heart disease and biochemical determinants.
Stroke
Combined neurothrombectomy or thrombolysis with adjunctive delivery of 3K3A-activated protein C in acute ischemic stroke.
Stroke
Emerging risk factors for stroke: Patent foramen ovale, proximal aortic atherosclerosis, antiphospholipid antibodies, and activated protein C resistance.
Stroke
Endogenous activated protein C predicts hemorrhagic transformation and mortality after tissue plasminogen activator treatment in stroke patients.
Stroke
Evaluation of 3K3A-Activated Protein C to Treat Neonatal Hypoxic Ischemic Brain Injury in the Spiny Mouse.
Stroke
Fetal stroke and congenital parvovirus B19 infection complicated by activated protein C resistance.
Stroke
Hemodynamic effects of recombinant human activated protein C in patients with septic shock.
Stroke
Hemostatic markers with bolus versus prolonged heparin after carotid artery stenting.
Stroke
Ischemic stroke associated with activated protein C resistance and aortic valvular papillary fibroelastoma.
Stroke
Multiple hemostatic abnormalities in young adults with activated protein C resistance and cerebral ischemia.
Stroke
Neurological outcome and inflammation after cardiac arrest--effects of protein C in rats.
Stroke
PAR1 biased signaling is required for activated protein C in vivo benefits in sepsis and stroke.
Stroke
Phenotypic APC resistance as a marker of hypercoagulability in primitive cerebral lymphoma.
Stroke
Postmenopausal hormone replacement therapy and cardiovascular disease: the value of transdermal estradiol and micronized progesterone.
Stroke
Protein S deficiency, activated protein C resistance and sticky platelet syndrome in a young woman with bilateral strokes.
Stroke
Prothrombotic factors and the risk of acute onset non-cardioembolic stroke in young Asian Indians.
Stroke
Resistance to activated protein C as a risk factor of stroke in a thalassemic patient.
Stroke
Resistance to activated protein C as an etiology for stroke in a young adult: a case report.
Stroke
Resistance to activated protein C: arterial thrombosis associated with autoimmune features.
Stroke
Response to activated protein C in subjects with and without dementia. The Dutch Vascular Factors in Dementia Study.
Stroke
The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects.
Stroke
[Brain stem ischemia in a boy with resistance to C activated protein and elevated lipoprotein A]
Subarachnoid Hemorrhage
Inhibitory effect of activated protein C on cerebral vasospasm after subarachnoid hemorrhage in the rabbit.
Tachycardia, Ventricular
Intracardiac thrombus causing systemic embolism in a child with idiopathic ventricular tachycardia and heterozygous activated protein C resistance.
Thrombocythemia, Essential
Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden.
Thrombocythemia, Essential
Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis.
Thrombocythemia, Essential
The transjugular intrahepatic portosystemic stent-shunt (TIPS) as rescue therapy for complete Budd-Chiari syndrome and portal vein thrombosis.
Thrombocythemia, Essential
Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera.
Thrombocythemia, Essential
[Mesenteric and splenic vein thrombosis in a female patient with essential thrombocytosis and activated protein C resistance]
Thrombocytopenia
Antibodies associated with heparin-induced thrombocytopenia (HIT) inhibit activated protein C generation: new insights into the prothrombotic nature of HIT.
Thrombocytopenia
Heparin-induced thrombocytopenia and fatal thrombosis in a patient with activated protein C resistance.
Thrombocytopenia
Pregnancy associated coagulopathies in selected community hospitals in Southwest Nigeria.
Thrombocytopenia
Primary pulmonary artery sarcoma resembling chronic thromboembolic pulmonary disease.
Thrombocytopenia
Puerperal streptococcal toxic shock syndrome treated with recombinant human activated protein C and intravenous immunoglobulin.
Thrombocytopenia
Use of activated protein C in liver transplantation patients with septic shock.
Thrombocytosis
Recurrent thrombosis after carotid endarterectomy secondary to activated protein C resistance and essential thrombocytosis: A case report.
Thrombocytosis
[Mesenteric and splenic vein thrombosis in a female patient with essential thrombocytosis and activated protein C resistance]
Thromboembolism
A role for thrombomodulin in the pathogenesis of thrombin-induced thromboembolism in mice.
Thromboembolism
Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism.
Thromboembolism
Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein c reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation.
Thromboembolism
Activated protein C (APC) resistance in Indian children with thromboembolism.
Thromboembolism
Activated protein C concentrate: a new tool for the treatment of acute thromboembolism in patients with congenital protein C deficiency.
Thromboembolism
APC resistance in childhood thromboembolism: diagnosis and clinical aspects.
Thromboembolism
Cross-comparison of the genome sequences from human, chimpanzee, Neanderthal and a Denisovan hominin identifies novel potentially compensated mutations.
Thromboembolism
Fetal stroke and congenital parvovirus B19 infection complicated by activated protein C resistance.
Thromboembolism
Phospholipid antibodies and resistance to activated protein C in women with thrombophilia.
Thromboembolism
Physiological anticoagulation. Resistance to activated protein C and venous thromboembolism.
Thromboembolism
Plasma homocysteine concentration is not associated with activated protein C resistance in patients investigated for hypercoagulability.
Thromboembolism
Recurrent thrombosis after carotid endarterectomy secondary to activated protein C resistance and essential thrombocytosis: A case report.
Thromboembolism
Resistance to activated protein C (APCR) in children with venous or arterial thromboembolism.
Thromboembolism
The predictability of factor V Leiden (FV:Q(506)) gene mutation via clotting-based diagnosis of activated protein C resistance.
Thromboembolism
Thromboembolism and resistance to activated protein C in children with underlying cardiac disease.
Thromboembolism
Thromboembolism and resistance to activated protein C in patients with inflammatory bowel disease.
Thromboembolism
[Acute coronary syndrome following massive pulmonary embolism in a 81-year-old woman with thrombophilia]
Thromboembolism
[Multiple phlebothrombosis following cesarean section due to heterozygous factor V Leiden mutation detected post partum]
Thromboinflammation
COVID-19 hypothesis: Activated protein C for therapy of virus-induced pathologic thromboinflammation.
Thrombophilia
A 9-year retrospective assessment of laboratory testing for activated protein C resistance: evolution of a novel approach to thrombophilia investigations.
Thrombophilia
A case of hereditary thrombophilia in a Chinese Han patient with both antithrombin deficiency and Factor V Leiden: A case report and literature review.
Thrombophilia
A case report of recurrent vascular access thrombosis in a hemodialysis patient reveals combined acquired and inherited thrombophilia.
Thrombophilia
A clinical audit of congenital thrombophilia investigation in tertiary practice.
Thrombophilia
A matrix-assisted laser desorption/ionization time-of-flight based method for screening the 1691G --> A mutation in the factor V gene.
Thrombophilia
A multi-laboratory assessment of congenital thrombophilia assays performed on the ACL TOP 50 family for harmonisation of thrombophilia testing in a large laboratory network.
Thrombophilia
A new locus on chromosome 18 that influences normal variation in activated protein C resistance phenotype and factor VIII activity and its relation to thrombosis susceptibility.
Thrombophilia
A new method to measure plasma levels of activated protein C in complex with protein C inhibitor in patients with acute coronary syndromes.
Thrombophilia
Acquired activated protein C resistance and thrombosis in multiple myeloma patients.
Thrombophilia
Acquired activated protein C resistance, thrombophilia and adverse pregnancy outcomes: a study performed in an irish cohort of pregnant women.
Thrombophilia
Activated protein C anticoagulant system dysfunction and thrombophilia in Asia.
Thrombophilia
Activated protein C resistance and acute ischaemic stroke: relation to stroke causation and age.
Thrombophilia
Activated protein C resistance due to a common factor V gene mutation is a major risk factor for venous thrombosis.
Thrombophilia
Activated protein C resistance in patients following venous thromboembolism receiving rivaroxaban versus vitamin K antagonists: assessment using Russell viper venom time-based assay.
Thrombophilia
Activated protein C resistance, factor V Leiden and peripheral vascular disease.
Thrombophilia
Activated protein C resistance, thrombophilia, and inflammatory bowel disease.
Thrombophilia
Activated protein C resistance: from phenotype to genotype and clinical practice.
Thrombophilia
Acute Budd-Chiari syndrome with fulminant hepatic failure in a pregnant woman with factor V Leiden mutation.
Thrombophilia
Allele-specific PCR amplification of factor V Leiden to identify patients at risk for thromboembolism.
Thrombophilia
Analysis of blood clotting factor activities in canine Legg-Calvé-Perthes' disease.
Thrombophilia
Anticardiolipin antibodies do not seem to be associated with APC resistance in vivo or in vitro.
Thrombophilia
APC-resistance as measured by a Textarin time assay: comparison to the APTT-based method.
Thrombophilia
APCR, factor V gene known and novel SNPs and adverse pregnancy outcomes in an Irish cohort of pregnant women.
Thrombophilia
Arg506Gln factor V mutation and Val34Leu factor XIII polymorphism in Finnish patients with inflammatory bowel disease.
Thrombophilia
Association between in vitro fertilization outcomes and inherited thrombophilias: a meta-analysis.
Thrombophilia
Association between prothrombin gene polymorphisms and hereditary thrombophilia in Xinjiang Kazakhs population.
Thrombophilia
Blood coagulation factor Va abnormality associated with resistance to activated protein C in venous thrombophilia.
Thrombophilia
Budd-Chiari syndrome associated with factor V leiden mutation: a report of 6 patients.
Thrombophilia
Budd-Chiari syndrome in a patient with factor V Leiden--successful treatment by TIPSS placement followed by liver transplantation.
Thrombophilia
Case Study of Pediatric Cerebral Sinus Venous Thrombosis Center of a Low Middle-Income Country.
Thrombophilia
Cerebral venous sinus thrombosis as presenting feature of ulcerative colitis.
Thrombophilia
Clinical importance of prothrombotic risk factors in pediatric patients with malignancy--impact of central venous lines.
Thrombophilia
Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis.
Thrombophilia
Coexistence of factor V Leiden and primary antiphospholipid syndrome: a patient with recurrent myocardial infarctions and thrombocytopenia.
Thrombophilia
Combined heterozygous plasminogen deficiency and factor V Leiden defect in the same kindred.
Thrombophilia
Comparison of Russell viper venom-based and activated partial thromboplastin time-based screening assays for resistance to activated protein C.
Thrombophilia
Complexes between activated protein C and protein C inhibitor measured with a new method: comparison of performance with other markers of hypercoagulability in the diagnosis of deep vein thrombosis.
Thrombophilia
Comprehensive review of the impact of direct oral anticoagulants on thrombophilia diagnostic tests: Practical recommendations for the laboratory.
Thrombophilia
Deficiencies of proteins C, S and antithrombin and activated protein C resistance--their involvement in the occurrence of Arterial thromboses.
Thrombophilia
Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families.
Thrombophilia
Direct Oral Anticoagulants in Patients with Thrombophilia: Challenges in Diagnostic Evaluation and Treatment.
Thrombophilia
Discrimination between normal wildtype and carriers of coagulation factor V Leiden mutation by the activated protein C resistance test in the presence of factor V deficient plasma.
Thrombophilia
Do placental lesions reflect thrombophilia state in women with adverse pregnancy outcome?
Thrombophilia
Effect of platelet phospholipid exposure on activated protein C resistance: implications for thrombophilia screening.
Thrombophilia
Effect of thrombophylaxis on uterine and fetal circulation in pregnant women with a history of pregnancy complications.
Thrombophilia
Efficacy and safety of nadroparin and unfractionated heparin for the treatment of venous thromboembolism during pregnancy and puerperium.
Thrombophilia
Elevated levels of prothrombin activation fragment 1 + 2 in plasma from patients with heterozygous Arg506 to Gln mutation in the factor V gene (APC-resistance) and/or inherited protein S deficiency.
Thrombophilia
Endogenous thrombin potential for predicting risk of venous thromboembolism in carriers of factor V Leiden.
Thrombophilia
Evaluation of a tissue factor dependent factor V assay to detect factor V Leiden: demonstration of high sensitivity and specificity for a generally applicable assay for activated protein C resistance.
Thrombophilia
Evaluation of risk factors for thrombophilia in patients with cerebral venous thrombosis.
Thrombophilia
Evaluation of the roles of the Leiden V mutation and ACE I/D polymorphism in subtypes of ischaemic stroke.
Thrombophilia
Exogenous estrogen may exacerbate thrombophilia, impair bone healing and contribute to development of chronic facial pain.
Thrombophilia
Factor V Leiden (R506Q) and risk of venous thromboembolism: a case-control study based on the Spanish population.
Thrombophilia
Factor V Leiden and other coagulation factor mutations affecting thrombotic risk.
Thrombophilia
Factor V Leiden in absence of activated protein C resistance after orthotopic liver transplantation in a patient without thrombosis but with familial thrombophilia.
Thrombophilia
Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia.
Thrombophilia
Factor V Leiden: an additional risk factor for thrombosis in protein S deficient families?
Thrombophilia
Familial antithrombin III deficiency in a Malay patient with massive thrombosis.
Thrombophilia
Familial thrombophilia and activated protein C resistance: thrombotic risk in pregnancy?
Thrombophilia
Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.
Thrombophilia
Familial thrombophilia: clinical and molecular analysis of Swedish families with inherited resistance to activated protein C or protein S deficiency.
Thrombophilia
Functional activated protein C resistance assays: correlation with factor V DNA analysis is better with RVVT-than APTT-based assays.
Thrombophilia
Genetic polymorphisms on the factor V gene in women with recurrent miscarriage and acquired APCR.
Thrombophilia
Guidelines for the management of thrombophilia. Department of Haematology, The Royal London Hospital, Whitechapel, London, UK.
Thrombophilia
Heightened thrombin generation in individuals with resistance to activated protein C.
Thrombophilia
Heparin-induced thrombocytopenia and fatal thrombosis in a patient with activated protein C resistance.
Thrombophilia
Heritable thrombophilia-hypofibrinolysis and osteonecrosis of the femoral head.
Thrombophilia
Heterozygosity for the factor V Leiden (G1691A) mutation predisposes renal transplant recipients to thrombotic complications and graft loss.
Thrombophilia
Heterozygosity for the Leiden mutation of the factor V gene, a common pathoetiology for osteonecrosis of the jaw, with thrombophilia augmented by exogenous estrogens.
Thrombophilia
High prevalence of thrombophilia among young patients with myocardial infarction and few conventional risk factors.
Thrombophilia
Hypercoagulability Evaluation in Antiphospholipid Syndrome without Anticoagulation Treatment with Thrombin Generation Assay: A Preliminary Study.
Thrombophilia
Hypercoagulability in patients with primary biliary cirrhosis and primary sclerosing cholangitis evaluated by thrombelastography.
Thrombophilia
Hypercoagulable states in renal transplant candidates: impact of anticoagulation upon incidence of renal allograft thrombosis.
Thrombophilia
Implementation of a cost-effective unlabeled probe high-resolution melt assay for genotyping of factor v leiden.
Thrombophilia
Incidence of activated protein C resistance caused by the ARG 506 GLN mutation in factor V in 113 unrelated symptomatic protein C-deficient patients. The French Network on the behalf of INSERM.
Thrombophilia
Increased resistance to activated protein C and factor V Leiden in recurrent abortions. Review of other hypercoagulability factors.
Thrombophilia
Induction of a hypercoagulability state and endothelial cell activation by granulocyte colony-stimulating factor in peripheral blood stem cell donors.
Thrombophilia
Inherited activated protein C resistance in a patient with familial primary antiphospholipid syndrome.
Thrombophilia
Inherited defects of the protein C anticoagulant system in childhood thrombo-embolism.
Thrombophilia
Inherited resistance to activated protein C caused by presence of the FV:Q506 allele as a basis of venous thrombosis.
Thrombophilia
Inherited resistance to activated protein C, a major cause of venous thrombosis, is due to a mutation in the factor V gene.
Thrombophilia
Inherited thrombophilia in unprovoked venous thromboembolism: Is non 'O' blood group an additional culprit in Indian patients?
Thrombophilia
Inherited thrombophilia: memorandum from a joint WHO/International Society on Thrombosis and Haemostasis meeting.
Thrombophilia
Inherited thrombophilia: resistance to activated protein C as a pathogenic factor of venous thromboembolism.
Thrombophilia
Investigation of inherited thrombophilias in patients with pulmonary embolism.
Thrombophilia
Ischemic stroke subtypes and thrombophilia in young and elderly Brazilian stroke patients admitted to a rehabilitation hospital.
Thrombophilia
Laboratory screening of thrombophilia. Evaluation of the diagnostic efficacy of a global test to detect congenital deficiencies of the protein C anticoagulant pathway.
Thrombophilia
Lack of rivaroxaban influence on a prothrombinase-based assay for the detection of activated C protein resistance: an Italian ex vivo and in vitro study in normal subjects and factor V Leiden carriers.
Thrombophilia
Learning from peer assessment: the role of the external quality assurance multilaboratory thrombophilia test process.
Thrombophilia
Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis.
Thrombophilia
Liver transplantation for acute Budd-Chiari syndrome in identical twin sisters with Factor V leiden mutation.
Thrombophilia
Long term anticoagulation (4-16 years) stops progression of idiopathic hip osteonecrosis associated with familial thrombophilia.
Thrombophilia
Low birthweight in relation to placental abruption and maternal thrombophilia status.
Thrombophilia
Low-Molecular-Weight Heparin Added to Aspirin in the Prevention of Recurrent Early-Onset Preeclampsia in women with Inheritable Thrombophilia: the FRUIT-RCT.
Thrombophilia
Maximising the diagnostic potential of APTT-based screening assays for activated protein C resistance.
Thrombophilia
Mechanical prosthetic heart valve thrombosis despite optimal anticoagulation in a patient with congenital thrombophilia (factor V Leiden).
Thrombophilia
Membrane autoantibodies in systemic lupus erythematosus: a case of autoimmune hemolytic anemia, antiphospholipid antibodies, and transient acquired activated protein C resistance.
Thrombophilia
Molecular genetics of thrombophilia: factor V gene mutation causing resistance to activated protein C as a basis of the hypercoagulable state.
Thrombophilia
Multilaboratory testing of thrombophilia: current and past practice in Australasia as assessed through the Royal College of Pathologists of Australasia Quality Assurance Program for Hematology.
Thrombophilia
Mutation screening for thrombophilia: two cases with factor V Cambridge without activated protein C resistance.
Thrombophilia
New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis.
Thrombophilia
Oral Contraceptives and Venous Thromboembolism: Focus on Testing that May Enable Prediction and Assessment of the Risk.
Thrombophilia
Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives.
Thrombophilia
Overall haemostasis potential assays performed in thrombophilic plasma: the effect of preactivating protein C and antithrombin.
Thrombophilia
Pathology consultation on the laboratory evaluation of thrombophilia: when, how, and why.
Thrombophilia
Phenotype and genotype expression in pseudohomozygous factor VLEIDEN : the need for phenotype analysis.
Thrombophilia
Phenotypic APC resistance as a marker of hypercoagulability in primitive cerebral lymphoma.
Thrombophilia
Phospholipid antibodies and resistance to activated protein C in women with thrombophilia.
Thrombophilia
Plasma homocysteine concentration is not associated with activated protein C resistance in patients investigated for hypercoagulability.
Thrombophilia
Plasma hypercoagulability in the presence of thrombomodulin but not of activated protein C in patients with cirrhosis.
Thrombophilia
Prevalence of factor V gene mutation amongst myocardial infarction patients and healthy controls is higher in Sweden than in other countries.
Thrombophilia
Prevalence of factor V Leiden mutation in young adults with cerebral ischaemia: a case-control study on 225 patients.
Thrombophilia
Prevalence of resistence to activated protein C (APC-resistance) in blood donors in Kosovo.
Thrombophilia
Prevalence of the Factor V Leiden Mutation Arg534Gln in Western Region of Saudi Arabia: Functional Alteration and Association Study With Different Populations.
Thrombophilia
Prevalence of thrombophilia in women with severe ovarian hyperstimulation syndrome and cost-effectiveness of screening.
Thrombophilia
Primary thrombophilia in Mexico IV: frequency of the Leiden, Cambridge, Hong Kong, Liverpool and HR2 haplotype polymorphisms in the factor V gene of a group of thrombophilic Mexican Mestizo patients.
Thrombophilia
Primary Thrombophilia in México XI: Activated Protein C Resistance Phenotypes are Multifactorial.
Thrombophilia
Primary thrombophilia in Mexico. II. Factor V G1691A (Leiden), prothrombin G20210A, and methylenetetrahydrofolate reductase C677T polymorphism in thrombophilic Mexican mestizos.
Thrombophilia
Primary thrombophilia in Mexico: a single tertiary referral hospital experience.
Thrombophilia
Prothrombin fragment 1+2 and thrombin-antithrombin complex levels in patients with inherited APC resistance due to factor V Leiden mutation.
Thrombophilia
Rapid multiplex analysis for the factor V Leiden and prothrombin G20210A mutations associated with hereditary thrombophilia.
Thrombophilia
Relevance of Inherited Thrombophilia Screening in Adult Kidney Transplant Recipients.
Thrombophilia
Resistance to activated protein C and low levels of free protein S in Greek patients with inflammatory bowel disease.
Thrombophilia
Resistance to activated protein C as pathogenic factor of venous thromboembolism.
Thrombophilia
Resistance to activated protein C due to mutated factor V as a novel cause of inherited thrombophilia.
Thrombophilia
Resistance to activated protein C in an unselected population of patients with pulmonary embolism.
Thrombophilia
Resistance to activated protein C mimicking dysfunctional protein C: diagnostic approach.
Thrombophilia
Risk factors and management of patients with upper limb deep vein thrombosis.
Thrombophilia
Risk of myocardial infarction related to factor V Leiden mutation: a meta-analysis.
Thrombophilia
Risk of venous thromboembolism with third-generation oral contraceptives: A review.
Thrombophilia
Sensitivity and specificity of the APC resistance assay in detection of individuals with factor V Leiden.
Thrombophilia
Sensitivity to activated protein C in patients with deep vein thrombosis during early puerperium period.
Thrombophilia
Successful liver transplantation in a patient with Budd-Chiari syndrome caused by homozygous factor V Leiden.
Thrombophilia
Successful Living-Related Renal Allograft in a Recipient With Factor V Leiden Deficiency: A Case Report.
Thrombophilia
The adsorption of dabigatran is as efficient as addition of idarucizumab to neutralize the drug in routine coagulation assays.
Thrombophilia
The anticoagulant potential of the protein C system in hereditary and acquired thrombophilia: pathomechanisms and new tools for assessing its clinical relevance.
Thrombophilia
The frequency of factor V Leiden and concomitance of factor V Leiden with prothrombin G20210A mutation and methylene tetrahydrofolate reductase C677T gene mutation in healthy population of Denizli, Aegean region of Turkey.
Thrombophilia
The Leiden mutation and activated protein C resistance as risk factors for disseminated intravascular coagulation in acutely poisoned patients.
Thrombophilia
The Normal anticoagulant system and risk of placental abruption: protein C, protein S and resistance to activated protein C.
Thrombophilia
The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects.
Thrombophilia
The prevalence of thrombophilia in patients with symptomatic peripheral vascular disease.
Thrombophilia
The role of hypercoagulability in the development of osteonecrosis of the femoral head.
Thrombophilia
The VITA Project: heritability of resistance to activated protein C. Vincenza Thrombophilia and Arteriosclerosis.
Thrombophilia
The VITA project: phenotypic resistance to activated protein C and FV Leiden mutation in the general population. Vicenza Thrombophilia and Atherosclerosis.
Thrombophilia
Thrombophilia in patients with chronic venous leg ulcers-a study on patients with or without post-thrombotic syndrome.
Thrombophilia
Thrombophilia prevalence in patients seeking laparoscopic sleeve gastrectomy: extended chemoprophylaxis may decrease portal vein thrombosis rate.
Thrombophilia
Thrombophilia Profile in Budd-Chiari Syndrome and Splanchnic Vein Thrombosis: A Study from Western India.
Thrombophilia
Thrombophilic abnormalities and recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatment.
Thrombophilia
Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years. Relationships to hormone replacement therapy.
Thrombophilia
Use of modified functional assays for activated protein C resistance in patients with basally prolonged aPTT.
Thrombophilia
Use of selective factor V Leiden screening in pregnancy to identify candidates for anticoagulants.
Thrombophilia
Usefulness of screening for congenital or acquired hemostatic abnormalities in women with previous complicated pregnancies.
Thrombophilia
Utility of the clinical practice of administering thrombophilic screening and antithrombotic prophylaxis with low-molecular-weight heparin to healthy donors treated with G-CSF for mobilization of peripheral blood stem cells.
Thrombophilia
Vascular graft thrombosis secondary to activated protein C resistance: a case report and literature review.
Thrombophilia
Venous thromboembolism, factor V Leiden, and methylenetetrahydrofolate reductase in a sickle cell anemia patient.
Thrombophilia
Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study.
Thrombophilia
Venous thrombosis in a replanted finger with underlying factor V Leiden mutation.
Thrombophilia
Whole blood screening test for factor V Leiden using a Russell viper venom time-based assay.
Thrombophilia
[A new cause of familial thrombophilia: resistance to the effect of activated protein C]
Thrombophilia
[Activated protein C resistance and venous thrombophilia: molecular genetic prevalence study in the German population]
Thrombophilia
[Activated protein C resistance--a recently discovered hereditary thrombophilia]
Thrombophilia
[Factor V leiden and venous thromboembolism in a woman taking second generation oral contraceptives: a case report]
Thrombophilia
[Initial experience in the diagnosis of thrombophilia due to activated protein C resistance]
Thrombophilia
[Intravenous recombinant tissue plasminogen activator in an 18-week pregnant woman with embolic stroke]
Thrombophilia
[Occurrence of gene mutations in factor V Leiden, prothrombin and methylenetetrahydrofolate reductase in patients with pre-eclampsia]
Thrombophilia
[Resistance to activated protein C. The most common cause of familial thrombophilia]
Thrombophilia
[Risk of thrombosis with oral contraceptives: value of a thrombophilia screening test]
Thrombophilia
[Significance of hereditary thrombophilia for risk of thrombosis with oral contraceptives]
Thrombophilia
[Study of activated protein C resistance(APC-R) and FV Leiden in healthy blood donors and patients with thrombosis]
Thrombophilia
[Thrombophilia in a family with resistance to activated protein C and protein S deficiency]
Thrombophilia
[Thrombophilias in patients with ischemic stroke. Indication and calculated costs for evidence-based diagnostics and treatment]
Thrombophlebitis
Activated protein C resistance and its correlation with thrombophlebitis in Behçet's disease.
Thrombosis
"Pseudo homozygous" activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds.
Thrombosis
A case of deep vein thrombosis in idiopathic nephrotic syndrome with resistance to activated protein C.
Thrombosis
A clinical audit of congenital thrombophilia investigation in tertiary practice.
Thrombosis
A new locus on chromosome 18 that influences normal variation in activated protein C resistance phenotype and factor VIII activity and its relation to thrombosis susceptibility.
Thrombosis
Acquired activated protein C resistance and thrombosis in multiple myeloma patients.
Thrombosis
Acquired activated protein C resistance associated with anti-protein S antibody as a strong risk factor for DVT in non-SLE patients.
Thrombosis
Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism.
Thrombosis
Acquired APC resistance in neurosurgical patients may not be a risk factor for postoperative deep vein thrombosis.
Thrombosis
Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein c reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation.
Thrombosis
Activated protein C (APC) resistance in indian juvenile deep vein thrombosis (DVT)
Thrombosis
Activated protein C accelerates venous thrombus resolution through heme oxygenase-1 induction.
Thrombosis
Activated protein C cleaves factor Va more efficiently on endothelium than on platelet surfaces.
Thrombosis
Activated protein C generation is greatly decreased in plasma from newborns compared to adults in the presence or absence of endothelium.
Thrombosis
Activated protein C in sepsis: emerging insights regarding its mechanism of action and clinical effectiveness.
Thrombosis
Activated protein C inhalation: a novel therapeutic strategy for acute lung injury.
Thrombosis
Activated protein C preserves functional islet mass after intraportal transplantation: a novel link between endothelial cell activation, thrombosis, inflammation, and islet cell death.
Thrombosis
Activated protein c resistance (APC) and inherited factor V (FV) mis-sense mutation in patients with venous and arterial thrombosis in a haematology clinic.
Thrombosis
Activated protein C resistance (factor V Leiden) associated with thrombosis in pregnancy.
Thrombosis
Activated protein C resistance (FV(Leiden)) and thrombosis: factor V mutations causing hypercoagulable states.
Thrombosis
Activated protein C resistance and acute ischaemic stroke: relation to stroke causation and age.
Thrombosis
Activated protein C resistance and deficiencies of antithrombin III, protein C or protein S and the risk of thromboembolic disease in users of oral contraceptives.
Thrombosis
Activated protein C resistance and false type 2 protein C deficiency detected after multiple shunt failures in a patient with hydrocephalus.
Thrombosis
Activated protein C resistance and the factor V Leiden mutation in children with thrombosis.
Thrombosis
Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation.
Thrombosis
Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families.
Thrombosis
Activated protein C resistance due to factor V Leiden, elevated coagulation factor VIII and postoperative deep vein thrombosis in late breast reconstruction with a free TRAM flap: a report of two cases.
Thrombosis
Activated protein C resistance in cord blood from healthy and complicated newborns.
Thrombosis
Activated protein C resistance, the factor V Leiden mutation, and a laboratory testing algorithm.
Thrombosis
Activated protein C resistance: a study among 60 thromboembolic patients in the Singapore population.
Thrombosis
Activated protein C resistance: What have we learned now that the dust has settled?
Thrombosis
Activated protein C: potential therapy for severe sepsis, thrombosis, and stroke.
Thrombosis
Allograft loss in renal transplant recipients with Fabry's disease and activated protein C resistance.
Thrombosis
An antifibrinolytic mechanism describing the prothrombotic effect associated with factor VLeiden.
Thrombosis
An assessment of the comparative utility of functional and molecular level analyses in the investigation of patients with thrombophilia.
Thrombosis
An underestimated combination of opposites resulting in enhanced thrombotic tendency.
Thrombosis
Anti-beta(2)-glycoprotein I antibody-mediated inhibition of activated protein C requires binding of beta(2)-glycoprotein I to phospholipids.
Thrombosis
Anti-Domain I ?2-Glycoprotein I Antibodies and Activated Protein C Resistance Predict Thrombosis in Antiphospholipid Syndrome: TAC(I)T Study.
Thrombosis
Antiphospholipid antibodies and thrombosis: association with acquired activated protein C resistance in venous thrombosis and with hyperhomocysteinemia in arterial thrombosis.
Thrombosis
Antithrombotic action of endogenous porcine protein C activated with a latent porcine thrombin preparation.
Thrombosis
Antithrombotic activity of protein S infused without activated protein C in a baboon thrombosis model.
Thrombosis
Antithrombotic and anticoagulant effects of wild type and Gla-domain mutated human activated protein C in rats.
Thrombosis
Antithrombotic effects of activated protein C and protein S in a rabbit model of microarterial thrombosis.
Thrombosis
Antithrombotic strategies targeting thrombin activities, thrombin receptors and thrombin generation.
Thrombosis
Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestogens.
Thrombosis
Association of increased C-Reactive Protein and hypocomplementemia with risk factors for thrombosis in women who have susceptibility for poor gestational outcome; importance of preconceptional counseling.
Thrombosis
Association of primary antiphospholipid syndrome with inherited activated protein C resistance.
Thrombosis
Association of resistance to activated protein with the presence of Leiden and Cambridge Factor V mutations in Mexican patients with primary thrombophilia.
Thrombosis
Bench-to-bedside review: thrombocytopenia-associated multiple organ failure--a newly appreciated syndrome in the critically ill.
Thrombosis
Beta2-glycoprotein I is necessary to inhibit protein C activity by monoclonal anticardiolipin antibodies.
Thrombosis
Blocking endothelial protein C receptor (EPCR) accelerates thrombus development in vivo.
Thrombosis
Brief report: variability of thrombosis among homozygous siblings with resistance to activated protein C due to an Arg-->Gln mutation in the gene for factor V.
Thrombosis
Central retinal vein thrombosis associated with resistance to activated protein C.
Thrombosis
Changes of resistance to activated protein C in the course of pregnancy and prevalence of factor V mutation.
Thrombosis
Clinical importance of prothrombotic risk factors in pediatric patients with malignancy--impact of central venous lines.
Thrombosis
Clinical sciences and orthopaedics: case report homozygous APC resistance in an elite athlete.
Thrombosis
Co-segregation of thrombosis with the factor V Q506 mutation in an extended family with resistance to activated protein C.
Thrombosis
Coagulation factor V gene mutation associated with activated protein C resistance leading to recurrent thrombosis, leg ulcers, and lymphedema: successful treatment with intermittent compression.
Thrombosis
Combination of activated protein C resistance and antibodies to phospholipids in the development of thrombosis.
Thrombosis
Combined thrombophilic risk factors and essential thrombocythemia in patient with recurrent venous thromboembolic episodes-thirty-three-year follow-up.
Thrombosis
Comparison of functional testing for resistance to activated protein C and molecular biological testing for factor V R506Q in 370 patients.
Thrombosis
Complexes between activated protein C and protein C inhibitor measured with a new method: comparison of performance with other markers of hypercoagulability in the diagnosis of deep vein thrombosis.
Thrombosis
Correlation between the potency of a beta2-glycoprotein I-dependent lupus anticoagulant and the level of resistance to activated protein C.
Thrombosis
Deficiencies of proteins C, S and antithrombin and activated protein C resistance--their involvement in the occurrence of Arterial thromboses.
Thrombosis
Detection of a common mutation in factor V gene responsible for resistance to activate protein C causing predisposition to thrombosis.
Thrombosis
Detection of marked reduction of sensitivity to activated protein C prior to the onset of thrombosis during puerperium as detected by endogenous thrombin potential-based assay.
Thrombosis
Determination of functional levels of protein C, an antithrombotic protein, using thrombin-thrombomodulin complex.
Thrombosis
Differential effects of high prothrombin levels on thrombin generation depending on the cause of the hyperprothrombinemia.
Thrombosis
Dural sinus thrombosis associated with activated protein C resistance: MR imaging findings and proband identification.
Thrombosis
Effect of exogenous estrogen on atherothrombotic vascular disease risk related to the presence or absence of the factor V Leiden mutation (resistance to activated protein C).
Thrombosis
Effect of protein C and activated protein C on coagulation and fibrinolysis in normal human subjects.
Thrombosis
Effects of switching from oral to transdermal or transvaginal contraception on markers of thrombosis.
Thrombosis
Elevated levels of prothrombin activation fragment 1 + 2 in plasma from patients with heterozygous Arg506 to Gln mutation in the factor V gene (APC-resistance) and/or inherited protein S deficiency.
Thrombosis
Endocardial Endothelial Dysfunction Progressively Disrupts Initially Anti then Pro-Thrombotic Pathways in Heart Failure Mice.
Thrombosis
Enhanced induction of heme oxygenase-1 suppresses thrombus formation and affects the protein C system in sepsis.
Thrombosis
Extensive venous and arterial thrombosis associated with an inhibitor to activated protein C.
Thrombosis
Factor V A4070G (His1299Arg) mutation in Turkish pediatric patients with thrombosis.
Thrombosis
Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa.
Thrombosis
Factor V Cambridge: a new mutation (Arg306-->Thr) associated with resistance to activated protein C.
Thrombosis
Factor V gene mutation causing inherited resistance to activated protein C as a basis for venous thromboembolism.
Thrombosis
Factor V I359T: a novel mutation associated with thrombosis and resistance to activated protein C.
Thrombosis
Factor V Leiden (Arg506Gln), a confounding genetic risk factor but not mandatory for the occurrence of venous thromboembolism in homozygotes and obligate heterozygotes for cystathionine beta-synthase deficiency.
Thrombosis
Factor V Leiden in absence of activated protein C resistance after orthotopic liver transplantation in a patient without thrombosis but with familial thrombophilia.
Thrombosis
Factor V Leiden is associated with repeated and recurrent unexplained fetal losses.
Thrombosis
Factor V Leiden mutation in Turkish patients with homozygous cystathionine beta-synthase deficiency.
Thrombosis
Factor V Leiden mutation: an unrecognized cause of hemiplegic cerebral palsy, neonatal stroke, and placental thrombosis.
Thrombosis
Factor V Leiden mutation: potential thrombogenic role in renal vein, dialysis graft and transplant vascular thrombosis.
Thrombosis
Factor V Leiden: is it the chief contributor to activated protein C resistance in Asian-Indian patients with deep vein thrombosis?
Thrombosis
Familial protein S deficiency presenting as deep vein thrombosis occurring during pregnancy.
Thrombosis
Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.
Thrombosis
Fatal pulmonary artery thrombosis in a patient with Behçet's disease, activated protein C resistance and hyperhomocystinemia.
Thrombosis
Female gender and resistance to activated protein C (FV:Q506) as potential risk factors for thrombosis after elective hip arthroplasty.
Thrombosis
Frequency of factor V Leiden mutation in Egyptian cases with myocardial infarction.
Thrombosis
FV HR2 haplotype as additional inherited risk factor for deep vein thrombosis in individuals with a high-risk profile.
Thrombosis
Gain in translation: heme oxygenase-1 induced by activated protein C promotes thrombus resolution.
Thrombosis
Generation of fibrinolytic activity by infusion of activated protein C into dogs.
Thrombosis
Genetic analysis of factor V Leiden in a family with history of thrombosis and venous leg ulcers.
Thrombosis
Genetic susceptibility to thrombosis and its relationship to physiological risk factors: the GAIT study. Genetic Analysis of Idiopathic Thrombophilia.
Thrombosis
Hemorrhagic and thrombotic disorders due to factor V deficiencies and abnormalities: an updated classification.
Thrombosis
Heparin-induced thrombocytopenia and fatal thrombosis in a patient with activated protein C resistance.
Thrombosis
High prevalence of a mutation in the factor V gene within the U.K. population: relationship to activated protein C resistance and familial thrombosis.
Thrombosis
Homozygous APC-resistance combined with inherited type I protein S deficiency in a young boy with severe thrombotic disease.
Thrombosis
Human protein C and activated protein C Components of the human anticoagulation system.
Thrombosis
Human recombinant activated protein C-coated stent for the prevention of restenosis in porcine coronary arteries.
Thrombosis
Hypercoagulable states in renal transplant candidates: impact of anticoagulation upon incidence of renal allograft thrombosis.
Thrombosis
Ile73Asn mutation in protein C introduces a new N-linked glycosylation site on the first EGF-domain of protein C and causes thrombosis.
Thrombosis
In Vitro Evaluation of Aptamer-Based Reversible Inhibition of Anticoagulant Activated Protein C as a Novel Supportive Hemostatic Approach.
Thrombosis
Incidence and clinical manifestations of activated protein C resistance and factor V Leiden in young patients with venous thromboembolic disease in Spain.
Thrombosis
Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation.
Thrombosis
Inherited resistance to activated protein C in a boy with multiple thromboses in early infancy.
Thrombosis
Inhibition of activated protein C by recombinant alpha 1-antitrypsin variants with substitution of arginine or leucine for methionine358.
Thrombosis
Inhibition of APC anticoagulant activity on oxidized phospholipid by anti-{beta}2-glycoprotein I monoclonal antibodies.
Thrombosis
Inhibition of platelet-dependent thrombus formation by human activated protein C in a primate model.
Thrombosis
Inhibition of transforming growth factor-? restores endothelial thromboresistance in vein grafts.
Thrombosis
Inhibitory effects of activated protein C and heparin on thrombotic arterial occlusion in rat mesenteric arteries.
Thrombosis
Internal jugular vein thrombosis caused by resistance to activated protein C as a complication of ovarian hyperstimulation after in-vitro fertilization.
Thrombosis
Intracardiac thrombus causing systemic embolism in a child with idiopathic ventricular tachycardia and heterozygous activated protein C resistance.
Thrombosis
Iron-deficiency anaemia in childhood: a risk factor for severe venous thrombosis?
Thrombosis
Ischemic colitis and acquired resistance to activated protein C in a woman using oral contraceptives.
Thrombosis
Ischemic colitis, pulmonary embolism, and right atrial thrombosis in a patient with inherited resistance to activated protein C.
Thrombosis
Kallikrein augments the anticoagulant function of the protein C system in thrombin generation.
Thrombosis
Laboratory assessment of Activated Protein C Resistance/Factor V-Leiden and performance characteristics of a new quantitative assay.
Thrombosis
Life threatening pulmonary embolus in a factor V Leiden carrier on oral contraceptives: a case report.
Thrombosis
Liver transplant acquired activated protein C resistance presenting with deep vein thrombosis 4 years after transplant.
Thrombosis
Location and extent of deep vein thrombosis in patients with and without FV:R 506Q mutation.
Thrombosis
Low prevalence of activated protein C resistance and coagulation factor V Arg506 to Gln mutation among Japanese patients with various forms of thrombosis, and normal individuals.
Thrombosis
Low prevalence of activated protein C resistance and coagulation factor V Arg506 to Gln mutation among Korean patients with deep vein thrombosis.
Thrombosis
Low prevalence of thrombophilic coagulation defects in patients with deep vein thrombosis of the upper limbs.
Thrombosis
Measuring thrombin generation based sensitivity to activated protein C using an automated coagulometer (ACL 9000).
Thrombosis
Mechanisms of enhanced thrombus formation in cerebral microvessels of mice expressing hemoglobin-S.
Thrombosis
Mesenteric arterial thrombosis due to activated protein C resistance (factor V Leiden)
Thrombosis
Mesenteric artery occlusion secondary to activated protein C resistance: a life-threatening combination.
Thrombosis
Modification of the ProC Global assay using dilution of patient plasma in factor V-depleted plasma as a screening assay for factor V Leiden mutation.
Thrombosis
Molecular characterization of a type I quantitative factor V deficiency in a thrombosis patient that is "pseudo homozygous" for activated protein C resistance.
Thrombosis
Molecular detection of a common mutation in coagulation factor V causing thrombosis via hereditary resistance to activated protein C.
Thrombosis
Molecular mechanisms of activated protein C resistance. Properties of factor V isolated from an individual with homozygosity for the Arg506 to Gln mutation in the factor V gene.
Thrombosis
Multi-chamber intracardiac thrombi associated with activated protein C resistance in a patient with dilated cardiomyopathy.
Thrombosis
Mycoplasma pneumonia and pulmonary embolism in a child due to acquired prothrombotic factors.
Thrombosis
N-Terminal domain linkage modulates the folding properties of protein S epidermal growth factor-like modules.
Thrombosis
New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis.
Thrombosis
No association between thrombosis and factor V gene polymorphisms in Chinese Han population.
Thrombosis
Non-catheter-related aortic thrombosis and resistance to activated protein C in a premature newborn.
Thrombosis
Paediatric thrombo-embolism: the influence of non-genetic factors and the role of activated protein C resistance and protein C deficiency.
Thrombosis
Pharmacological profile of recombinant, human activated protein C (LY203638) in a canine model of coronary artery thrombosis.
Thrombosis
Phenotypic homozygous activated protein C resistance associated with compound heterozygosity for Arg506Gln (factor V Leiden) and His1299Arg substitutions in factor V.
Thrombosis
Placental thrombosis and second trimester miscarriage in association with activated protein C resistance.
Thrombosis
Plasma levels of activated protein C-protein C inhibitor complex in patients with hypercoagulable states.
Thrombosis
Plasma protein S activity correlates with protein S genotype but is not sensitive to identify K196E mutant carriers.
Thrombosis
Plasma resistance to activated protein C: an important link between venous thromboembolism and combined oral contraceptives--a short review.
Thrombosis
Platelet protein S limits venous but not arterial thrombosis propensity by controlling coagulation in the thrombus.
Thrombosis
Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden.
Thrombosis
Poor response to activated protein C as a prominent risk predictor of advanced atherosclerosis and arterial disease.
Thrombosis
Postpartum seizures after epidural analgesia: a patient with a mutation of the factor V Leiden and prothrombin gene.
Thrombosis
Predictors of left ventricular thrombus formation in patients with anterior myocardial infarction: role of activated protein C resistance.
Thrombosis
Predictors of left ventricular thrombus formation in patients with dilated cardiomyopathy: role of activated protein C resistance.
Thrombosis
Predisposition to thrombosis by a factor V mutation causing hereditary resistance to activated protein C.
Thrombosis
Pregnancy-associated changes in the hemostatic system in wild-type and factor V Leiden mice.
Thrombosis
Prevalence of activated protein C resistance (Factor V Leiden) in Lagos, Nigeria.
Thrombosis
Prevalence of Factor V Genetic Variants Associated With Indian APCR Contributing to Thrombotic Risk.
Thrombosis
Prevalence of factor V Leiden (APCR) and other inherited thrombophilias in young patients with myocardial infarction and normal coronary arteries.
Thrombosis
Prevention of arterial reocclusion after thrombolysis with activated protein C. Comparison with heparin in a canine model of coronary artery thrombosis.
Thrombosis
Prevention of thrombosis following deep arterial injury in rats by bovine activated protein C requiring co-administration of bovine protein S.
Thrombosis
Primary Thrombophilia in México XI: Activated Protein C Resistance Phenotypes are Multifactorial.
Thrombosis
Progressive gangrene of the hand following extravasation of antibiotics associated with hereditary resistance to activated protein C.
Thrombosis
Prospective cross-sectional study of haemostatic factors in patients with and without coronary artery disease.
Thrombosis
Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation.
Thrombosis
Protein S as an in vivo cofactor to activated protein C in prevention of microarterial thrombosis in rabbits.
Thrombosis
Prothrombin gene mutation G20210A, homocysteine, antiphospholipid antibodies and other hypercoagulable states in ocular thrombosis.
Thrombosis
Pulmonary fibrosis is increased in mice carrying the factor V Leiden mutation following bleomycin injury.
Thrombosis
Recombinant human activated protein C, drotrecogin alfa (activated): a novel therapy for severe sepsis.
Thrombosis
Recombinant human activated protein C: current insights into its mechanism of action.
Thrombosis
Recurrent thrombosis after carotid endarterectomy secondary to activated protein C resistance and essential thrombocytosis: A case report.
Thrombosis
Recurrent thrombosis in a patient with pseudohomozygous activated protein C resistance and homozygosity for MTHFR gene polymorphism C677T.
Thrombosis
Recurrent thrombosis of the superior vena cava associated with activated protein C resistance: imaging findings.
Thrombosis
Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis.
Thrombosis
Relative antithrombotic and antihemostatic effects of protein C activator versus low-molecular-weight heparin in primates.
Thrombosis
Resistance to activated protein C (APC): mutation at Arg506 of coagulation factor V and vascular access thrombosis in haemodialysis patients.
Thrombosis
Resistance to activated protein C and FV leiden mutation in patients with a history of acute myocardial infarction or primary hypertension.
Thrombosis
Resistance to activated protein C and low levels of free protein S in Greek patients with inflammatory bowel disease.
Thrombosis
Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S.
Thrombosis
Resistance to activated protein C as risk factor for thrombosis: molecular mechanisms, laboratory investigation, and clinical management.
Thrombosis
Resistance to activated protein C due to a factor V gene mutation The most common inherited risk factor of thrombosis.
Thrombosis
Resistance to activated protein C due to factor V Leiden mutation: high prevalence in patients with post-thrombotic leg ulcers.
Thrombosis
Resistance to activated protein C in thalassaemic patients: an underlying cause of thrombosis.
Thrombosis
Resistance to activated protein C in unselected patients with arterial and venous thrombosis.
Thrombosis
Resistance to activated protein C, associated with oral contraceptives use; effect of formulations, duration of assumption, and doses of oestro-progestins.
Thrombosis
Resistance to activated protein C--frequent etiologic factor for venous thrombosis.
Thrombosis
Resistance to activated protein C: arterial thrombosis associated with autoimmune features.
Thrombosis
Response to activated protein C during normal menstrual cycle and ovarian stimulation.
Thrombosis
Risk of Venous Thrombosis in Carriers of a Common Mutation in the Homocysteine Regulatory Enzyme Methylenetetrahydrofolate Reductase.
Thrombosis
Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis.
Thrombosis
Role of protein S and tissue factor pathway inhibitor in the development of activated protein C resistance early in pregnancy in women with a history of preeclampsia.
Thrombosis
Role of the factor V Leiden mutation in septic peritonitis assessed in factor V Leiden transgenic mice.
Thrombosis
Role of the protein C pathway in the extraintestinal thrombosis associated with murine colitis.
Thrombosis
Search for mutations in the genes for coagulation factors V and VIII with a possible predisposition to activated protein C resistance.
Thrombosis
Sensitivity to activated protein C in patients with deep vein thrombosis during early puerperium period.
Thrombosis
Simple and rapid detection of factor V Leiden by allele-specific PCR amplification.
Thrombosis
Soluble Endothelial Protein C Receptor and Coagulation Parameters as Prognostic Factors in Non-Small Cell Lung Cancer.
Thrombosis
Spontaneous central vein thrombosis in a patient with activated protein C resistance and dengue infection: An association or causation?
Thrombosis
Successful management of a pregnant woman with heterozygous protein C deficiency using activated protein C concentrate.
Thrombosis
Successful treatment of deep vein thrombosis in homozygous protein C deficiency with activated protein C.
Thrombosis
Superficial vein thrombosis, thrombin generation and activated protein C resistance as predictors of thromboembolic events in lupus and antiphospholipid patients. A prospective cohort study.
Thrombosis
Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden.
Thrombosis
The 1691 G-->A mutation in the factor V gene: relationship to activated protein C (APC) resistance and thrombosis in 65 patients.
Thrombosis
The antithrombotic effect of human activated protein C on He-Ne laser-induced thrombosis in rat mesenteric microvessels.
Thrombosis
The carbohydrate moiety of factor V modulates inactivation by activated protein C.
Thrombosis
The cofactor role of protein S in the acceleration of whole blood clot lysis by activated protein C in vitro.
Thrombosis
The factor V Leiden (R506Q) mutation and risk of thrombosis in renal transplant recipients.
Thrombosis
The factor V Leiden mutation which predisposes to thrombosis is not common in patients with antiphospholipid syndrome.
Thrombosis
The frequency of factor V Leiden and concomitance of factor V Leiden with prothrombin G20210A mutation and methylene tetrahydrofolate reductase C677T gene mutation in healthy population of Denizli, Aegean region of Turkey.
Thrombosis
The incidence of activated protein C resistance among patients with deep vein thrombosis and healthy subjects in Osaka.
Thrombosis
The response to activated protein C after cardiopulmonary bypass: impact of factor V leiden.
Thrombosis
The thrombin mutant W215A/E217A shows safe and potent anticoagulant and antithrombotic effects in vivo.
Thrombosis
Three novel variants in the coagulation factor V gene associated with deep venous thrombosis in Chilean patients with Amerindian ethnic background.
Thrombosis
Urgent care in gynaecology: resuscitation and management of sepsis and acute blood loss.
Thrombosis
Utilization of testing for activated protein C resistance in a reference laboratory.
Thrombosis
Vascular graft thrombosis secondary to activated protein C resistance: a case report and literature review.
Thrombosis
Venous thromboembolism at a young age in a brother and sister with coinheritance of homozygous 20210A/A prothrombin mutation and heterozygous 1691G/A factor V Leiden mutation.
Thrombosis
Venous thromboembolism, factor V Leiden, and methylenetetrahydrofolate reductase in a sickle cell anemia patient.
Thrombosis
Venous thrombosis in a replanted finger with underlying factor V Leiden mutation.
Thrombosis
What is the impact of resistance to activated protein C (Leiden mutation to factor V) in inflammatory bowel disease?
Thrombosis
[A new hereditary cause of portal vein thrombosis: the abnormal resistance to activated protein C by the Arg 506-->Gln mutation of the gene of factor V]
Thrombosis
[A newly discovered blood coagulation disorder. Resistance to activated protein C as a cause of thrombosis]
Thrombosis
[Activated protein C resistance, Leiden mutation, anticoagulant proteins and fibrinogen levels in patients with deep venous thrombosis]
Thrombosis
[Antiphospholipid thrombosis syndrome and acquired activated protein C resistance]
Thrombosis
[APC resistance. Resistance against activated Protein C, a frequent cause of congenital thrombosis susceptibility]
Thrombosis
[Application of recombinant human activated protein C with blood product administration and deep vein thrombosis in severe sepsis]
Thrombosis
[Brain stem ischemia in a boy with resistance to C activated protein and elevated lipoprotein A]
Thrombosis
[Clinical usefulness of global assays of the anticoagulant pathway of protein C]
Thrombosis
[Congenital deficiencies of natural anticoagulant systems responsible for recurrent thromboembolism]
Thrombosis
[Effects of low doses of activated protein C in experimental arterial thrombosis in rats]
Thrombosis
[Mesenteric and splenic vein thrombosis in a female patient with essential thrombocytosis and activated protein C resistance]
Thrombosis
[Point mutation G-->A nucleotide 1691 factor V gene as a cause of developing thrombotic complications in a family with plasma resistance to activated protein C]
Thrombosis
[Prevalence of genetic prothrombotic factors (factor V Leiden and II20210 prothrombin mutation) in glomerular nephropathies with or without thrombosis]
Thrombosis
[Resistance to activated protein C and portal vein thrombosis: two new cases and review of the literature]
Thrombosis
[Resistance to activated protein C by mutation of the factor V gene. Most frequent blood coagulation defect in venous thromboses]
Thrombosis
[Resistance to activated protein C disclosed by postphlebitic disease. Two cases]
Thrombosis
[Resistance to activated protein C in venous thromboembolic complications. Incidence and clinical manifestations]
Thrombosis
[Resistance to activated protein C. A common genetic risk factor in venous thrombosis]
Thrombosis
[Role of the hemostasis laboratory in the etiologic approach to deep vein thrombosis]
Thrombosis
[Study of activated protein C resistance(APC-R) and FV Leiden in healthy blood donors and patients with thrombosis]
Thrombotic Microangiopathies
Microvascular thrombosis in pediatric multiple organ failure: Is it a therapeutic target?
Thyroid Cancer, Papillary
Receptor for activated protein C kinase 1 (RACK1) is overexpressed in papillary thyroid carcinoma.
Tuberculosis
A thrombomodulin mutation that impairs activated protein C generation results in uncontrolled lung inflammation during murine tuberculosis.
Tuberculosis
The endothelial protein C receptor and activated protein C play a limited role in host defense during experimental tuberculosis.
Urinary Tract Infections
Recombinant human activated protein C treatment of septic shock syndrome in a patient at 18th week of gestation: a case report.
Uveitis, Posterior
Haplotypes of the endothelial protein C receptor gene and Behçet's disease.
Vascular Diseases
Hypercoagulable states in renal transplant candidates: impact of anticoagulation upon incidence of renal allograft thrombosis.
Vascular System Injuries
Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats.
Vascular System Injuries
Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production.
Vascular System Injuries
Recombinant human soluble thrombomodulin reduces endotoxin-induced pulmonary vascular injury via protein C activation in rats.
Vasospasm, Intracranial
Inhibitory effect of activated protein C on cerebral vasospasm after subarachnoid hemorrhage in the rabbit.
Venous Insufficiency
[Resistance to activated protein C disclosed by postphlebitic disease. Two cases]
Venous Thromboembolism
?2-Macroglobulin Is a Significant In Vivo Inhibitor of Activated Protein C and Low APC:?2M Levels Are Associated with Venous Thromboembolism.
Venous Thromboembolism
A case control study of deep venous thrombosis in relation to factor V G1691A (Leiden) and A4070G (HR2 Haplotype) polymorphisms.
Venous Thromboembolism
A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype.
Venous Thromboembolism
A FV multiallelic marker detects genetic components of APC resistance contributing to venous thromboembolism in FV Leiden carriers.
Venous Thromboembolism
A monoclonal antibody to human protein S used as the capture antibody for measuring total protein S by enzyme immunoassay.
Venous Thromboembolism
A Rapid Activated Protein C Sensitivity Test as a Diagnostic Marker for a Suspected Venous Thromboembolism in Pregnancy and Puerperium.
Venous Thromboembolism
Acquired activated protein C resistance associated with IgG antibodies against beta2-glycoprotein I and prothrombin as a strong risk factor for venous thromboembolism.
Venous Thromboembolism
Acquired activated protein C resistance in postmenopausal women is dependent on factor VIII:c levels.
Venous Thromboembolism
Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism.
Venous Thromboembolism
Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism.
Venous Thromboembolism
Activated protein C plasma levels in the fasting and postprandial states among patients with previous unprovoked venous thromboembolism.
Venous Thromboembolism
Activated protein C resistance -- in the absence of factor V Leiden -- and pregnancy.
Venous Thromboembolism
Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism.
Venous Thromboembolism
Activated protein C resistance assay detects thrombotic risk factors other than factor V Leiden.
Venous Thromboembolism
Activated protein C resistance in patients following venous thromboembolism receiving rivaroxaban versus vitamin K antagonists: assessment using Russell viper venom time-based assay.
Venous Thromboembolism
Activated protein C resistance, factor V Leiden and peripheral vascular disease.
Venous Thromboembolism
Activated protein C resistance: from phenotype to genotype and clinical practice.
Venous Thromboembolism
Activated protein C resistance: the most common risk factor for venous thromboembolism.
Venous Thromboembolism
Age as a risk factor for myocardial infarction in Leiden mutation carriers.
Venous Thromboembolism
An underestimated combination of opposites resulting in enhanced thrombotic tendency.
Venous Thromboembolism
Anti-protein C antibodies are associated with resistance to endogenous protein C activation and a severe thrombotic phenotype in antiphospholipid syndrome.
Venous Thromboembolism
APC resistance in neonates and infants: adjustment of the APTT-based method.
Venous Thromboembolism
Arterial and venous thromboembolism with fatal outcome and resistance to activated protein C.
Venous Thromboembolism
Assessment of activated protein C resistance using a new and rapid venom-based test: STA Staclot APC-R.
Venous Thromboembolism
Association between increased tumor necrosis factor alpha levels and acquired activated protein C resistance in patients with metastatic colorectal cancer.
Venous Thromboembolism
Association of the Thrombomodulin Gene c.1418C>T Polymorphism With Thrombomodulin Levels and With Venous Thrombosis Risk.
Venous Thromboembolism
Cleaved protein S (PS), total PS, free PS, and activated protein C cofactor activity as risk factors for venous thromboembolism.
Venous Thromboembolism
Combined heterozygous plasminogen deficiency and factor V Leiden defect in the same kindred.
Venous Thromboembolism
Combined thrombophilic risk factors and essential thrombocythemia in patient with recurrent venous thromboembolic episodes-thirty-three-year follow-up.
Venous Thromboembolism
Development and application of an automated chromogenic thrombin generation assay that is sensitive to defects in the protein C pathway.
Venous Thromboembolism
Diminished response to activated protein C is not correlated with severity of peripheral arterial occlusive disease.
Venous Thromboembolism
DOAC-Remove abolishes the effect of direct oral anticoagulants on activated protein C resistance testing in real-life venous thromboembolism patients.
Venous Thromboembolism
Effects on hemostatic variables of desogestrel- and gestodene-containing oral contraceptives in comparison with levonorgestrel-containing oral contraceptives: a review.
Venous Thromboembolism
Exogenous hormones, the risk of venous thromboembolism, and activated protein C resistance.
Venous Thromboembolism
Factor V gene mutation causing inherited resistance to activated protein C as a basis for venous thromboembolism.
Venous Thromboembolism
Factor V Leiden and pulmonary embolism in a young woman taking an oral contraceptive.
Venous Thromboembolism
Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective.
Venous Thromboembolism
Factor V variants, activated protein C resistance and venous thromboembolism.
Venous Thromboembolism
Factor V:Q506 mutation-resistance to activated protein C (APC): clinical implications with respect to family screening.
Venous Thromboembolism
FV-ARG-506-GLN-Mutation-associated resistance to activated protein C in ischemic stroke.
Venous Thromboembolism
Heritability of plasma concentrations of activated protein C in a Spanish population.
Venous Thromboembolism
Incidence of factor V Leiden in patients with acute myocardial infarction.
Venous Thromboembolism
Influence of factor VIII/von Willebrand complex on the activated protein C-resistance phenotype and on the risk for venous thromboembolism in heterozygous carriers of the factor V Leiden mutation.
Venous Thromboembolism
Inherited thrombophilia: resistance to activated protein C as a pathogenic factor of venous thromboembolism.
Venous Thromboembolism
Intraindividual consistency of the activated protein C resistance phenotype.
Venous Thromboembolism
Is APC resistance a risk factor for venous thromboembolism in patients over 70 years?
Venous Thromboembolism
Low level of circulating activated protein C is a risk factor for venous thromboembolism.
Venous Thromboembolism
Markers of activated coagulation in patients with factor V Leiden and/or G20210A prothrombin gene mutation.
Venous Thromboembolism
Normalized activated protein C ratio itself not associated with increased risk of venous thromboembolism.
Venous Thromboembolism
Oral contraceptive use in women with poor anticoagulant response to activated protein C but not carrying the factor V Leiden mutation increases the risk of venous thrombosis.
Venous Thromboembolism
Physiological anticoagulation. Resistance to activated protein C and venous thromboembolism.
Venous Thromboembolism
Plasma levels of activated protein C in healthy subjects and patients with previous venous thromboembolism: relationships with plasma homocysteine levels.
Venous Thromboembolism
Plasma resistance to activated protein C: an important link between venous thromboembolism and combined oral contraceptives--a short review.
Venous Thromboembolism
Postmenopausal hormone replacement therapy and cardiovascular disease: the value of transdermal estradiol and micronized progesterone.
Venous Thromboembolism
Prevalence of APC resistance and its relationship to arterial and venous thromboembolism in a general population sample of elderly Swedish men: The Study of Men Born in 1913.
Venous Thromboembolism
Prevalence of phenotypic activated protein C resistance (APCR) in venous thromboembolic patients.
Venous Thromboembolism
Prevalence of the Factor V E666D Mutation and Its Correlation With Activated Protein C Resistance in the Chinese Population.
Venous Thromboembolism
Prevalence of the factor V-Leiden mutation in four distinct American ethnic populations.
Venous Thromboembolism
Prevalence of the factor VLeiden mutation among autopsy patients with pulmonary thromboembolic disease using an improved method for factor VLeiden detection.
Venous Thromboembolism
Probability of recurrence of thrombosis in patients with and without factor V Leiden.
Venous Thromboembolism
Resistance to activated protein C (APCR) in children with acute lymphoblastic leukaemia--the need for a prospective multicentre study.
Venous Thromboembolism
Resistance to activated protein C (APCR) in children with venous or arterial thromboembolism.
Venous Thromboembolism
Resistance to activated protein C and ischemic arterial disease in a young man.
Venous Thromboembolism
Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives.
Venous Thromboembolism
Resistance to activated protein C as pathogenic factor of venous thromboembolism.
Venous Thromboembolism
Resistance to activated protein C caused by factor V Leiden mutation and orthotopic liver transplantation.
Venous Thromboembolism
Resistance to activated protein C, highly prevalent amongst users of oral contraceptives with venous thromboembolism.
Venous Thromboembolism
Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency, or activated protein C resistance: a multicenter collaborative family study.
Venous Thromboembolism
Role of activated protein C resistance in left atrial thrombogenesis in patients with mitral stenosis.
Venous Thromboembolism
Soluble Endothelial Protein C Receptor and Coagulation Parameters as Prognostic Factors in Non-Small Cell Lung Cancer.
Venous Thromboembolism
The association between extrinsic activated protein C resistance and venous thromboembolism in women.
Venous Thromboembolism
The clinical application of a new specific functional assay to detect the factor V(Leiden) mutation associated with activated protein C resistance.
Venous Thromboembolism
The factor V R2 allele: risk of venous thromboembolism, factor V levels and resistance to activated protein C.
Venous Thromboembolism
The risk of recurrent venous thromboembolism in patients with an Arg506-->Gln mutation in the gene for factor V (factor V Leiden).
Venous Thromboembolism
The VITA Project: heritability of resistance to activated protein C. Vincenza Thrombophilia and Arteriosclerosis.
Venous Thromboembolism
The VITA project: phenotypic resistance to activated protein C and FV Leiden mutation in the general population. Vicenza Thrombophilia and Atherosclerosis.
Venous Thromboembolism
Thrombin generation and activated protein C resistance in the absence of factor V Leiden correlates with the risk of recurrent venous thromboembolism in women aged 18-65 years.
Venous Thromboembolism
Use of calibrated automated thrombinography +/- thrombomodulin to recognise the prothrombotic phenotype.
Venous Thromboembolism
Venous thromboembolism during pregnancy is not associated with persistent elevated activated protein C (APC) sensitivity ratio based on the endogenous thrombin potential.
Venous Thromboembolism
Venous thromboembolism in carriers of the Factor V Leiden mutation and in patients without known thrombophilic risk factor; prediction of recurrence and APC-PCI complex concentration and/or soluble thrombomodulin antigen and activity.
Venous Thromboembolism
[Activated protein C resistance--a recently discovered hereditary thrombophilia]
Venous Thromboembolism
[Analysis of activated protein C resistance, factor V coagulation activity and gene polymorphisms in patients with venous thromboembolism]
Venous Thromboembolism
[Brain stem ischemia in a boy with resistance to C activated protein and elevated lipoprotein A]
Venous Thromboembolism
[Diagnosis of thrombophilia based on coagulation and genetic studies]
Venous Thromboembolism
[The significance of APC resistance (activated protein C) for clinical practice]
Venous Thrombosis
A case of deep vein thrombosis in idiopathic nephrotic syndrome with resistance to activated protein C.
Venous Thrombosis
A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis.
Venous Thrombosis
A single genetic origin for a common Caucasian risk factor for venous thrombosis.
Venous Thrombosis
Absence of mutations at the activated protein C cleavage sites of factor VIII in 125 patients with venous thrombosis.
Venous Thrombosis
Acquired activated protein C resistance associated with anti-protein S antibody as a strong risk factor for DVT in non-SLE patients.
Venous Thrombosis
Acquired APC resistance in neurosurgical patients may not be a risk factor for postoperative deep vein thrombosis.
Venous Thrombosis
Activated protein C (APC) resistance in indian juvenile deep vein thrombosis (DVT)
Venous Thrombosis
Activated protein C levels in Behçet's disease and risk of venous thrombosis.
Venous Thrombosis
Activated protein C resistance (factor V Leiden) associated with thrombosis in pregnancy.
Venous Thrombosis
Activated protein C resistance acquired through liver transplantation and associated with recurrent venous thrombosis.
Venous Thrombosis
Activated protein C resistance and anticardiolipin antibodies in patients with venous leg ulcers.
Venous Thrombosis
Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation.
Venous Thrombosis
Activated protein C resistance as a "new" cause of deep venous thrombosis in aviators.
Venous Thrombosis
Activated protein C resistance caused by a common factor V mutation has a single origin.
Venous Thrombosis
Activated protein C resistance caused by factor V gene mutation: common coagulation defect in chronic venous leg ulcers?
Venous Thrombosis
Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women.
Venous Thrombosis
Activated protein C resistance due to a common factor V gene mutation is a major risk factor for venous thrombosis.
Venous Thrombosis
Activated protein C resistance due to factor V Leiden, elevated coagulation factor VIII and postoperative deep vein thrombosis in late breast reconstruction with a free TRAM flap: a report of two cases.
Venous Thrombosis
Activated protein C resistance--low incidence in glaucomatous optic disc haemorrhage and central retinal vein occlusion.
Venous Thrombosis
Activated protein C resistance: a comparison between two clotting assays and their relationship to the presence of the factor V Leiden mutation.
Venous Thrombosis
Activated protein C resistance: What have we learned now that the dust has settled?
Venous Thrombosis
An assessment of the comparative utility of functional and molecular level analyses in the investigation of patients with thrombophilia.
Venous Thrombosis
Anti-protein C antibodies and acquired protein C resistance in SLE: novel markers for thromboembolic events and disease activity?
Venous Thrombosis
Antiphospholipid antibodies and thrombosis: association with acquired activated protein C resistance in venous thrombosis and with hyperhomocysteinemia in arterial thrombosis.
Venous Thrombosis
Antiphospholipid syndrome and factor V Leiden. Three cases with recurrent venous thrombosis.
Venous Thrombosis
Apparent different thrombotic tendency in patients with factor V Leiden and protein C deficiency due to selection of patients.
Venous Thrombosis
Arg506Gln mutation of the coagulation factor V gene not detected in Japanese pulmonary thromboembolism.
Venous Thrombosis
Assessment of acquired activated protein C resistance with the FibWave and comparison with the ETP-based APC resistance.
Venous Thrombosis
Association of increased fibrinogen concentration with impaired activation of anticoagulant protein C.
Venous Thrombosis
Association of resistance to activated protein C and dural arteriovenous fistulas.
Venous Thrombosis
Atypical presentation of livedo racemosa in a factor V Leiden heterozygous positive patient with Pseudomonas aeruginosa urosepsis.
Venous Thrombosis
Bilateral renal venous thrombosis in a neonate associated with resistance to activated protein C.
Venous Thrombosis
Central retinal vein thrombosis associated with resistance to activated protein C.
Venous Thrombosis
Cerebral venous thrombosis. Role of activated protein C resistance and factor V gene mutation.
Venous Thrombosis
Changes in the plasma levels of protein C system parameters in pregnancy.
Venous Thrombosis
Characterization of an immunologic polymorphism (D79H) in the heavy chain of factor V.
Venous Thrombosis
Circulating activated protein C in subjects with heterozygous Gln506-factor V.
Venous Thrombosis
Clinical evaluation of a functional prothrombin time-based assay for identification of factor V Leiden carriers in a group of Italian patients with venous thrombosis.
Venous Thrombosis
Coagulation factor V G allele and HR2 haplotype: factor V activity, activated protein C resistance and risk of venous thrombosis.
Venous Thrombosis
Coagulation factor V gene mutation associated with activated protein C resistance leading to recurrent thrombosis, leg ulcers, and lymphedema: successful treatment with intermittent compression.
Venous Thrombosis
Coagulation factor V Leiden mutation in sudden fatal pulmonary embolism and in a general northern European population sample.
Venous Thrombosis
Combined genetic defect (homogeneity for factor V Leiden and heterogeneity for prothrombin G20210A allele), in a young patient, with recurrent deep vein thrombosis and serious postphlebitic syndrome--a case report.
Venous Thrombosis
Combined thrombophilic risk factors and essential thrombocythemia in patient with recurrent venous thromboembolic episodes-thirty-three-year follow-up.
Venous Thrombosis
Comparative analysis of "APTT vs RVVT" based activated protein C resistance assay in the diagnosis of Factor V Leiden mutation.
Venous Thrombosis
Comparison of three activated protein C resistance tests in the risk assessment of venous thrombosis in non-carriers of the factor V Leiden mutation.
Venous Thrombosis
Complexes between activated protein C and protein C inhibitor measured with a new method: comparison of performance with other markers of hypercoagulability in the diagnosis of deep vein thrombosis.
Venous Thrombosis
Decreased plasma sensitivity to activated protein C by oral contraceptives is associated with decreases in plasma glucosylceramide.
Venous Thrombosis
Deep venous thrombosis in a preterm newborn of a mother with activated protein C resistance.
Venous Thrombosis
Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial.
Venous Thrombosis
Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women.
Venous Thrombosis
Evaluation of the roles of the Leiden V mutation and ACE I/D polymorphism in subtypes of ischaemic stroke.
Venous Thrombosis
Expression of the normal factor V allele modulates the APC resistance phenotype in heterozygous carriers of the factor V Leiden mutation.
Venous Thrombosis
Factor V Cambridge: a new mutation (Arg306-->Thr) associated with resistance to activated protein C.
Venous Thrombosis
Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women.
Venous Thrombosis
Factor V Leiden and acquired activated protein C resistance among 1000 women with recurrent miscarriage.
Venous Thrombosis
Factor V Leiden and its relation to left ventricular thrombus in acute myocardial infarction.
Venous Thrombosis
Factor V Leiden mutation and its relation to left atrial thrombus in chronic nonrheumatic atrial fibrillation.
Venous Thrombosis
Factor V Leiden mutation in a case with ischemic stroke: which relationship? A case report.
Venous Thrombosis
Factor V Leiden mutation is associated with ocular involvement in Behçet disease.
Venous Thrombosis
Factor V Leiden: is it the chief contributor to activated protein C resistance in Asian-Indian patients with deep vein thrombosis?
Venous Thrombosis
Factor V mutations in Iranian patients with activated protein C resistance and venous thrombosis.
Venous Thrombosis
Factor V Q506 (resistance to activated protein C) and prognosis after acute coronary syndrome.
Venous Thrombosis
Factor V R506Q gene mutation analysis by PCR-RFLP: optimization, comparison with functional testing for resistance to activated protein C, and establishment of cell line controls.
Venous Thrombosis
Factor V R506Q mutation (activated protein C resistance) is an additional risk factor for early renal graft loss associated with acute vascular rejection.
Venous Thrombosis
Factor V:Q506 mutation and anticardiolipin antibodies in systemic lupus erythematosus.
Venous Thrombosis
Female gender and resistance to activated protein C (FV:Q506) as potential risk factors for thrombosis after elective hip arthroplasty.
Venous Thrombosis
Fibrinogen ?' increases the sensitivity to activated protein C in normal and factor V Leiden plasma.
Venous Thrombosis
Frequency of a defective response to activated protein C in patients with a history of venous thrombosis.
Venous Thrombosis
Heterozygosity for the Leiden mutation of the factor V gene, a common pathoetiology for osteonecrosis of the jaw, with thrombophilia augmented by exogenous estrogens.
Venous Thrombosis
High prevalence of a mutation in the factor V gene within the U.K. population: relationship to activated protein C resistance and familial thrombosis.
Venous Thrombosis
High prevalence of activated protein C resistance and factor V Leiden mutation in an Arab population and patients with venous thrombosis in Kuwait.
Venous Thrombosis
High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance)
Venous Thrombosis
Homozygosity for factor V Leiden leads to enhanced thrombosis and atherosclerosis in mice.
Venous Thrombosis
Homozygous hereditary resistance to activated protein C presenting as cerebral venous thrombosis.
Venous Thrombosis
Hypercoagulability in various autoimmune diseases: no association with factor V Leiden mutation.
Venous Thrombosis
Hypercoagulable states in renal transplant candidates: impact of anticoagulation upon incidence of renal allograft thrombosis.
Venous Thrombosis
Identification and functional characterization of a novel F5 mutation (Ala512Val, FVB onn ) associated with activated protein C resistance.
Venous Thrombosis
Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C.
Venous Thrombosis
Impaired APC cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations.
Venous Thrombosis
Incidence and clinical manifestations of activated protein C resistance and factor V Leiden in young patients with venous thromboembolic disease in Spain.
Venous Thrombosis
Increased hemostasis potential persists in women with previous thromboembolism with or without APC resistance.
Venous Thrombosis
Increased incidence of venous thrombosis in patients with shortened activated partial thromboplastin times and low ratios for activated protein C resistance.
Venous Thrombosis
Increased rate of factor V Leiden mutation in patients with cerebral venous thrombosis.
Venous Thrombosis
Increased resistance to activated protein C after short-term oral hormone replacement therapy in healthy post-menopausal women.
Venous Thrombosis
Increased risk of venous thrombosis by AB alleles of the ABO blood group and Factor V Leiden in a Brazilian population.
Venous Thrombosis
Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation.
Venous Thrombosis
Inherited resistance to activated protein C caused by presence of the FV:Q506 allele as a basis of venous thrombosis.
Venous Thrombosis
Inherited resistance to activated protein C, a major basis of venous thrombosis, is caused by deficient anticoagulant cofactor function of factor V.
Venous Thrombosis
Inherited resistance to activated protein C, a major cause of venous thrombosis, is due to a mutation in the factor V gene.
Venous Thrombosis
Iron-deficiency anaemia in childhood: a risk factor for severe venous thrombosis?
Venous Thrombosis
Ischemic stroke in the elderly. Role of the common factor V mutation causing resistance to activated protein C.
Venous Thrombosis
Less effect of intranasal than oral hormone therapy on factors associated with venous thrombosis risk in healthy postmenopausal women.
Venous Thrombosis
Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis.
Venous Thrombosis
Liver transplant acquired activated protein C resistance presenting with deep vein thrombosis 4 years after transplant.
Venous Thrombosis
Low prevalence of activated protein C resistance and coagulation factor V Arg506 to Gln mutation among Korean patients with deep vein thrombosis.
Venous Thrombosis
Low prevalence of factor V:Q506 in 41 patients with isolated pulmonary embolism.
Venous Thrombosis
Modified APC-resistance test: variable ratios with respect to source of factor V-deficient plasma.
Venous Thrombosis
Molecular detection of a common mutation in coagulation factor V causing thrombosis via hereditary resistance to activated protein C.
Venous Thrombosis
Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men.
Venous Thrombosis
Mutations at the activated protein C cleavage sites Arg336 and Arg562 of factor VIII in Thai patients with venous thrombosis.
Venous Thrombosis
New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis.
Venous Thrombosis
No interaction between factor V Leiden and hyperhomocysteinemia or MTHFR 677TT genotype in venous thrombosis. Results of a meta-analysis of published studies and a large case-only study.
Venous Thrombosis
Oral contraceptive use in women with poor anticoagulant response to activated protein C but not carrying the factor V Leiden mutation increases the risk of venous thrombosis.
Venous Thrombosis
Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives.
Venous Thrombosis
Patients with persistent APC-resistance without factor V Leiden mutation.
Venous Thrombosis
Phenotypic APC resistance in carriers of the A20210 prothrombin mutation is associated with an increased risk of venous thrombosis.
Venous Thrombosis
Plasma levels of activated protein C-protein C inhibitor complex in patients with hypercoagulable states.
Venous Thrombosis
Plasma protein S activity correlates with protein S genotype but is not sensitive to identify K196E mutant carriers.
Venous Thrombosis
Population study of the G1691A mutation (R506Q, FV Leiden) in the human factor V gene that is associated with resistance to activated protein C.
Venous Thrombosis
Postpartum cerebral venous thrombosis, congenital protein C deficiency, and activated protein C resistance due to heterozygous factor V Leiden mutation.
Venous Thrombosis
Prevalence of common thrombophilia markers and risk factors in Indian patients with primary venous thrombosis.
Venous Thrombosis
Prevalence of factor V gene mutation amongst myocardial infarction patients and healthy controls is higher in Sweden than in other countries.
Venous Thrombosis
Protein C antigen levels in major abdominal surgery: relationships to deep vein thrombosis, malignancy and treatment with stanozolol.
Venous Thrombosis
Protein S levels modulate the activated protein C resistance phenotype induced by elevated prothrombin levels.
Venous Thrombosis
Prothrombotic Factors Have Significant Association with Arterial and Venous Strokes in Indian Tamilians.
Venous Thrombosis
Pseudohomozygosity for activated protein C resistance is a risk factor for venous thrombosis.
Venous Thrombosis
Pulmonary embolism and deep venous thrombosis during pregnancy or oral contraceptive use: prevalence of factor V Leiden.
Venous Thrombosis
Rapid detection of factor V Leiden (FVQ506) by non-radioactive single strand conformation polymorphism (SSCP).
Venous Thrombosis
Rapid multiplex analysis for the factor V Leiden and prothrombin G20210A mutations associated with hereditary thrombophilia.
Venous Thrombosis
Recurrent deep-vein thrombosis based on homozygous factor V Leiden mutation acquired after liver transplantation.
Venous Thrombosis
Recurrent venous thrombosis despite correction of activated protein C resistance following orthotopic liver transplantation.
Venous Thrombosis
Reduced response to activated protein C is associated with increased risk for cerebrovascular disease.
Venous Thrombosis
Regulation of thrombin formation by activated protein C: effect of the factor V Leiden mutation.
Venous Thrombosis
Resistance to activated protein C activity of an anti-beta 2-glycoprotein I antibody in the presence of beta 2-glycoprotein I.
Venous Thrombosis
Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis.
Venous Thrombosis
Resistance to activated protein C as an underlying cause of recurrent venous thrombosis during relapsing nephrotic syndrome.
Venous Thrombosis
Resistance to activated protein C caused by the factor VR506Q mutation is a common risk factor for venous thrombosis.
Venous Thrombosis
Resistance to activated protein C caused by the R506Q mutation in the gene for factor V is a common risk factor for venous thrombosis.
Venous Thrombosis
Resistance to activated protein C due to factor V R506Q mutation as a cause of venous thrombosis.
Venous Thrombosis
Resistance to activated protein C in healthy women taking oral contraceptives.
Venous Thrombosis
Resistance to activated protein C in unselected patients with arterial and venous thrombosis.
Venous Thrombosis
Resistance to activated protein C is a risk factor for pregnancy-related venous thrombosis in the absence of the F5 rs6025 (factor V Leiden) polymorphism.
Venous Thrombosis
Resistance to activated protein C, associated with oral contraceptives use; effect of formulations, duration of assumption, and doses of oestro-progestins.
Venous Thrombosis
Resistance to activated protein C, the FV:Q506 allele, and venous thrombosis.
Venous Thrombosis
Resistance to activated protein C: a common anticoagulant deficiency in patients with venous leg ulceration.
Venous Thrombosis
Resistance to activated protein C: a common inherited cause of venous thrombosis.
Venous Thrombosis
Resistance to activated protein C: a major cause of inherited thrombophilia.
Venous Thrombosis
Resistance to activated protein C: role in venous and arterial thrombosis.
Venous Thrombosis
Risk factor profiles in patients with different clinical manifestations of venous thromboembolism: a focus on the factor V Leiden mutation.
Venous Thrombosis
Screening for the FV:Q506 mutation--evaluation of thirteen plasma-based methods for their diagnostic efficacy in comparison with DNA analysis.
Venous Thrombosis
Sensitivity to activated protein C during the menstrual cycle in women with and without factor VLeiden.
Venous Thrombosis
Sensitivity to activated protein C in patients with deep vein thrombosis during early puerperium period.
Venous Thrombosis
Signal transduction induced by activated protein C: no role in protection against sepsis?
Venous Thrombosis
Significantly increased prevalence of factor V Leiden in patients with dural arteriovenous fistulas.
Venous Thrombosis
Spontaneous central vein thrombosis in a patient with activated protein C resistance and dengue infection: An association or causation?
Venous Thrombosis
Successful liver transplantation in a patient with Budd-Chiari syndrome caused by homozygous factor V Leiden.
Venous Thrombosis
Successful management of a pregnant woman with heterozygous protein C deficiency using activated protein C concentrate.
Venous Thrombosis
Successful treatment of deep vein thrombosis in homozygous protein C deficiency with activated protein C.
Venous Thrombosis
Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden.
Venous Thrombosis
The diagnosis and clinical manifestations of activated protein C resistance: a case report and review of the literature.
Venous Thrombosis
The effect of different hormonal contraceptives on plasma levels of free protein S and free TFPI.
Venous Thrombosis
The factor V Leiden mutation increases the risk of venous thrombosis in patients with inflammatory bowel disease.
Venous Thrombosis
The factor VR506Q mutation causing APC resistance is highly prevalent amongst unselected outpatients with clinically suspected deep venous thrombosis.
Venous Thrombosis
The HR2 haplotype of factor V: effects on factor V levels, normalized activated protein C sensitivity ratios and the risk of venous thrombosis.
Venous Thrombosis
The incidence of activated protein C resistance among patients with deep vein thrombosis and healthy subjects in Osaka.
Venous Thrombosis
The polymerase chain reaction with sequence specific primers for the detection of the factor V mutation associated with activated protein C resistance.
Venous Thrombosis
The Prevalence of Activated Protein C Resistance and F V Leiden in Healthy Population of Edirne, Turkey.
Venous Thrombosis
The prevalence of factor V R506Q mutation-Leiden among apparently healthy Lebanese.
Venous Thrombosis
The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects.
Venous Thrombosis
The risk of venous thrombosis associated with a high endogenous thrombin potential in the absence and presence of activated protein C.
Venous Thrombosis
The role of activated protein C resistance in the pathogenesis of venous thrombosis.
Venous Thrombosis
Three-year evaluation of late breast reconstruction with a free transverse rectus abdominis musculocutaneous flap in a county hospital in Sweden: a retrospective study.
Venous Thrombosis
Thromboembolism and resistance to activated protein C in patients with inflammatory bowel disease.
Venous Thrombosis
Thrombotic tendency in 75 symptomatic, unrelated patients with APC resistance.
Venous Thrombosis
Thyroid function, activated protein C resistance and the risk of venous thrombosis in users of hormonal contraceptives.
Venous Thrombosis
Urgent care in gynaecology: resuscitation and management of sepsis and acute blood loss.
Venous Thrombosis
Use of first nucleotide change technology to determine the frequency of factor V Leiden in a population of Australian blood donors.
Venous Thrombosis
Usefulness of screening for congenital or acquired hemostatic abnormalities in women with previous complicated pregnancies.
Venous Thrombosis
Venous thromboembolism, factor V Leiden, and methylenetetrahydrofolate reductase in a sickle cell anemia patient.
Venous Thrombosis
Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study.
Venous Thrombosis
Venous thrombosis with oral postmenopausal hormone therapy: Roles of activated protein C resistance and tissue factor pathway inhibitor.
Venous Thrombosis
[A new cause of hereditary venous thrombosis: activated protein C resistance]
Venous Thrombosis
[A new hereditary cause of portal vein thrombosis: the abnormal resistance to activated protein C by the Arg 506-->Gln mutation of the gene of factor V]
Venous Thrombosis
[Activated C protein resistance: laboratory study and prevalence of the defect in the Chilean population]
Venous Thrombosis
[Activated protein C resistance and venous thrombophilia: molecular genetic prevalence study in the German population]
Venous Thrombosis
[Activated protein C resistance in patients with central retinal vein occlusion in comparison to patients with a history of deep-vein thrombosis and a healthy control group]
Venous Thrombosis
[Activated protein C resistance, Leiden mutation, anticoagulant proteins and fibrinogen levels in patients with deep venous thrombosis]
Venous Thrombosis
[Application of recombinant human activated protein C with blood product administration and deep vein thrombosis in severe sepsis]
Venous Thrombosis
[Chronic abdominal pain due to bowel ischemia in a patient with Leiden factor V mutation]
Venous Thrombosis
[Effects of factor V Leiden mutations on prognosis in patients with acute myocardial infarction]
Venous Thrombosis
[Factor V Leiden mutation leads to enhanced atherosclerosis in apolipoprotein E deficient mice]
Venous Thrombosis
[G20210A transition in the prothrombin gene and venous thromboembolic disease]
Venous Thrombosis
[Hereditary disorders of the protein C system in central artery and branch arteriolar occlusions]
Venous Thrombosis
[Oral contraceptives and activated protein C resistance: a paradigmatic example of genotype and environment interaction in the development of deep venous thrombosis]
Venous Thrombosis
[Resistance to activated protein C and portal vein thrombosis: two new cases and review of the literature]
Venous Thrombosis
[Resistance to activated protein C by mutation of the factor V gene. Most frequent blood coagulation defect in venous thromboses]
Venous Thrombosis
[Resistance to activated protein C disclosed by postphlebitic disease. Two cases]
Venous Thrombosis
[Resistance to activated protein C. A common genetic risk factor in venous thrombosis]
Venous Thrombosis
[The role of resistance to C active protein (R-APC) in a pediatric stroke]
Ventilator-Induced Lung Injury
Effects of Activated Protein C on Ventilator-Induced Lung Injury in Rats.
Ventilator-Induced Lung Injury
Inhaled activated protein C protects mice from ventilator-induced lung injury.
Virus Diseases
RACK1 is indispensable for porcine reproductive and respiratory syndrome virus replication and NF-?B activation in Marc-145 cells.
Virus Diseases
Systemic host inflammatory and coagulation response in the Dengue virus primo-infection.
Virus Diseases
Voltage-Dependent Anion Channel Protein 2 (VDAC2) and Receptor of Activated Protein C Kinase 1 (RACK1) Act as Functional Receptors for Lymphocystis Disease Virus Infection.
html completed